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This thesis reports the examination of microvascular and alveolar 
epithelial permeability indices in clinical and experimentally-induced 
acute lung injury. It was prompted initially by the requirement for a 
direct and specific method of diagnosing and monitoring lung injury in 
patients with the adult respiratory distress syndrome (ARDS). An 
additional objective was the use of these techniques as sensitive 
end-points of lung injury, in studies which examined important aspects 
. ol the syndrome• s pathogenesis and modulation. Previous experience 
with alternative methods of directly or indirectly assessing 
alveolar-capillary integrity, is, as discussed in the initial 
chapters, largely unsatisfactory. 
Two nuclear medicine techniques were modified and developed - the 
pulmonary transvascular flux of 113min-transfer~in and the 
pulmonary clearance of aerosolised 99mTcDTPA (diethylene triamine 
pent acetate) as indices of microvascular and epithelial integrity 
respectively. The first study used both techniques to investigate 
patients with established AROS. All patients had increased 
99mTcOTPA clearance, but the finding· was non-specific as the 
increased rate of solute clearance was similar to that found in 
smoking control subjects. Increased transvascular protein flux 
appeared however, to be specific to the ARDS patients. A close 
correlation was demonstrated between the two permeability indices in 
the ARDS patients, implying proportionate functional injury to both 
components of the alveolar-capillary unit. Studies which examined 
aspects of lung injury pathogenesis, focussed on both cellular and 
humoral factors. The role of the neutrophil was addressed in a series 
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of clinical and experimental investigations. Pulmonary clearance of 
99mTcDTPA was assessed in nonsmoking neutropaenic patients 
developing ARDS after bone marrow transplantation. Increased clearance 
was a uniform finding and histological studies confirmed both severe 
diffuse alveolar damage and an absence of sequestered intrapulmonary 
neutrophils. This study demonstrated for the first time that, at least 
in a ·specific sub-group of ARDS patients, a neutrophil-independent 
mechanism could be invoked. Experimentally, lung injury was induced 
in dogs by cardiopulmonary bypass, a model which was felt to have more 
widespread pathophysiological and clinical relevance than a direct 
toxic injury. This procedure was associated with increased 
transvascular protein flux and morphological e~dothelial cell injury. 
The microvascular permeability index correlated well with both 
intrapulmonary neutrophil sequestration and lung tissue peroxidation. 
This suggested a possible role for the neutrophil and its oxidant 
products in this model of 'lung injury. In contrast~ endotoxin 
infusion in dogs produced severe persistent neutropaenia, implying 
intrapulmonary sequestration, but no change in transvascular 
transferrin flux. Of the humoral mediators examined, only platelet 
activating factor appears likely to play a role in the clinical 
syndrome. Infusion in dogs produced an increase in extravascular lung 
water, increased transferrin transvascular flux, and morphological 
confirmation of endothelial injury. Haemodynamic changes were 
pronounced but transient; the permeability increase however, was 
delayed, becoming significant an hour after infusion. Histamine 
produced a transient increase in 99mTcDTPA clearance in humans and 
this appeared to be H2-receptor mediated. Bradykinin did not alter 
pulmonary clearance of the solute. 
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Further studies assessed the effect of positive end-expiratory 
pressure (PEEP) on either or both permeability index, before and after 
lung injury. PEEP increased DTPA clearance markedly in normal 
nonsmokers but had no effect in smokers. After lung injury induced by 
canine cardiopulmonary bypass, PEEP had no effect on DTPA clearance. 
Prior to bypass, it produced a marked increase in clearance. 
Transvascular protein flux was unaffected by PEEP either before, or 
after bypass. The influence of beta adrenergic agonists on established 
lung injury was studied in an acid-aspiration model in the rat. 
Salbutamol produced significant accentuation of both increased DTPA 
clearance and extravascular lung water in acid-treated rats, pointing 
to a pulmonary haemodynamically-mediated effect. 
This research programme has particularly, pointed to the 
specificity and sensitivity of transvascular transferrin flux as an 
index of microvascular permeability. Additionally, important insights 
have been gained into central issues of lung inj1ury pathogenesis and 
modulation. The pathophysiological and clinical implications of these 
findings are outlined and discussed. 
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PLAN OF THESIS 
This thesis is presented in four sections. Section 1 starts by 
reviewing, from a historical perspective, the physiological principles 
and experimental observations pertaining to acute lung injury. The 
development of the clin~cal concept of a syndrome of ''acute 
respiratory distress' • in adults is traced and the aims of the thesis 
described. The requirement for a marker of alveolar-capillary 
integrity is discussed, and previous experience reviewed. In Chapter 
3, the methodology of the permeability techniques used in these 
studies is discussed in detail, and the initial validating study where 
they are examined in patients with established adult respiratory 
distress syndrome, is outlined in Chapter 4. 
Section 2 (Chapters 5 to 10) describes the use of these 
techniques in clinical and e'xperimental studies which assessed 
pathogenetic aspects of acute lung injury. The role of the neutrophi 1 
is examined in a variety of studies including experimental 
.cardiopulmonary bypass and endotoxin infusion. Neutropaenic patients 
developing acute respiratory dysfunction after bone marrow transplant 
were studied as they constituted a natural clinical experiment to 
examine the possibility of a neutrophil-independent mechanism. The 
latter chapters of this section are devoted to an assessment of 
putative humoral mediators of lung· injury. The following section 
(Chapters 11 to 13) assesses the possible modulating effect of 
se 1 ected interventions, . i ncl udi ng positive end-expiratory pressure and 
beta adrenergic agonists, on the permeability indices. These are 
studied in humans and in animal experiments, both in the context of 
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pulmonary injury and in normal lungs. 
Although each study is discussed in the relevant chapter, the 
final section (Chapter 14) summarises the most important findings and 
discusses them in a broader, overall perspective. Figures and tables, 
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1. HISTORICAL REVIEW AND INTRODUCTION 
Acute diffuse injury to the alveolar-capillary gas exchanging 
units of the lung results in a constellation of physical signs that, 
over the last 20 years, have come to be recognised as the adult 
respiratory distress syndrome (ARDS). This syndrome represents a final 
·common pathway for many insults that injure the lung directly or 
indirectly. It is characterised by pulmonary oedema with normal left 
heart filling pressures in association with specific abnormalities of 
gas exchange and lung mechanics. Although clinical recognition is 
relatively recent, the basic physiological concepts governing lung 
water and solute balance (whose derangement is the key initial step in 
the syndrome's pathophysiology) were described at the end of the 19th 
century. In this historical review the evolution of our understanding 
of the physiological principles governing transcapillary fluid and 
solute balance and the early experimental work pertaining to acute 
lung injury will be outlined. In addition the increasing clinical 
awareness of ARDS-like syndromes over the last 40 years will be 
reviewed and the requirement for a specific marker of 
alveolar-capillary integrity discussed. From this perspective, the 
aims of this thesis are outlined. 
1.1 - Physiological principles 
Starling, working at the physiological laboratories of Guy's 
Hospital, described the principles governing transcapillary fluid 
balance in 1896 (1), although these were not expressed in equation 
form until 1948 (2). At the time of .Starling's original experiments 
--
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the secretion/filtration controversy of lymph formation had not yet 
been resolved. Heidenhain, a German worker, dominated physiological 
thinking at the time with his secretion theory of lymph formation (3). 
Starling, in collaboration with Bayliss, initially repeated 
Heidenhain•s experiments and showed like him that ligation of the 
inferior vena cava dropped arterial blood pressure and increased lymph 
production {4). Unlike Heidenhain who interpreted this as being 
incompatible with filtration, Starling showed that inferior vena caval 
ligation actually increased capillary pressure and that the increased 
flow of lymph was readily accounted for by filtration. It was however, 
in his seminal paper in 1896 (1) that he expanded on the original idea 
of filtration and investigated further the forces governing fluid 
filtration. His hypothesis is summarised in one of the concluding 
paragraphs of the paper: 
• • •••• whereas capillary pressure determines transudation the osmotic 
pressure of the proteids of the serum determines absorption •••••••• the 
osmotic attraction of the serum for the extravascular fluid will be 
. proportional to the force expended in the production of this latter, 
so that, at any given time there must be a balance between the 
hydrostatic pressure of the blood in the capillaries and the osmotic 
attraction of the blood for the surrounding fluids.• • 
In equation form this states that net fluid flow is the product of the 
barrier conductance and the driving pressure. In symbols the 
relationship is expressed as: 
Q = Kf (Pmv - Ppmv) - r (IImv - Ilpmv) 
where Q is the nett transvascular filtration rate 
22 
Kf is the hydraulic conductance or porosity of the microvascular 
barrier 
P is the hydrostatic pressure in the microvascular lumen (mv) 
and perimicrovascular interstitial fluid (pmv) 
r is a reflection coefficient for solutes which describes the 
effective transvascular oncotic pressure difference. This is 
dependent on how truly the membrane can act as a semi-permeable 
membrane and tends to decreake with decreasing molecular size of 
so 1 ute. 
II is the oncotic pressure in the plasma (mv) and permicrovascular 
compartments (pmv). 
The corollary of this equation is that oedema in any tissue is due 
either to increasing driving pressure or altered integrity of the 
microvascular membrane. Support for the applicability of Starling•s 
original hypothesis to human tissue was provided initially by Landis 
and Gibbon (5). They showed a linear relationship in the forearm 
between fluid filtration and increasing venous pressure. It was not 
however until 1959 that the Starling equation was applied to lung 
fluid balance studies by Guyton and Lindsey (6). In a classic study, 
they demonstrated that 'the cr_itical left atrial pressure at which 
pulmonary oedema develops 
protein concentration. In 
decreases with reduction of the plasma 
additional support of Starling•s 
relationship they showed that once the critical left atrial pressure 
had been exceeded the rate of fluid accumulation was unaffected by 
plasma protein concentration. Thus, although animals with lower 
plasma oncotic pressures had significant lung water accumulation at a 
lower critical left atrial pressure, once that pressure had been 
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exceeded the rate of water accumulation was similar to animals with 
normal plasma oncotic pressure who had reached their own critical 
left atrial pressure. This finding was of great importance as it 
confirmed in the lung the validity of the Starling concept of a 
balance between capillary and oncotic pressures. The actual rate of 
water accumulation once the critical pulmonary microvascular pressure 
had been exceeded was dependent only on Kf, the hydraulic 
conductance of the barrier to water. 
As Staub (7) and Michel (8) have pointed out, the Starling 
equation refers essentially to fluid flux; solute flux is the sum of 
simple diffusive and convective flux. The equation describing solute 
flux is derived from the work of Kedem and Katchalsky (9) and is 
expressed as follows: 
Qs = PSs (Cmv - Cpmv) + 1 - r(CmQ) 
where Qs is the solute flux 
PSs is the permeability:surface area product for diffusion of 
solute 
C is the solute concentration in the microvascular lumen (mv) or 
perimicrovascular (pmv) space 
r is the reflection coefficient 
Q is the fluid flux and em is the mean concentration of solute 
across the microvascular membrane 
In acute lung injury the pulmonary microvasculature becomes very 
1 eaky to so 1 ute and when these 1 eaks are 1 a rge enough to permit 
proteins to cross the wall, the reflection coefficient falls towards 
-
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zero and the osmotic pressure gradient disappears. The hydraulic 
conductivity, K, increases and (from Starling•s equation) -the fluid 
flux is now crucially dependent on the pulmonary microvascular 
pressure gradient. From consideration of the solute flux equation it 
is apparent that in this situation marked increases would be seen 
because of changes in both diffusive and convective flux. This is 
because acute lung injury results in increased capillary 
permeability; this alone would increase diffusive flux although it is 
negated by loss of solute concentration gradient. As the reflection 
coefficient falls to zero, convective solute flux becomes more' 
important. Thus in clinical or experfmental lung injury, alterations 
in all three inherent properties of the pulmonary microvascular 
membrane (hydraulic conductivity, reflection coefficient and the 
permeability:surface area product) are seen. Theoretical models which 
represent fluid and protein flux do however allow separation of fluid 
and protein flow (10). A model based on pores of different sizes 
would allow increased flow of water and electrolytes through very 
small pores while still remaining totally impermeable to protein. 
Alternatively, purely increased protein permeability is feasible if a 
pathway such as endothelial vesicles, which is independent of water 
flow is hypothesised. Practically however, permeabilty oedema is 
always associated with increases in water and solute flow (7). 
Little is known about the relative importance physiologically of 
alveolar epithelial and microvascular endothelial integrity in 
preventing alveolar flooding in pulmonary oedema. Staub maintains 
that, on the basis of his group•s experimental work, that injury to 
the microvascular endothelial component of the barrier is crucially 
25 
significant in permeability oedema (7). Of particular interest 
however, is the realisation recently that the lung interstitium is 
not • •dry• • physiologically and that there is constant transfer of 
fluid from the microvasculature into the lymphatics. The lymphatics 
have emerged as a key defence mechanism against extravascular lung 
water accumulation, as they are able to deal with a several fold 
increase in lymph flow (8). 
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1.2 - Experimental and pathological observations 
Drinker, a Harvard professor of physiology in the interwar years 
was a. pioneer in the investigation of pulmonary oedema pathogenesis. 
He was a remarkably innovative worker whose contributions included 
the use of right thoracic duct lymph flow and protein concentration 
as indices of lung fluid and protein flux (11)~ Although it is now 
recognised that lymph flow from the right thoracic duct is 
significantly influenced by non-pulmonary sources (12), this work did 
lead to the development of more selective methods of lymph collection 
which, particularly in the sheep (13), are now established 
investigative tools. In addition he developed what was probably the 
first experimental model of acute lung injury, using a thiourea 
derivative to produce fulminant pulmonary oedema (11). He did 
however, perpetuate the myth that hypoxia per se was responsible for, 
and accentuated increased capillary permeability. This contention was 
based on an experiment in which a dog breathed 10% oxygen and 90% 
nitrogen for over an hour (14). Towards the end of an hour the 
cardiac output dropped dramatically, lung lymph flow increased while 
its protein concentration dropped. In this case increased lymph flow 
was due not to increased permeability but increased pulmonary 
microvascular pressures and surface area probably due to a failing 
left heart. Subsequent studies by another group using isolated 
perfused dog lungs showed no increase in lung weight even with 0% 
oxygen ventilation (15). A further study by this latter group used 
albumin as the tracer to examine alveolar-capillary permeability 
(16). The results here confirmed their previous study and have 
established conclusively that alveolar hypoxia per se has no effect 
+~-------· 
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on microvascular or alveolar epithelial permeability. Although true 
increases in capillary permeability and hypoxemia did co-exist in 
some of Drinker•s experiments they were almost certainly epiphenomena 
rather than cause and effect relationships. 
Moon, an American pathologist, provided an early pointer to the 
existence of a syndrome of acute lung injury occurring without 
primary insult to the lungs. In 1941 he published data showing a high 
incidence of pulmonary oedema in servicemen dying from non-thoracic 
trauma, burns, acute pancreatitis and infections (17). Interestingly, 
in the light of current thinking of acute lung injury 
pathophysiology, some of the patients he described showed 
histologically (in addition to intra-alveolar haemorrhage and oedema) 
pulmonary leucocytic infiltrates. At about the same time Eaton 
published his experimental work carried out in dogs, confirming that 
acute blood loss with resultant hypovolemia produced increased 
pulmonary lymph flow with evidence morphologically of pulmonary 
oedema and endothelial cell damage (18). Like Drinker and others at 
the time, he considered that pulmonary endothelial cell injury with 
consequent oedema formation was the direct result of hypoxemia. Eaton 
did however, make the highly original observation that the oedema 
fluid in the dogs with blood loss-induced lung injury was relatively 
protein-rich. This was a key observation as it implied that this type 
of pulmonary oedema was associated with increased pulmonary capillary 
permeability. Systematic c 1 i ni ca 1 confirmation of this chance 
experimental finding only came nearly 30 years later (19). 
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1.3- Recognition of clinical acute~ injury 
During the second world war surgeons of the United States armed 
forces provided one of the first clinical descriptions of an 
ARDS-like syndrome (20). Although. their description of • •wet lung in 
war casualties• • dealt largely with blood in the bronchial tree from 
intra-pulmonary haemorrhage, they did describe a case of true 
pulmonary oedema developing days after the initial trauma. They also 
stated that, pathologically, pulmonary oedema was the most 
significant finding at autopsy in patients who survived the initial 
shock but died later of their injuries. In the immediate post war 
years a similar syndrome was recognised largely by the description of 
the lung pathological features at autopsy. The term • •congestive 
· atelectasis•• was used to describe the gross and diffuse lung changes 
of intra-alveolar haemorrhage and oedema noted in patients who 
developed respiratory failure after a variety of precipitating 
events. Although this was thought initially to be a complication of 
intravenous fluids (21), Berry et al pointed out in 1963 that these 
changes could develop with normal central venous pressures (22). 
The first comprehensive clinical description of a syndrome of 
acute lung injury was by Ashbaugh and his co-workers in 1967 (23). 
Impressed by the resemblance of the clinical and pathological 
features to infant respiratory distress, they termed the syndrome 
• •acute respiratory distress in adults' •. Although this was purely a 
clinical contribution they did speculate accurately about possible 
·pathophysiological mechanisms: 
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• •rn view of the similar response of the lung to a variety of stimuli 
a common mechanism of injury may be postulated. The loss of lung 
compliance, refractory cyanosis and microscopic atelectasis _point to 
alveolar instability as a likely source of trouble• •. 
Further evidence of a syndrome of acute lung injury developing after 
major trauma came from the pathological and clinical ·findings in 
American combat casualties during the Vietnam war. An extremely high 
incidence of pulmonary oedema and intra-alveolar haemorrhage was· 
noted in soldiers who died within a few days of sustaining major 
trauma (24). Furthermore, similar pathological changes were noted in 
the vast majority of soldiers dying after head injury, including 
those who died within minutes of trauma (25). 
Clinical and experimental observations over the last 15 years 
have supported the original concept of a common clinical and 
pathological syndrome of acute lung injury developing after numerous, 
diverse precipitating events. Pulmonary oedema has been recognised 
as a basic abnormality in this syndrome (26); the advent of the 
Swan-Ganz flow directed catheter into clinical medicine (27) allowed 
the further accurate separation of this syndrome, with its normal 
left heart filling pressures, from hydrostatic pulmonary oedema. As 
previously mentioned, altered capillary permeability with 
protein-rich oedema fluid allows further differentiation from 
hydrostatic oedema. Adult respiratory distress syndrome represents 
however not a single disease, but a syndrome of acute diffuse 1 ung 
injury defined only by the presence of specific physiological and 
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radiological abnormalities. Indeed the very coining of the term by 
Petty and Ashbaugh in 1971 (28) aroused intense nosological debate 
(29,30,). Murray argued that not only was the pathophysiology 
entirely different from infant respiratory distress but that 11 
lumping together 1 1 diverse entities would obscure their probably 
different pathophysiology and reponses to therapy (30). Despite these 
misgivings the term has become established and is now virtually 
synonomous with permeability pulmonary oedema, although it is defined 
to include only the most severe cases of permeability type oedema. 
Usual criteria include abnormalities of gas exchange, reduced 
lung compliance, with diffuse radiological airspace infiltrates and 
normal left heart filling pressures as gauged by the pulmonary 
capillary wedge pressure. Exact values neccesary in order that these 
variables fulfill syndrome criteria are not uniform; in clinical or 
experimental studies reported in this thesis, specific values 
accepted for syndrome fulfillment will be outlined where appropriate. 
The pathological correlate of these clinical findings is diffuse 
alveolar-capillary injury with intra-alveolar oedema and haemorrhage 
(31). The development of the pathological features is usually 
divided into exudative, intermediate and proliferative phases. The 
exudative phase is predominant in the first few days after lung 
injury. Particular features include proteinaceous exudate in the 
interstitium and terminal airways, intra-alveolar haemorrhage and 
inflammatory infiltration of the alveolar walls. This merges into the 
intermediate phase where hyaline membranes are prominent and obvious 
oedema and exudate diminishes. During the proliferative phase, which 
is usually only seen after a week, hyperplasia of type i pneumocytes 
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as a healing response to type 1 cell injury is seen. Later 
fibroblastic proliferation with laying down of collagen is noted. It 
appears that despite marked proliferative changes virtually full 
resolution can take place (31). The dichotomy of functional and 
structural injury should h~wever be emphasised; experimental work 
suggests that increases in vascular permeability and pulmonary oedema 
can be demonstrated by physiological measurements where there is no 
obvious structural abnormality (32),(33). It is possible, as Staub 
has emphasised (7), that early or mild cases of pulmonary oedema may 
not necessarily be associated with electron microscopic morphological 
changes. 
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1.4 - Requirement for~ specific marker of alveolar-capillary injury 
The above clinical and histological changes are passive or 
reactive changes to alveolar-capillary injury. As such they reflect 
only the sequalae of injury and probably represent an end-stage of 
the pathogenic process. Early in the development of lung injury, 
conventional measurements of gas exchange or lung mechanics are 
insensitive and do not quantitate the specific abnormalities that 
produce increased transcapillary water and solute flux and result in 
oedema formation (34). Because of this numerous groups world-wide 
have intensively investigated possible markers of tissue injury in 
the syndrome, in the hope that at-risk patients can be identified and 
appropiate therapy instituted as early as possible in the clinical 
course. This research effort has .been spurred not only by the 
imprecision of current diagnostic modalities, but also by the 
knowledge that mortality in ARDS (50-70% in most series) has not 
changed over the years since the syndrome was first reported (23). 
An additional motivation for developing such techniques is that 
clinical or experimental studies of lung injury pathogenesis or 
modulation, require specific and sensitive end-points of injury. 
These should preferably be based on dynamic information and for 
clinical studies the techniques should be as non-invasive as 
possible. Since altered permeability of the pulmonary endothelium and 
alveolar epithelium appear to be cardinal features of the syndrome 
the particular approach employed in this thesis was based on the 
development of nuclear medicine techniques to investigate. the barrier 
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·characteristics of the alveolar-capillary unit. Details of these 
techniques as well as the motivation for using them will be described 
fully in the following chapters. Initially, previous experience with 
alternative methods of alveolar-capillary functional assessment will 
be reviewed, with particular reference to their specificity and 
sensitivity as early markers of lung injury. 
34 
1) To develop and assess two nuclear medicine techniques to provide 
indices of permeability of both lung microvascular endothelium and 
alveolar epithelium. 
To use these techniques to address the following specific issues in 
lung injury diagnosis, pathogenesis and modulation: 
2) the assessment and comparison of both techniques in patients with 
established severe acute lung injury manifesting clinically as the 
adult respiratory distress syndrome. 
3) the use of either or both techniques as sensitive end-points of 
lung damage in order to investigate: 
a) key aspects of lung injury pathogenesis including the role of the 
neutrophil and that of putative humoral factors. 
b) the modulation of lung penneability characteristics by selected 
mechanical or phannacological· interventions. 
4) To develop an animal model of acute lung injury with clinical and 
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:2. THE SEARCH FOR A MARKER OF ALVEOLAR-CAPILLARY INTEGRITY IN LUNG INJURY: A -- -- - ---
CRITICAL REV lEW 
The assessment of tissue dysfunction in disease requires an 
understanding of both normal cell biology and the pathophysiology of 
the particular disease state. This is exemplified by consideration of 
alveolar-capillary injury assessment in ARDS, since all markers 
studied have been based either on an alteration of normal endothelial 
and epithelial function, or on factors involved in the 
pathophysiology of injury. This review will therefore include a 
discussion of relevant cell biology as well as a brief consideration 
of current concepts of acute lung injury pathophysiology. Particular 
aspects of the latter will be discussed in more detail, where 
appropriate in succeeding chapters • 
. l·l - Aspects of normal pulmonary endothelial and alveolar cell 
bi o·logy 
I·l·l- Pulmonary endothelial cell 
Understanding of the cell biology of endothelium in general, and 
pulmonary endothelium in particular, has been transformed over the 
last 20 years (35). The original concept of a metabolically inert, 
semi-permeable barrier has been altered dramatically by the 
realisation that the endothelium has specific metabolic and synthetic 
functions as well as being important to haemostasis. In the lung the 
importance of the endothelium is magnified, since not only does it 
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have an important barrier function to leakage of water and 
macromolecules, but its venous effluent reaches the systemic arterial 
blood. 
a) Handling of biologically active substances by the lung 
Both serotonin and noradrenaline are taken up intracellularly and are 
enzymatically degraded· by a process that is energy dependent. The 
extent of this removal is over 95% of serotonin and 30-40% of 
noradrenaline •. Prostaglandins of the E and F series are also-
inactivated (36), but prostacyclin is unaffected by passage through 
the pulmonary circulation (37). Likewise the leukotrienes (LTC4 
and LTD4) are inactivated but the mechanism for this is uncertain 
(38). 
Angiotensin converting enzjme is situated on the luminal surface 
of predominantly pulmonary endothelium. It catalyses both the 
inactivation of bradykinin and the formation of angiotensin II from 
angiotensin I. The caveolae or pinocytic vesicles on the endothelial 
cell surface have enzymes including ATPase, ADPase and 5 1 nucleotide 
(39) which degrade adenosine mono, di and triphosphate in passage 
through the lung. Numer·ous iulpor·tdnt l>lolo~ical compounds, includiny 
adrenaline and angiotensin II are unaffected by passage through the 
lungs. 
b) Pulmonary generation of biologically active compounds 
.j 
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The most important role here is with regard to prostaglandin 
synthesis; they are formed from arachidonic acid, which is released 
from membrane phospholipids by the action of phospholipase A2• 
Some of the cycloxygenase and lipoxygenase products of arachadonic 
acid have potentially important roles in acute lung injury (40), and 
only these are discussed here. Prostacyclin and thromboxane A2 
have contrasting effects on platelet aggregation; prostacyclin is not 
only a potent inhibitor of platelet and neutrophil aggregation, but 
also is a potent pulmonary vasodilator. In contrast thromboxane 
increases pulmonary artery pressure (41) and promotes the interaction 
of neutrophils with the vessel wall (42). The leukotrienes 
particularly LTC4 and LTD4 (slow releasing substance of 
anaphylaxis) are chemoattractant for neutrophil s and increase 
microvascular permeability (43). In a preliminary study exogenous 
LTD4 caused significant lung injury with increase in 
extravascular lung water (44). 
-c) other important synthetic functions 
Pulmonary and other endothelium produces one of the components of the 
Factor 8 complex, the Factor 8 related antigen protein which contains 
von Willebrand•s factor (45). This component of Factor 8 is 
responsible for platelet adhesion to exposed collagen on damaged 
endothelium. Factor 8 procoagulant protein, the other component of 
the complex is not synthesised by endothelial cells (46) and is also 
distinct from von Willebrand factor; it (Factor 8:c) is a co-factor 
for Factor 10 in blood clotting. 
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Fibronectin is a large molecular weight (440,000) opsonically 
active glycoprotein. In tissue where it is insoluble, it exists in 
the extracellular matrix of cells as well as between endothelial 
cells and in the subendothelial space (47,48). It augments adhesion 
of fibroblasts and endothelial cells to a collagen matrix. Plasma 
fibronectin mediates clearance of blood-borne non-bacterial 
particulate matter by the reticuloendothelial system. It can be 
incorporated into the insoluble tissue pool of fibronectin (49) and 
is found in increased concentrations in areas of tissue injury and 
repair (50). 
d) Role in local haemostatic balance 
Adenosine diphosphate (ADP) is a potent platelet aggregator which is, 
as mentioned, degraded by ADPase in the caveolae to adenosine, which 
inhibits platelet aggregation (51). Thus, in addition to releasing 
adenosine and prostacyclin, inhibitors of platelet aggregation, the 
lung degrades ADP as well as serotonin (a platelet aggregator) and 
avoids intravascular thrombosis, maintaining microvascular 
integrity. 
£·1·£- Aspects of alveolar epithelial cell function 
Only type II pneumocyte function will be discussed, since it is 
the cell that both produces surfactant (52) and is involved in repair 
after diffuse alveolar injury (53). Surfactant is composed largely of 
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a highly surface active phospholipid which allows it to meet its 
physiological function of reducing surface tension and preventing 
alveolar collapse during expiration. Corticosteroids, adrenergic and 
cholinergic agents as well as a number of other physiological and 
pharmacological factors modulate surfactant secretion (54). 
Type I pneumocytes, which comprise over 90% of the alveolar 
surface, are particularly susceptible to injury. Necrosis is followed 
by Type II proliferation and subsequent differentation to Type I 
cells (55). In addition Type II cells are postulated to defend the 
lung against oxidant injury by increasing antioxidant enzyme activity 
(56). 
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2.2 - Current concepts of acute~ injury pathophysiology. 
Although multiple humoral and cellular factors undoubtedly play 
a role in lung injury, evidence suggests that the neutrophil is a 
pivotal cell in initiating the inflammatory response (57). 
Neutrophils migrate and sequester in the lungs in response to 
numerous chemotaxins; the most frequently cited is activated 
complement (58), although experimental· studies suggest a role for 
prostaglandins (59,60), alveolar macrophage products (61), fibrinogen 
fragments (62) and immune complex mediation (63). The sequestered, 
activated neutrophil injures the pulmonary endothelium by three 
principal mechanisms. These are discussed comprehensively in a 
recent authoritative review (57}, and as they are not directly 
relevant to this thesis will only be summarised here: 
(i) The release of oxygen free radicals which are generated by the 
burst of oxidative metabolism that occurs in neutrophils following 
membrane stimulation. These include superoxide anion, hydrogen 
peroxide and the hydroxyl radical which is formed by the action of a 
granular enzyme myeloperoxidase on hydrogen peroxide. These radicals 
. directly injure endothelial cells and indirectly promote injury by 
inactivating alpha Protease inhibitor (PI). 
(ii) Release of proteolytic enzymes, including elastase, collagenase, 
myeloperoxidase and others from neutrophil cytoplasmic granules. In 
addition to degrading lung tissue components, they lyse many other 
proteins including fibronectin and aPI. They also activate 
complement leading to further neutrophil activation and sequestration 
42 
in the lung. 
(iii) Production and release of a range of arachidonate derived 
products. The possible role of prostacyclin, thromboxane and the 
leukotrienes have been alluded to previously. 
A further possible mediator of neutrophil induced lung injury is 
the release of platelet activating factor (PAF). This is a potent 
inflammatory mediator released by a variety of activated inflammatory 
cells including human granulocytes, platelets, monocytes and alveolar 
macrophages (64). Once released it aggregates platelets and 
neutrophils with subsequent release by the neutrophil of proteolytic 
enzymes, oxygen free radicals and arachidonate derived products. It 
increases systemic microvascular permeability (65) and preliminary 
studies suggest it increases pulmonary microvasular permeability 
(66). The potential of this mediator to effect changes in pulmonary 
microvascular permeability is addressed in detail in Chapter 10 of 
this thesis. 
Disseminated intravasular coagulopathy is an occasional 
associated feature in patients with ARDS (67). Radiolabelled 
platelet kinetic studies in this group of patients demonstrate that 
platelet consumption and organ sequestration is a prominent finding 
(68). The radiological correlate of these findings are multiple 
pulmonary artery filling defects which occur in nearly half of ARDS 
patients (69). This suggests that platelet-fibrin thrombi may be 
playing a role in lung injury: possible mechanisms include 
43 
activation of complement by thrombin with subsequent pulmonary 
leucostasis and activation, physical entrapment by the fibrin network 
of platelets (with release of serotonin, thromboxanes and lysosomal 
enzymes) and leucocytes in the pulmonary microvessels or a direct 
permeability enhancing effect of fibrin-derived peptides (70). 
Additionally, the activation of the Hageman factor by tissue injury 
and activated complement not only activates factors 11 and 7, but may 
also proteolytically convert. prekallikrein to kallikrein with 
subsequent release of bradykinin, thrombin and plasmin (71) and 
potential for further capillary permeability increase. 
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I·l- Markers of alveolar-capillary injury. 
2.3.1. - Indices of tissue function. ---
a) Handling of biologically active substances. 
Although animal studies with experimentally induced pulmonary injury 
showed an initial transient rise in serum ACE (72-74), this has not 
been found in clinical studies. Fourrier and his associates showed 
that the level of serum ACE fell in the first few days of ARDS 
evolution reaching a nadir at 72-96 hours; thereafter levels rose 
gradually to reach baseline levels by the 7th day (75). In this 
study, the level of serum ACE had no prognostic value, and was not 
related to any particular precipitating cause. There was however, a 
tendency for patients with the lowest ACE levels to have disseminated 
intravascular coagulopathy suggesting that a low ACE may be 
reflecting loss of pulmonary microvascular perfusion. A more recent 
study confirmed a tendency to lower serum ACE in ARDS (76). The 
finding was, however, non-specific in that critically ill patients 
without ARDS also had low values and the level in an individual 
·patients neither reflected disease severity nor outcome. 
This study (76) also examined serum concentrations of another 
peptidase, neutral endopeptidase, in patients with ARDS. This 
enzyme, unlike ACE, is not associated with the endothelial luminal 
surface being found predominantly within alveolar epithelial cells in 
terminal airways. ·concentrations of this enzyme, unlike ACE, were 
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vastly elevated in ARDS patients, probably reflecting loss of 
alveolar capillary-integrity and release into the blood stream. 
Patients with cardiogenic pulmonary oedema and chronic obstructive 
lung disease also showed some rise in enzyme activation, although not 
to the extent of ARDS patients. 
In experimentally induced lung injury serotonin uptake appears 
to be a ~ensitive index of endothelial injury. With rats exposed to 
hyperoxia, depression in uptake appeared to antedate morphological 
and physiological alterations (77). This sensitivity was borne out ' 
in a later study with alpha naphthylthiourea (ANTU) with uptake 
depression antedating gravimetric lung water and morphological 
changes (78). Similar uptake depression has also been noted with a 
microembolisation model of lung injury (79). Additionally, serotonin 
is a potent platelet aggregator and may increase vascular 
permeability; this depression of uptake may actually play a 
physiological role in injury pathogenesis and progression. Morel and 
colleagues examined these considerations in patients with ARDS (80). 
They found that not only was serotonin uptake depressed compared to 
normal and at risk controls, but uptake depression appeared to 
correlate with disease severity. 
b) Synthetic function factor 8 complex. 
Grant and his co-workers were the first to point out that an altered 
factor 8 complex was a feature of pulmonary endothelial injury (81). 
They showed that i.n patients with acute respiratory insufficiency the 
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factor 8 related antigen was raised disproportionately to rises seen 
in factor 8 procoagulant activity, while the Von Willebrand factor 
was normal. These observations were later confirmed and extended by 
another group who demonstrated selective rises in factor 8 related 
antigen in acute lung injury patients (82). This was in contrast to 
critically ill patients without lung injury, where levels of the 
three components of the factor 8 complex were proportionately 
elevated. Additionally, an abnormal electrophoretic pattern of 
factor 8 related antigen was noted in lung injury patients, which 
returned to normal in patients who recovered. More recently, a 
preliminary study also indicated that factor 8 related antigen may be 
a predictor of progression to acute lung injury in septic patients 
with minimal or no lung injury when first identified (83). 
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I·l·I· -Markers implicated~ pathogenesis or formed~~ result of 
~injury 
a) Complement. 
Hammerschmidt and his co-workers in Minnesota measured plasma C5a 
concentrations in patients either with - or at risk of developing -
AROS (84). They found that not only were C5a assays positive in the 
vast majority of AROS patients but that the assay predicted 
accurately which at risk patients, followed prospectively," developed 
AROS. This potentially exciting finding suggesting that evidence of 
complement activation may be a useful predictor of AROS development, 
has not been borne out in follow-up studies by other groups. Indeed 
the very basis of the C5a assay used by the Minnesota group - the 
ability of plasma to aggregate polymorphonuclear leucocytes- may not 
have been accurate. Weinberg and colleagues in San Francisco 
measured C5a des arg and C3a des arg directly by radioimmunoassay in 
patients with sepsis and found that values correlated poorly with 
plasma neutrophil aggregating activity (85). In addition, they found 
that neither in~unological nor biological. markers of complement 
activation correlated with the initial severity nor predicted the 
development of the associated acute injury. A similar study recently 
reported by a Belgian group suggested that although C5a was 
significantly elevated in early AROS, it could not be regarded as a 
specific marker since similar elevations were noted in septic 
patients who did not develop lung injury (86). 
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b) Proteolytic enzymes. 
Patients with ARDS showed increased concentration of 
neutrophil-derived elastase in bronchoalveolar lavage (BAL) fluid. 
In an initial study, this appeared to be associated with reduced 
protease inhibitor functional activity and unassociated with any 
physiological index of lung injury (87). The basic finding of 
markedly elevated neutrophil elastase concentrations in ARDS lavage 
fluid has been c·onfirmed by subsequent studies (88,89) although the 
most recent study (89) did demonstrate an association between BAL 
elastase and alveolar-arterial Pa02 gradient. Similarly BAL 
fluid in ARDS patients shows collagenolytic activity directed against 
both types I and III collagen (90). The data in this study however, 
neither predicted nor was related to any gas exchange or haemodynamic 
index of lung injury severity. 
c) Markers of oxidant injury. 
Although animal studies suggest a role for free oxygen radicals in 
acute lung injury (91,92), few studies have examined this aspect 
clinically. A recent demonstration of increased levels of hydrogen 
peroxide in expired breath condensate in .ARDS patients not only 
supports the notion that oxidants are involved in the syndrome•s 
pathogenesis but suggests future use as a possible marker of 
oxida·nt-mediated lung injury (93). Since oral commensals influence 
peroxide production, this technique is probably limited to intubated 
patients. 
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d) Prostanoid measurements. 
In patients with septic shock, measurements of plasma thromboxane 
B
2 
were very significantly elevated in non-survivors compared to 
survivors (94). The implication of this finding with regard to 
development of an early predictor of lung injury in septic patients 
is uncertain. Patients who died did however, demonstrate a more 
severe gas exchange deficit, suggesting possible t~romboxane 
involvement in respiratory distress development. A further study 
confirmed elevation of TXB2 level in three groups of at risk 
patients who developed ARDS compared to those patients who did not 
(86). Sequential measurement ·after development of ARDS showed that 
TXB2 was relatively slow to rise, reaching maximal levels only by 
the 3rd to 4th day, thus ruling out its use as an early marker of 
lung injury. Measurement of 6 keto prostaglandin F1a (the stable 
metabolite of prostacyclin) showed no predictive ability for either 
ARDS development or mortality (86). 
e) Miscellaneous markers. 
The fibrinogen degradation product, 0-antigen, was elevated in ARDS 
,patients compared to disease matched controls who did not develop the 
syndrome (95). Concentrations of the antigen tended to parallel the 
clinical course but this study did not provide evidence to support an 
early diagnostic or prognostic role for this marker. 
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Recent work has pointed to significant elevation of 
immunoreactive trypsin (IRT) in septic patients with ARDS of 
non-pancreatic origin (96). Follow-up studies by a Swiss group have 
confirmed these findings with peak levels of IRT and serum lipase in 
ARDS patients comparable to those seen in patients with primary acute 
pancreatitis (97). The rise in IRT in ARDS was associated with a 
six-fold increase in trypsin inhibitory capacity (TIC) and a low 
TIC/IRT ratio appeared to be a poor prognostic sign. Levels of IRT 
do not, however, hold any promise of being a reliable early marker of 
ARDS evolution as peak values were only seen at 5-6 days. 
Significant plasma prekallikrein activation into plasma 
kallikrein was demonstrated in ARDS patients compared to critically 
ill patients without ARDS (98). This study was based on a small 
number of patients and blood samples were drawn at varying intervals 
after fulfilment of ARDS criteria. Clearly further studies are 
required to clarify the possible clinical usefulness of this marker. 
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I·l·l - Assessment of barrier function of pulmonary microvascular 
endothelium and alveolar epithelium~ acute~ injury 
As previously discussed in Chapter 1, acute lung injury with 
consequent loss of pulmonary microvascular and alveolar epithelial 
integrity results in increased transvascular water and solute flux. 
In this section, previous experience with assessment of both of these 
latter variables will be reviewed. 
l·l·l·l - Measurement of extravascular~ water. 
Gravimetric lung water. 
Use of this technique as an index of extravascular lung water (EVLW) 
is obviously confined to experimental work. Assessment of lung 
weight change during an experimental procedure cannot be performed in 
an intact animal and is confined to studies with isolated perfused 
lungs. In intact animals, assessment of lung weight can only be made 
at one point in time (post mortem) and is usually expressed as the 
ratio of lung weight to body weight. This particular method of lung 
water assessment is insensitive, with over 50% increase required for 
clear evidence of pulmonary oedema (7). The ratio of wet to dry 
weight, although also only measurable in whole lungs at one point in 
time, is more sensitive and more widely used. The sensitivity of 
this method is enhanced particularly by the classic correction for 
residual blood first introduced by Pearce et al. (99). This 
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correction is performed either by measurement of haemoglobin 
concentration in lung tissue or by tagging red blood cells 
isotopically. In much of the current literature this technique is 
the 11 gold standard 11 against which other parameters of lung water 
accumulation are compared. 
Chest radiography. 
Pistolesi and Guintini studied patients with cardiogenic 
pulmonary oedema, comparing EVLW using a multiple indicator dilution 
technique, with radiographic grading of oedema (100). Although there-
were occasional non-specific radiological abnormalities with no or 
minimal increase in EVLW, a linear relationship between these two 
vari ab 1 es was noted when EVLW was increased by more than 50%. This 
important observation· was extended by Snashall and colleagues in 
1979; they compared lung wet weight to dry weight ratios and 
radiographic grade in dog lung after experimentally induced 
hydrostatic and permeability oedema (101). No clear difference in 
radiographic patterns between the two types of oedema emerged from 
the study. The most striking feature was that increases in EVLW of 
greater than only 30% were necessary before oedema was unequivocally 
recognised by the radiologist. Thus the radiograph appears to be ·a 
reasonably sensitive index of lung EVLW accumulation with the 
particular advantages of being non-invasive, inexpensive and allowing 
assessment of regional differences. 
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Indicator dilution. 
This technique, once virtually abandoned in clinical practice, 
has increased in popularity over the last 7 years, largely because of 
the introduction of an easier and more reproducible method which, 
with an on-line dedicated mini-computer, allows repeated 
measurements. The indicator dilution measurement is based on the 
different volumes of di~tribution available to an intravascular, 
non-diffusible (usually isotopically labelled red cells or albumin), 
and a diffusi·ble indicator (usually tritiated water). Both· 
indicators are injected into a central vein and the extravascular 
lung water calculated from the difference in transit times between 
the intravascular and djffusible indicators. The transit times for 
both indicators are calculated by regular automated sampling of blood 
from a major artery (femoral artery clinically) where its 
concentration at each moment. in time is calculated relative to the 
~oncentration of the injected indicator. Both concentration curves 
are then plotted semi-logarithmically versus time. The conc~ntration 
curve of the non-diffusible indicator will obviously rise and also 
fall quicker than that of the diffusible indicator but the recovery 
of ·both indicators from the arterial catheter (expressed as area' 
under the curves) should be equa·l if both indicators have the same 
flow characteristics (102). The transit time itself is calculated by 
fitting a straight line to the descending limb of the curve and 
extrapolating it to the modal value (103). The EVLW is then 
calculated as 
EVLW = Intravascular water flow (tdiff - tnon-diff) 
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where intravascular water flow = cardiac output x 
fractional water content of blood. 
tdiff = transit time of diffusible indicator 
t = transit time of non-diffusible indicator non-diff 
This technique, with the indicators as described above, is 
tedious to perform, requires large samples of blood to be drawn and 
probably underestimates true extravascular lung water calculated 
gravimetrically by as much as 50% (7). Because of this, the technique 
fell into disrepute; there has however, been a marked resurgence of 
interest with the introduction of an elegant ·modification which, 
aided by the introduction of microprocessor technology, has overcome 
many of the previous theoretical and practical problems. It is based 
on the use of a thermal and dye marker as diffusible and 
non-diffusible indicators respectively. The particular indicators 
used are indocyanine green dye and iced dextrose solution which are 
prepared and injected in the same syringe. Blood is withdrawn in a 
sterile manner from the femoral . artery, and dye concentration and 
thermal signal interpreted by a densitometer and a thermistor in the 
femoral a_rtery catheter. A mini-computer accepts signals from both 
and computes cardiac output and mean transit time for each 
indicator. 
In contradistinction to the previous method, this technique is 
suitable for bedside use and all blood withdrawn is injected back 
into the patient at the end of the measurement. Since its original 
descripti~n by -Lewis and colleagues (104), EVLW as measured by this 
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technique has been demonstrated to correlate well with gravimetric 
EVLW in animal (105) and clinical studies (106). Clinical studies 
with this technique suggest that patients with permeability pulmonary 
oedema have greater lung water content than patients with hydrostatic 
oedema, although there is significant overlap between the two groups 
(107). In this study (107), there was a positive but poor correlation 
between- EVLW and pulmonary capillary wedge pressures. Brigham and 
colleagues however, showed no correlation between EVLW (using a 
multiple tracer rather than thermal-dye technique) and either 
·pulmonary microvascular pressure or gas exchange deficit (108). 
Despite the greater clinical use of EVLW measurement in recent years, 
substantial theoretical and practical problems remain: 
(i) the invasive nature of the procedure, which requires either a 
central venous or pulmonary artery catheter in addition to a femoral 
artery catheter, restricts its use to intensive care patients only. 
(ii) information derived from an individual measurement is 
non-dynamic and even if serial measurements were used, would give 
only an approximate guide to clinical progress. 
(iii) available data suggests that the extent of EVLW increase in 
ARDS is not predictive of outcome (108). 
(iv) the technique is highly perfusion dependent and this poses 
difficulties in critically ill AROS patients. This is because 
associated inhomogeneities in perfusion may theoretically result in 
underestimation of lung water, and additionally any small error in 
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transit time calculation would be magnified should cardiac output be 
high. 
(v) theoretically in early or mild lung injury transvascular water 
and solute flux may be increased, but observed EVLW will not reflect 
this until lymphatic clearance is overcome. This theoretical 
consideration appears to have practical basis since mild experimental 
lung injury, .induced with a low dose thiourea, results in increase in 
an index of microvascular permeability, but no increase in EVLW 
(109}. 
(vi) measurement of EVLW in an individual patient does not appear to 
discriminate totally between cardiogenic and permeability pulmonary 
oedema (107}. 
Other methods of assessing lung water. 
Soluble gas uptake. 
This is based on the Cander-Foster principle (110) that the 
concentration in lung gas (relative to their inspired concentration) 
of two inspired gases of different solubility depends on their 
solubility coefficient and tissue volume. Since the solubility 
coefficients of the insoluble (usually helium) and soluble 
(acetylene) are known, the tissue volume can be calculated. This 
technique does not however, differentiate between vascular and 
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extravascular compartments while tissue and water in non-ventilated 
areas of the lung cannot be detected. 
Measurement of extravascular lung density. 
Positron lung scanning provides tomographic images of the 
distribution of both vascular and extravascular lung density (111). 
Although non-invasive and non-traumatic, this technique because of 
the very sophisticated technology required, can only be used as a 
research tool in major centres. 
Transthoracic electrical impedance. 
The principle here is to measure the impedance of the lung and 
thoracic wall to alternating current. Severinghaus and co-workers 
-used specially modified electrodes to measure lung impedance-
independently of chest wall and mediastinal structures (112). The 
technique, however, appears poorly sensitive with an increase in lung 
water of over 50% required before a significant change in impedance 
was noted. 
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2.3.3.2 ---- Assesment of pulmonary microvascular and alveolar 
epithelial permeability characteristics. 
Pulmonary microvascular permeability techniques 
As discussed in Chapter 1, the advent of the Swan Ganz 
flow-directed catheter revolutionised the perception of ARDS 
pathogenesis. The original description by Ashbaugh and colleagues 
(23) is essentially a clinical description of.the syndrome although a 
prescient allusion to 11 alveolar instability 11 as a possible 
contributory factor was made. Separate descriptions in the early 
1970s of cases presenting with pulmonary oedema and normal _pulmonary 
capillary wedge pressures (113-115) resulted in the awareness that-
(i) acute respiratory distress and non-hydrostatic pulmonary oedema 
were part and parcel of the same clinical problem. 
(ii) since wedge pressures were normal, the likelihood was that 
pulmonary oedema resulted from an increase in microvascular 
permeability. This view was reinforced by the demonstration that 
oedema fluid protein concentration was generally over 0.7 of plasma 
protein concentration (19,113,114). 
Systematic clinical measurements of lung vascular permeability would 
represent a crucial advance in lung injury diagnosis and management, 
since it would allow direct assessment of an index of pulmonary 
capillary damage. The vast majority of vascular permeability 
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techniques measure protein permeability. This is logical since 
macromolecules both provide a meaningful index of capillary injury 
and also have important physiological implications. Clinical and 
experimental experience of methods of permeability measurement will 
be reviewed by reference to dynamic and· non-dynamic techniques. The 
latter, like indicator dilution lung water estimations, provide an 
index of content, while dynamic techniques measure flow. Staub has 
emphasised the insensitivity of content measurements in early 
pulmonary oedema (7); the theoretical basis for this is (as discussed 
earlier in the chapter) that fluid and solute flux may be increased 
in early or mild lung injury but content will not increased until the 
major inherent lung oedema defence mechanism, lymphatic clearance, is 
overcome. 
Non-dynamic techniques. 
The studies described here are all based on the finding of 
either increased protein concentration in pulmonary oedema fluid or 
increased clearance of an exogenous isotopically labelled protein 
into oed~ma or lavage fluid •. Sibbald and his group in Ontario, 
Canada, have concentrated on clearance studies using 
131 r-labelled albumin. They reported initially in 1979 that 
sepsis-associated pulmonary oedema patients with normal wedge 
pressures demonstrated 10 times the mean albumin clearance of 
patients with left ventricular failure (116). Subsequently they 
extended these observations to compare clearance into lavage fluid of 
labelled albumin with a small molecular weight chelate 
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(111 -InOTPA) in patients with cardiogenic and non-cardiogenic 
pulmonary oedema. The clearance of both molecular weight solutes was 
increased in the non-cardiogenic group, with the extent of clearance, 
particularly of labelled OTPA, showing a significant positive 
correlation with the net driving pressure (wedge pressure minus 
colloid oncotic pressure) (117). A further study from this group 
showed positive correlation in AROS between albumin clearance and 
indices of a hyperdynamic haemodynamic state (118). 
Potential criticism of the accuracy of these studies relates to 
the actual method of data acquisition. Since it is a clear.ance 
measurement, the calculation is based on -
Tracer concentrations in BAS 
X BAS volume 
Tracer concentrations in plasma 
where BAS = brochoalveolar secretions 
Secretions are aspi"rated by passing a catheter blindly 11 deep into the 
right and left bronchial trees ... Since the total volume aspirated, 
which inherently must be subject to many extraneous variables, is 
crucial to the clearance calculation, there is potential for 
subjectivity and inaccuracies. Additionally this clearqnce method may 
be measuring airway rather than microvascular tracer clearance. 
Sprung and co-workers compared total protein, albumin and 
globul_in concentrations in oedema fluid and plasma in patients with 
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cardiac and non-cardiac pulmonary oedema (119). Oedema fluid to 
plasma ratio for all three measurements was significantly greater in 
the non-cardiogenic group, but there was significant overlap between 
the groups. The authors concluded that the differentiation of 
cardiogenic from non-cardiogenic oedema was less important, than 
actually determining the degree of penneabi 1 ity. This concept of a 
spectrum of permeabflity change in pulmonary oedema is not only 
intellectually attractive, but it also avoids classifying cases on 
the basis of an arbitrarily chosen value of pulmonary capillary wedge 
pressure. Use of lung lavage studies to assess microvascular 
permeability is however problematical, in that changes in protein 
concentrations may reflect only faster or slower water clearance. 
Additionally, the data reflect not only microvascular permeability 
but also that of the alveolar, and to a varying extent, the airway 
epithelium. 
Dynamic techniques. 
Study of lung lymph. 
This is an excellent kinetic method for examination of lung fluid and 
protein balance which, because of its inherently invasive nature, is 
confined to experimental animals. As mentioned in Chapter 1, Drinker 
at Harvard was the first to popularise the technique but his 
cannulation of the right lymph duct was only suitable for acute 
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studies and was significantly contaminated by non-pulmonary sources. 
Staub and associates in San Francisco have subsequently modified the 
method so that it is now suitable for chronic studies with pure lung 
lymph obtainable from awake sheep for up to 4 weeks (120). The 
preparation involves detailed knowlege of sheep lymphatic anatomy and 
requires cannulation of an efferent of a large mediastinal lymph node 
which receives the majority of lung lymph. The procedure entails 
three separate thoracotomies at 3 to 5 day intervals with careful 
ligation of all systemic lymph contributions. Two major indices are 
routinely studied: 
(i) Lymph flow- increases in flow per se, could reflect either 
hydrostatic or permeability causation. 
(ii) Lymph to plasma protein (L:P) ratio is used to calculated 
transvascular protein clearance (flow x L:P protein ratio). Thus 
hydrostatic oedema is associated with increased flow but reduction in 
L:P protein ratio. In permeability oedema, although flow increases, 
the L:P ratio does not fall and, therefore, protein clearance 
increases. 
The preparation is eminently suitable for chronic studies with 
repeated interventions, and hitherto has been virtually the standard 
animal investigative tool for lung fluid and protein balance 
Studies. It has been pointed out that the preparation should be used 
with caution acutely, since baseline L:P ratios in this situation are 
higher than in chronic studies (121). This implies that the 
permeability of the microvasculature is greater in acutely prepared 
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animals, possibly because of the more immediate surgical trauma to 
the lungs. 
Scintigraphic techniques. 
~) Pulmonary microvascular permeability 
Gorin and co-workers were the first to describe a scintigraphic 
technique for kinetic measurement of transvascular protein flux in 
man (122). They used a two. compartment model in which the flux of a 
labelled protein from the intravascular pool (monitored with blood 
samples) into the lung (monitored with a scintillation probe 
detector) was examined. Flux into tha l~ng of labelled protein was 
calculated relative to an intravascular indicator, labelled red 
cells. They had previously shown that transvascular protein flux 
with this method correlated clc~ely with protein clearance into lymph 
in the sheep model (123). Although the mathematics for these flux 
measurements were relatively complex and no studies were performed in 
clinical lung injury, Gorin 1 s work did point to the validity and 
suitability of external radioflux techniques in clinical 
investigation. At approximately the same time, Prichard and 
colleagues published their data showing that a similar radioflux 
technique could be used successfully for vascular permeability 
assessment in the dog (124). 
Despite these innovative early studies, little work has 
subsequently been done to adapt these techniques for routine bedside 
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vascular permeability measurements. Computerised gamma scintigraphy 
was used to study in ARDS patients the flux of a single intravenously 
injected tracer (99mTc human serum albumin) from the 
intravascular pool into the lung, using the heart as the region of 
interest for the former (125). This was a small study with normal 
values derived from only 5 control studies and lack of an 
intravascular marker meant that any change in pulmonary blood volume 
was uncorrected for. These factors probably accounted for the wide 
variation in results in the ARDS patients studied - only 6 out of 11 
patients showing a significant protein leak. 
A more recent study 'in ARDS patients used a similar. approach to 
that described above, although a diffusible and intravascular 
radiotracer was used, thus correcting for any pulmonary blood volume 
change during the course of the study (126). All patients with ARDS 
demonstrated abnormal pulmonary transvascular protein leak, although 
as in the above study the normal range was derived from very few 
control studies. The major problem with this study however, was that 
only one scintillation detector was used. This detector was moved 
from lung to heart so that each region of interest was consecutively 
monitored. This meant that, not only were counts from the two· 
regions not assessed simultaneously, but that potentially a new 
region of lung interest was being studied ·with each counting period. 
The authors recognised this methodological problem and marked the 
skin in a 11 their studies. My unpub 1 i shed experience however, is 
that after any movement of a portable scintillation detector, it is 
virtually impossible to monitor counts again from the identical 
region of interest as previously. All results in the above study 
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(126) were based on only 15 to 20 data points and together with the 
above reservations would tend to invalidate the study's results and 
conclusions. 
Multiple indicator dilution technique. 
This technique is used almost exclusively by Brigham's group at 
Vanderbilt University in Nashville, USA (127). ·Two intravascular 
indicators, labelled red cells and labelled albumin, together with 
two diffusible indicators, triated water and 14curea, are 
injected into a central vein. Indicator curves are constructed as 
discussed in the lung water section, although the intravascular curve 
here is a composite of both intravascular tracer curves. The 
permeability:surface area product for urea is derived by complex 
mathematical manipulation of all four indicator curves. Further 
disadvantages of this technique are the multiple radiotr-acers 
required, the numerous blood samples and the invasive procedures 
necessary. An advantage of this technique over the others discussed, 
is that it alone provides an index of both vascular permeability and 
exchanging vessel surface area. 
£) Alveolar epithelial permeability technique. 
Clinical and experimental interest in solute exchange across 
pulmonary epithelium has grown considerably over the last 10 years. 
The rationale for the study of alveolar epithelial permeability 
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characteristics arises particularly from the awareness that it, 
rather than vascular endothelium, is the rate limiting step to solute 
exchange across the alveolar capillary barrier. Taylor and Gaar 
showed that the reflection coefficient for a solute depended on its 
molecular radius and tended to decrease as the molecular radius 
decreased (128). For any given molecular radius the~ alveolar 
epithelium had a reflection coefficient vastly greater· than the 
endothelium. Staub, reviewing the published data, suggested that over 
the range of molecular weight solutes that hitherto_had been studied, 
the permeabi 1 ity of the endothelium was at least. ten times that of 
the epithelium (7). Thus on theoretical grounds,. the permeability 
characteristics ·of the alveolar epithelium should reflect the 
permeability of the whole alveolar-capillary barrier·, especially if 
the transport of a solute from the alveolar to vascurar space~ (thus 
including the resistance of the endothelial layer) was:: studied. 
Based on the above considerations, a technique has been 
introduced over the last 10 years which enables· measurement of an 
index of alveoar permeability to be made routinely in humans. The 
key .initial work was performed virtually simultaneously in three 
centres: Los Angeles (UCLA), San Francisco (Cardiovascular Research 
Institute) and London (Northwick Park Clinical R·esearch Centre). It 
involves measurement of the lung to blood clearance of· an aerosolised 
low molecular weight, inert· and neutral hy.droph i 1 i c so 1 ute, 
diethylene triamine pentacetate (DTPA). This. chelate is usually 
labelled with 99mTc and is aerosolised with partjcle size 
modified to ensure predominant deposition on peripheral non-ciliated 
epithelium.· Since the technique employed in this thesis is a 
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modification of this method, the detailed methodology will be 
outlined in the next chapter. Previous clinical and research 
experience with this technique will be discussed in Chapter 4. 
CHAPTER 3 




3. PULMONARY MICROVASCULAR AND ALVEOLAR EPITHELIAL PERMABILITY INDICES: 
METHODOLOGY 
3.1. -Pulmonary microvascular permeability index. 
This was determined by assessing the dynamic accumulation in the 
extravascular tissues of the lung of an is~topically labelled, 
intravenously injected protein, transferrin. The technique 
represents a modification of that initially described by Gorin and 
colleagues (122) and more recently by Dauber and his co-workers 
(109). 
Like these studies, the method described here is based on 
external counting of two intravenously introduced isotopes and a 
simple two compartment model of the lung. The rationale is discussed 
in some detail in section 3.1.2 but will be briefly summarised here: 
The flux of intravascular labelled transferrin into the extravascular 
compartment is dependent on the concentration gradient and the 
permeability characteristics of the pulmonary microvasculature. 
Scintillation detectors over the lung and heart detect activity due 
to 113mrn-transferrin. Since the lung probe is ''seeing'' both 
intra and extravascular protein, dividing its counts by the blood 
pool counts (from the heart probe) allows correction for the 
intravascular component of the lung probe counts. Subsequent 





over time must therefore represent either increases in iung 
extravascular protein or lung intravascular blood volume. Chan~es due 
only to alterations in pulmonary blood volume are corrected for by 
simultaneously monitoring 99mTc labelled red cells in an 
identical fashion. An increase in the corrected ratio 
lung/heart labelled protein 
lung/heart red cells 
over time can therefore be due only to an increase in lung 
extravascular protein accumulation. This method has advantages over 
conventional lung lavage estimations of pulmonary vascular 
permeability since it is non-invasive, provides dynamic information 
and is independent of alveolar epithelial permeability. Additionally, 
it provides a true index of macromolecular transvascular flux, while 
the lung lavage protein concentration may reflect only changes in 
lung water clearance, as discussed. 
l·l·l· - Radiopharmaceuticals. 
Red cell labelling. 
Subjects were pretreated with 0.03 ml/Kg of Stannous agent (4.0 mg 
stannous fluoride, 6.8 mg sodium medronate, Amersham International, 
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Amersham, UK) intravenously which had been reconstituted with 6 ml of 
normal saline. When erythrocytes are preloaded with stannous ion, 
the 99mTc when subsequently injected is reduced, and becomes 
tightly bound to the beta chains of globin (129). When red cells are 
not preloaded with stannous ion, pertechnetate can diffuse freely 
into and out of the erythrocyte. Twenty minutes after injection of 
Stannous agent, a 10 ml sample of heparinised blood was drawn from a 
central venous line in patients, and from a 21 gauge forearm 
butterfly needle in control subjects. Using sterile solutions and 
containers, the heparinised blood was centrifuged and the supernatant 
plasma discarded. After washing the packed red cells in saline, they 
were incubated in vitro at room temperature with approximately 
millicurie ( mCi) of 99mTc for five minutes. The labelled cells 
were then again washed in saline prior to the suspension being made 
up to 10 ml with normal saline. These labelled· cells were then 
injected intravenously and used as the blood pool marker. Repeated 
estimation showed red cells binding efficiency using this method to 
be consistently greater than 95%. 
Labelling of transferrin with 113mindium. 
Together with the autologous labelled red cells approximately 1 
mCi of 113min (half-life 100 minutes) was injected 
intravenously. The 113min was obtained from a commercially 
available generator (Amersham International, Amersham, UK) in which 
the Indium is formed by isomeric transition from the long half-life 
(118 days) parent radionuclide 113mTin (Sn). ·The formed 
113min is then eluted as the hydrochloride by the injection into 
the generator of 6 ml of 0.04 molar hydrochloric acid. 
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In vivo Indium binds to the beta globulin transferrin (molecular 
weight 76,000) (130). The specificity of this binding to plasma 
transferrin was verified in the following experiment: 
Thirty minutes after injection of 113min, 10 ml of heparinised 
blood was drawn and the plasma separated. This plasma was then 
ultrafiltrated (Micropartition system, Amicon, Gloucester, UK) with 
the intention of separating protein bound from free 113min. This 
is performed by convective filtration of free radiotracer through a 
hydrophilic ultrafiltration membrane with the driving force for 
filtration provided by centrifugation at 2,000 g. Plasma components 
(including 113min bound transferrin) larger than the membrane 
pores are retained above the membrane while ultrafiltrate containing 
free radiotracer collects below in the filtrate cup. This system 
normally results in retention of more than 99.9% of serum protein. 
By counting radioactivity in the filtrate cup as a percentage of the 
total radioactivity in the plasma subjected to ultrafiltration, an 
index of 113min binding to macromolecular protein was derived. 
Five separate experiments showed binding of the tracer to protein was 
never less than 97%. An additional experiment was performed to 
confirm that the 113min was bound exclusively to transferrin 
rather than any other plasma prqtein. Plasma was electrophoresed on 
acrylamide gel; subsequently the gel was sliced and the components 
counted in a gamma scintillation well counter. This confirmed that 
113min was bound e~clusively to a protein whose electrophoretic 
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mobility was consistent with the known molecular weight of 
transferrin. 
3.1.2. - Special instrumentation. 
Fifteen minutes after the injection was allowed for isotopic 
equilibration. Scintillation detectors were then placed over the lung 
(right upper zone) and heart (as a measure of blood pool activity). 
The lung detector was placed in the same position in all human 
studies irrespective of the relative distribution of radiological 
abnormalities in the ARDS patients studied. The centre of the probe 
was placed anteriorly, just lateral to the mid-clavicular line at the 
level of the third interspace. The position of the heart detector 
was optimised by placing it where counts from 99mTc labelled red 
blood cells were maximal. Each detector comprised a 5.1 em x 5.1 em 
sodium iodide crystal (NE 5545, Nuclear Enterprises, Edinburgh, UK) 
fitted with a flat field collimator. Included in the scintillation 
detector is a photomultiplier tube whose basic function is to convert 
the light energy into electrical energy. The magnitude of the 
photomultiplier tube output is proportional to the energy of the 
incident gamma ray photon with a mono-energetic beam incident on a 
sodium iodide crystal producing a main photopeak and a broader 
scatter band (the Compton scatter) (131). The signal output from the 
probes was processed by the spectrometer (NE 4697, Nuclear 
Enterprises, Edinburgh, UK) which was specially modified to include 
two pulse height analysers and two ratemeters. The pulse height 
analyser looks at the frequency distribution of the pulse amplitude 
----------~~-------------~~--~- -·~-~~ 
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and selects the part of the photo-electric spectrum to be counted, 
while the ratemeter counts the pulses fed to it by the pulse height 
analyser. Having a second pulse height analyser and ratemeter 
enables two radioisotopes of different energy peaks (99mTc = 0.14 
MeV; 113min = 0.392 MeV) from each scintillation detector to be 
assessed simultaneously. 
The output of the ratemeter was interfaced with a dedicated 
mini-computer (Dragon 64, Compusense Ltd, London, UK) which 
facilitated display and recording of data. The computer was 
programmed see Appendix 2) to define the time period over which 
scintillations were to be counted. Counting was continuous except 
for 1 second breaks between counting periods. Thus for each counting 
period, counts were obtained for activity due to both 99mTc and 
113min from both the lung and heart detectors. In all studies 
counts were recorded for at least 30 minutes. Initially the 
background in the room was subtracted and a correction factor for the 
Compton scatter effect of the higher energy 113min on 99mTc 
was derived, and applied to subsequent 99mTc counts. For each 
counting period the computer calculated (see Appendix 2) a lung to 
heart ratio for 113min transferrin and to correct for any dynamic 
changes in pulmonary blood volume that value (for transferrin) was 
divided by the lung heart ratio for labelled red cells. The rate of 
change of this corrected lung heart labelled transferrin ratio was 
used as the dynamic index of pulmonary transvascular protein leak. 
To reiterate, the rationale for the above is as follows: at the 
time of injection of both radioisotopes, all radioactivity is 
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intravascular and, therefore, the radioactivity the lung probe is 
11 Seeing 11 at that point is an indicator only of the blood volume in 
the field of the probe. Additionally it is influenced by physical 
factors which may affect the relationship of true counts to external 
counts, i.e. chest wall geometry, tissue penetrance of isotope, the 
contribution of the chest wall and the counting efficiency of the 
detector system. To the extent that all red cells remain 
intravascular and the physical factors remain constant, subsequent 
changes in red cell counts could be due to changes in activity of the 
blood or changes in blood volume under the lung probe. Since the 
intravascular activity is being constantly monitored by the heart 
probe, changes in the external lung probe 99mTc red cell signal 
relative to the heart probe are due to changes in blood volume. 
Similarly for labelled protein, changes in the lung to heart ratio 
could be due either to changes in blood volume or extravascular 
movement of protein. Since changes in blood volume are known from the 
respective red cell ratio, any changes over time in the corrected 
ratio reflect transvascular protein flux. 
Corrected ratio = 113mrn lung counts I 99mTc lung counts 
-------------------- I --------------------
113mrn heart counts I 99mTc heart counts 
The rate of change of this corrected ratio was quantitated by 
plotting the individual points versus time and drawing a 
computer-fitted linear regression line. The slope of this line, 
derived from the linear regression equation, was used as an index of 
·lung transvascular protein leak. Extrapolating the line back to time 
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0, allow calculation of theY intercept of the regression line. The 
rate of increase in the corrected lung to heart ratio of 
113min-transferrin (the slope) was divided by this intercept to 
correct for the physical factors involved in external measurement of 
gamma counts. This correction was introduced by Dauber and 
colleagues (109) and is an elegant method of dealing with the only 
remaining uncorrected variable. Since at time 0 there is no 
extravascular labelled transferrin, the ratio at this time point 
reflects only how the physical factors have altered the intravascular 
volume within the probe field. Dividing the slope by. the intercept 
in each experiment, corrects for phys i ca 1 factors differing between 
experiments. This quotient was used as the index of vascular 
permeability and expressed a protein flux units (x10-3/min). A 
representative· study is shown in Figure 1. 
This method differs from that described by Dauber (109) and 
earlier Gorin (122) who both used blood sampling instead of probe 
counts over the heart as their measure of intravascular isotope 
activity. In three studies, the heart probe was compared with blood 
samples taken every five minutes to assess the comparability of 
monitoring isotope activity with both methods. A 2 ml blood sample 
was drawn on each occasion, the haematocrit determined and the sample 
weighed. The 99mTc and 113min activity of each sample was 
then measured in a well counter and corrected for haematocrit and 
weight. The corrected lung to blood pool ratio versus time was then 
computed using both methods. The results obtained indicated that the 
heart probe was a reliable indicator of the intravascular pool and 
consequently this method was continued in all studies. Its advantage 
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is that it does not required repeated blood sampling and analysis and 
in addition gives a continuous assessment of intravascular activity. 
Since ratios are being determined, there is no requirement to correct 
values for radioactive decay as each isotope is decaying at an 
equivalent rate in the fields of both detectors. 
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l·l.- Alveolar epithelial permeability index: pulmonary clearance of 
99mTc-DTPA. 
An index of alveolar epithelial permeability was deri~ed from 
the lung to blood clearance of the stable hydrophilic chelate, 
diethylene triamine pentace~ate (DTPA). Its molecular size and radius 
are approximately 500 daltons and 0.57 nm respectively (132). It wa·s 
labelled with the gamma ~mitting isotope 99mTc, as discussed in 
chapter 2. Since DTPA diffuses slowly across intact alveolar 
epithelium, and· this accounts for well over 90% of the resistance to 
its paracellular transport, accelerated clearance of DTPA into the 
blood suggests that the permeability of the epithelium is increased 
(132). Factors other than the integrity of the alveolar epithel~um 
may theoretically influence DTPA clearance pulmonary blood flow, 
lymphatic drainage or mucociliary clearance could conceivably affect 
tracer clearance. The molecular.weight of DTPA and it's hydrophilic 
character does however, suggest that clearance is largely diffusion, 
rather than perfusion dependent (133). This has been borne out in an 
experimental study by Rizk and co-workers who showed that clearance 
of DTPA was not affected by changes in pulmonary blood flow, unless 
the pulmonary artery to the relevant lobe was obstructed completely 
(134). Lymphatic dra1naye does not dp!Jear to play a siynificant role 
because DTPA diffuses readily through lymphatic walls (135). 
Mucociliary clearance could be important, but this process is too 
slow to account for overall DTPA clearance (136), and certainly could 
not affect alveolar clearance. 
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Clearance of DTPA was measured largely as previously described 
(137), but because of modifications, the method will be outlined in 
detail here. A 4 ml solution of 99mTcDTPA (1 mCi per ml) in 
normal saline was nebulised (airflow 8 litres/minute) using a 
commercially available Acorn device, shielded in a lead pot. Since 
the technique•s aim was to measure alveolar rather than airway 
permeability, it was crucial to ensure that the vast majority of 
particles were appropriately deposited. The Acorn nebuliser alone 
produces particles with a mass median aerodynamic diameter (MMAD) of 
3.8 micrometers (138) and at this MMAD there will be significant 
airway deposition (139), particularly in patients with chronic 
airflow obstruction (140). To ensure maximal alveolar region and 
minimal tracheobronchial deposition, particles should have 
aerodynamic diameters in the range 0.5 to 2.0 microns (141). A 
modification to the Acorn nebuliser has been developed by Royston and 
colleagues which ensures aqueous particles with ·an MMAD of 0.44 
microns (141). Using this particular system, only 6% of all 
particles are above 2 microns in aerodynamic diameter. With this 
particle size, the DTPA aerosol will be deposited in the alveoli and 
distal conducting airways - large airway labelling is not observed 
(137). Because the surface area of the respiratory tract increases 
immensely distal to the terminal bronchioles, alveolar and 
respiratory bronchiolar deposition will predominate, even if a small 
amount of tracer solute is deposited on small conducting airways. 
The separator, consisting of a tube with 2 em inner diameter 
partially filled with 3 mm ball bearings attached to the outlet of 
the nebuliser, is now commercially available (CIS Ltd, London, UK) 
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and was utilised in this study. The output from the nebuliser and 
separator is passed into a 2 litre reservoir bag with a one way valve 
distal to the bag. The bag and one way valve allows subjects to 
breathe at their own rate and tidal volume. In subjects breathing 
spontaneously the nose was occluded and each subject inhaled the 
aerosol for 2-3 minutes until 20,000 to 30,000 counts per minute were 
recorded over the chest. In intubated patients being ventilated, the 
radioactivity was introduced by manual ventilation using a 
non-rebreathing system. 
Two scintillation detectors identical to those described earlier 
were placed over the right anterior chest (same positi9n as in 
protein flux study, in patients or volunteers having both studies). 
and right thigh. Once sufficient counts had been achieved, the 
breathing circuit and aerosol generator were removed from the 
vicinity ·of the detectors. With the subject resting supine, counts 
were monitored for 40 second periods of each minute. With time, the 
counts over the lung fell as the radiotracer particles were cleared 
into the blood. Accumulation in blood and tissue was verified by 
gradually increasing counts from the field detected by the thigh 
detector. All data was plotted on a semilogarithmic scale versus 
time (see Figure 2), once corrected for background activity in the 
room. When the chest counts had fallen to approximately 50% of their 
initial value, a bolus o~ 99mTcDTPA (approx. 100 uCi) was 
injected intravenously and counted continued for a further 10 to 15 
minutes. The purpose of this intravenous injection was to correct 
for 99mTcDTPA accumulating intravascularly and in the chest wall 
in the field of the lung probe. This produces a curvilinear 
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disappearance curve to the plotted chest probe counts (see Figure 
2). The intravenously introduced isotope is distributed in the 
fields seen by both probes producing a step-wise increase in counts 
in the two regions. Once both curves have equilibrated and 
stablised, they are extrapolated backwards to the moment of injection 
and a correction factor (increase in lung counts/increase in thigh 
counts) derived. All thigh counts are then multiplied by the 
correction factor and subtracted from the chest count to produce a 
lung clearance curve corrected for blood and tissue background (see 
Figure 2). Thus: 
Corrected chest count = chest count - (correction factor X thigh 
count) 
The rationale of the correction factor manoeuvre is that it attempts 
to relate accumulation of isotope in blood and tissue of the thigh to 
similar accumulation (due to recirculation) in the field of the chest 
probe. The product of the correction factor itself (based on 
relative accumulation of intravenous isotope in the counting fields) 
and the thigh count is then an estimation of the blood and tissue 
radioactivity in the field of the chest probe. The corrected 
clearance curve thus loses ·its c.u.rvilinearity and is normally 
mono-exponential. 
What are the relative advantages and disadvantages of using 
scintillation detectors, rather than a gamma camera, to assess DTPA 
clearance. The most important disadvantage is the lack of regional 
information; although clearance is increased apically compared to the 
bases (143), assessment of a region of interest in the upper lobe (as 
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performed in this thesis) does appear to give reliable data, since 
increased clearance is reflected in all zones (143). Jefferies and 
associates compared a portable scintillation detector with a gamma 
camera (144). They showed that results with both methods correlated 
closely, thus establishing the probe as a valid method of assessing 
alveolar epithelial permeability, providing regional information is 
not specifically required. 
Pulmonary 99mTcDTPA clearance is expressed either as the 
half time of clearance, i.e. the time taken for the corrected initial 
lung counts to halve, or.as the rate constant (per cent per minute) 
of corrected disappearance. This rata constant K is derived from the 
half time by the use of the following formula: 
half-time of clearance 
The relationship between these two parameters of DTPA clearance is 
described in figure 3. The values themselves are derived from a 
linear regression line fitted to the semilogarithmic plot of the 
corrected curve. In this thesis, all DTPA data has been calculated 
with a specially written computer programme (see Appendix 1) used on 
an Apple II mini-computer (Apple Computer Inc, California, USA). In 
the studies to be described in this thesis, either the half-time or 
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42 
A representative protein flux study in a patient with severe ARDS. The 
lung: heart ratio for 99mTc labelled red. cells is essentially 
unchanged over the period of study. In contrast, a similar ratio for 
113mrn-transferrin gradually rises. The uppermost slope represents 
the corrected data; the linear regression. equati~~ is y = 1.01 + 0.0096 
x 1 (r=0.94). Therefore the calculated protein flux index, allowing ·for 
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A representatiye OTPA clearance study showing the curvilinear appearance 
to the uncorrected data (open circles). The use of the intravenous 
injection of. 99mTcDTPA to yield a correction factor for blood and 
tissue background is illustrated (see· text). The half time or rate 
constant of disappearanc~ of the corrected (filled circles} data is used· 
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A diagram to illustrate the relationship between the 2 methods of 
expressing DTPA clearance, both of which are used in this thesis. As the 
half-time falls clearance and therefore, by implication, epithelial 
permeability increases; the contrary is obviously true for the rate 
constant, K. The figure 0.693 is used as it is the loge2. 
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CHAPTER 4 
CLINICAL VALIDATION: ASSESSMENT OF LUNG PERMEABILITY INDICES IN PATIENTS ---
WITH ESTABLISHED ADULT RESPIRATORY DISTRESS SYNDROME. 
' ) 
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4. CLINICAL VALIDATION: ASSESSMENT OF LUNG PERMEABILITY INDICES IN PATIENTS 
WITH ESTABLISHED ADULT RESPIRATORY DISTRESS SYNDROME. 
4.1 - Introduction. 
This initial study sought to examine and compare the specificity 
and sensitivity of the indices of pulmonary microvascular and 
epithelial permeability which were described in the previous chapter. 
Of the two techniques, pulmonary clearance of inhaled, aerosol ;·sed 
99mTcDTPA (an index of epithelial permeability) has received by 
far the more attention both clinically and experimentally, in recent 
years. Although increased clearance of this tracer solute has been 
documented in a number of clinical situations, few studies have 
addressed the specificity of the technique in the assessment of 
patients with acute lung injury. 
The sensitivity of the pulmonary 99mTcDTPA technique has been 
appreciated virtually from the outset,· with the observation that 
otherwise · normal smokers demonstrate markedly increased rates of 
solute clearance. This observation was made initially by Jones and 
co-workers in London (145) and later confirmed by Mason and associates 
in Los Angeles (146). Both groups demonstrated 3 to 4 fold increased 
rates of solute clearance from the lungs of smokers compared to 
non-smokers, with rapid return towards the normal range 14 days after 
cessation of smoking (146,147). This finding was felt to represent 
subclinical respiratory or membranous bronchiolitis, especially since 
these airways are known to be susceptible to inflammation in smokers 
(148,149). It was not attributed to alveolar or major airway injury as 
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respectively, the alveoli do not show inflammatory change in young 
smokers (148) and both studies excluded airway deposition of tracer 
solute by scintigraphic studies (145,146). 
Further studies have shown increased pulmonary DTPA clearance in 
patients with systemic. sclerosis and pulmonary involvement (150), 
chronic interstitial lung disease, including cryptogenic fibrosing 
alveolitis, sarcoidosis and various occupational lung diseases (151), 
and more recently in neonatal hyaline membrane disease (152). Only 
one study hitherto however, has assessed the technique clinically in 
patients with cardiogenic and permeability pulmonary oedema (143). 
These workers showed that in all but 3 of 14 patients with 
non-cardiogenic pulmonary oedema (NCPO) studied, clearance rates of 
DTPA was increased above the 99% confidence limits derived from normal 
non-smokers. Patients with cardiogenic pulmonary oedema did not show 
significantly increased clearance rates compared to normals. The data 
in this study is unfortunately difficult to interpret as 10 of the 14 
patients with NCPO had a recent smoking history. In these patients an 
interval of 3 days to 3 weeks was documented between cessation of 
smoking and the study .. Although the increased clearance in smokers is 
reversible after cessation, as discussed above, complete 
normalisation, although usually rapid, can occasionally take up to 3 
months (146).. Thus the increased clearance demonstrated in the NCPO 
group was undoubtedly contributed to by the patient•s known smoking 
history. There is additional difficulty in differentiating the 
clearance in the 2 groups as only one of the patients with cardiogenic 
pulmonary oedema had smoked in. the six months prior to study. 
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An experimental study has however, pointed to the technique's 
specificity with the demonstration that dogs with elevated left atrial 
pressure had clearance rate constants for 99mTcDPTA similar to 
control dogs. Those animals who had lung injury induced with oleic or 
hydrochloric acid had clearances significantly greater than both the 
above mentioned groups (153). Notwithstanding this experimental data, 
clinically no study has assessed in a valid fashion the specificity of 
this technique in permeability pulmonary oedema. 
Even if pulmonary clearance of the tracer solute is truly 
increased in acute lung injury, it is imperative to compare the extent 
of this accele.rated clearance with that found in. otherwise normal 
smokers. This comparison, which has not previously been made, is 
crucial to the assessment of whether increased clearance in a known 
smoker with lung injury reveals anything about the acute pulmonary 
disease process. This study compared, therefore, the rate of 
clearance of inhaled aerosolised 99mTcOTPA in patients with 
established ARDS with that found in otherwise normal smokers. 
Previous clinical experience (125,126) with pulmonary 
microvascular permeability assessment was discussed in Chapter 2. As 
was mentioned, the data was both sparse and open to methodological 
criticism. The technique employed in this thesis overcomes the 
methodological shortcomings with continuous assessment of both lung 
and intravascular labelled protein and red cell isotopic activity. 
Additionally, previous studies did not define the potential role of 
smoking in modulating pulmonary microvascular permeability. This is 
potentially important, since a lung lavage study has shown increased 
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IgG IgA ratios in smokers compared to non-smokers (154). This 
finding implies possible transvascular leak of lgG in smokers, 
suggesting increased microvascular permeability. The relevance of 
this finding is however, uncertain as the contribution of local airway 
IgG synthesis and the amounts of airway versus alveolar spaces lavaged 
are both unkown. Despite these reservations, in order to clearly 
establ'ish the specificity of the technique further, the extravascular 
accumulation of labelled transferrin was assessed in both smokers and 
non-smokers, together with ARDS patients. This study represented the 
first attempt clinically to define the relationship, if any, in 
injured lungs between techniques which assessed the barrier function 
of both components of the alveolar-capillary barrier. This was of 
particular interest, since morphologists have noted in AROS 
disproportionate destruction of the alveolar squamous epithelium 
compared to the relatively intact capillary endothelium (155). 
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4.2 - Methods 
Subjects. 
The diagnosis of ARDS was based on the fulfillment of the 
following criteria: 
1) Sudden onset of acute respiratory failure requiring mechanical 
ventilation. 
2) Diffuse airspace infiltrates on chest radiograph. 
3) Evidence of severe gas exchange deficit with the ratio of arterial 
to alveolar partial pressure of oxygen less than 0.25. The alveolar 
P02 was derived from the simplified form of the alveolar gas 
equation: 
R 
PI02 is the partial pressure of inspired oxygen. This was derived 
from the known fraction of inspired oxygen and the barometric air 
pressure by use of the following formula: 
PI02 = the fraction of inspired oxygen x (barometric 
pressure -47) 
PAC0 2, the partial pressure of alveolar co2, was assumed to be 
equal to the arterial PC02• 
The value of 0.8 was used for R, the respiratory exchange ratio. 
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The arterial to alveolar tension ratio is more stable an index of gas 
exchange function than the alveolar minus arterial oxygen difference 
(A:a gradient) with changing values of inspired oxygen concentration 
(156). Thus it was felt more valid to use this former index when 
attempting to set a single standard for patients being ventilated with 
different fractions of inspired oxygen. 
4) Total thoracic compliance less than 35 ml/cmH2o. This measures 
the static compliance of the total respiratory system·by dividing the 
delivered tidal volume by the inspiratory plateau pressure. The 
latter is obtained by temporary occlusion of expiratory flow at the 
height of inspiration. This provides an index of elastic recoil 
pressure (157). 
5) Pulmonary capillary wedge pressure less than 16 mmHg or central 
venous pressure (from the mid axillary line) of less than 6 
cmH2o. 
Clinical details of the 14 non-smoking AROS patients studied 
consecutively are summarised in Table 1. Aetiological predisposing 
factors were as follows: 
Bone marrow transplantation (n = 6) 
Cardiopulmonary bypass (n = 2; patient 7 had associcated 
Staphylococcal septicaemia) 
Gram-negative septicaemia with renal failure (n = 1) 
Blood transfusion of more than 100 units in association with 3 
laparotomies (n = 1 ). 
Post-operative aspiration (n = 1) 
Acute fibrosing alveolitis (desquamative interstitial pneumonia or 
Hamman-Rich) (n = 1 ). 
Acute pancreatitis (n = 1) 
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Fulminant hepatic failure with clinical 
intracranial pressure (n = 1) 
features of raised 
All patients were studied as soon as possible after syndrome criteria 
were fulfilled. In all cases studies were performed within 24 hours 
of initiation of assisted positive pressure ventilation. Ten smoking 
and 10 non-smoking volunteers (respective age ranges 23-58 and 22-64 
years) were studied as control groups. All were healthy and none had 
a recent history of upper respiratory tract infection or medication 
use. The study was approved by the hospital Ethical Committee and 
subjects or their next of kin gave informed consent. 
Radionuclide techniques. 
The pulmonary clearance of 99mTcDTPA and the pulmonary 
transvascular flux of 113mrn-transferrin were performed as 
outlined in Chapter 3. The salient features, including any 
particularly modifications introduced will be briefly reiterated. All 
patients and volunteers were studied in the supine position. -All ARDS 
patients were being mechanically ventilated at the time of study and 
in 4 patients greater than 6 cmH2o positive end-expiratory 
pressure was being applied (maximum 10 em). Studies were performed 
consecutively; the DTPA clearance was measured initially and the 
transferrin flux study started within 30 minutes of its completion. 
This order of study was chosen as 99mTc which was used to label 
DTPA has a lower energy than 113mrn. 
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Pulmonary DTPA clearance. 
The DTPA aerosol was generated with a nebuliser equipped with a 
specially developed particle separator as previously described (142). 
In subjects breathing spontaneously, the nose was occluded and the 
aerosol inhaled for 2-3 minutes until approximately 30,000 
counts/minute were recorded in the field of the chest probe detector. 
In all of the ARDS patients radioactivity was introduced by manual 
ventilation using a non-rebreathing system. Radioactivity was 
countered with 2 scintillation detectors placed over the right 
anterior chest and right thigh. An intravenous dose of 99mTcDTPA 
was used for correction of blood and tissue background as previously 
described. The decrease in corrected lung counts was plotted 
semilogarithmically versus time. A regression line was fitted by 
computer, using the specially written computer programme previously 
described {for full details see appendix). From this the clearance 
rate constant K (per cent decline in corrected lung activity per 
minute) was derived. 
Transvascular protein flux. 
For this study, scintillation detectors were placed over the lung 
(right upper zone) and heart (to reflect blood pool activity). The 
position of the lung probe was uniform in all studies irrespective of 
the relative distribution of radiological abnormalities. The probe 
was centred anteriorly just lateral to the midclavicular line in the 
3rd right intercostal space. The heart detector was placed in 
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accordance with its known surface anatomy and the position then 
optimised by fine movements which maximised counts due to labelled red 
blood cells. Autologous red cells were labelled in vitro with 1mCi 
99mTc as discussed in Chapter 3. Counts due to labelled red cells 
were in all cases at least 10 times those due to residual 99mTc 
counts from the 99mTcOTPA study. Accordingly 99mTc counts from 
the latter source were ignored in the study. After injection of 1mCi 
of 113min, the effect of Compton scatter on- 99mTc counts was 
noted and a correction factor derived which was applied to subsequent 
ggmTc counts. After 15 minutes to allow for isotope equilibration, 
counts due to both 99mTc and 113m1n were monitored 
continuously from both scintillation det~ctors for at least 30 
minutes. 
The 113mrn-protein lung:heart ratio for each minute was 
computed as was a similar ratio for 99mTc labelled red cells. 
This latter ratio allowed for any dynamic changes in pulmonary blood 
volume over the course of the study. The rate of change of the 
corrected lung:heart 113min~transferrin ratio quantitated by 
plotting the individual points versus time and computing the linear 
regression equation. The linear regression equation-derived slope was 
divided by. the Y intercept at time 0 to correct for differences in 
physical factors between studies, as discussed in Chapter 3. This 
quotient was used as the index of vascular permeability and expressed 
as protein flux units (x 10-3/minute). Since data acquisition was 
continuous, the linear regression equation was derived from at least 
100 data points. This greater density of data allowed statistically 
reliable slopes to be derived in shorter periods of study than 
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reported by Dauber and colleagues (109). 
Statistics. 
For the DTPA clearance study, the 3 groups were analysed by one 
way analysis of variance and unpaired t tests on logarithmically 
transformed data. Transferrin flux was compared using the Mann-Whitney 
U test because of the larger variances. A p value less than 0.05 was 
deemed significant. All results are expressed as mean ± standard error 
of the mean. 
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4.3- Results 
The population of AROS patients studied consisted of 9 men and 5 
women with an overall mean age of 40 ± 5.4 years. The disease 
processes precipitating alveolar-capillary injury (Table 1) reflect 
the special interests at the Hammersmith Hospital which has an active 
bone marrow transplantation programme. One patient (no 14) was 
studied at Kings College Hospital (London) -the equipment and study 
protocol was identical to that of the other patients. Values for both 
permeability indices in the 14 AROS patients are outlined in Table 2, 
along with relevant physiological and haemodynamic information. The 
physiological characteristics of the patients studied were determined 
within an hour of study and reflect in all cases severe AROS. 
Indivjdual data for pulmonary clearance of 99mTcOTPA in the 
three study groups are represented in Fig.4. The linear correlation 
coefficient of the corrected DTPA clearance data plotted against time, 
from which the rate constant of clearance is derived, ranged between 
-0.96 and -1.0 in the 34 DTPA clearance studies performed. The rate 
constant K for DTPA clearance in normal non-smokers was 1.12 ± 0.1. 
This differed significantly from both smokers (4.40 ± 0.8) and ARDS 
patients (5.71 ± 1.0), p < 0.001. All 14 ARDS patients had rate 
constants for DTPA clearance that were greater than the 95% confidence 
limits (upper limit 1.7) derived from 10 normal non-smokers. Although 
the mean rate constant of clearance in the ARDS group was higher than 
that found in smokers, this did not reach statistical significance (p 
= 0.31). 
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Transvascular protein flux data in the 3 groups is shown in 
Fig.5. Unlike the DTPA data, no significant difference existed 
between the smokers (0.36 ± 0.1 protein flux units) and non-smokers 
(0.31 ± 0.1) and therefore their data was combined to form 1 control 
group (0.33 ± 0.1, n = 20). Results in this control group differed 
significantly from that of the 14 ARDS patients (3.70 ± 1.0, p < 
0.005). Within the ARDS group, there was significant Spearman•s rank 
correlation between the index of protein flux and rate constant for 
DTPA clearance in each individual patient (rs = 0.77, p < 0.01) 
(Fig. 6). Unlike the data for DTPA clearance, 3 of the ARDS group had 
values for the protein flux study that were within the 95% confidence 
limits established in the combined control group. Failure to detect 
increased protein flux did not imply a more favourably prognosis as 
none of these 3 patients survived. 
As outlined in Chapter 3 and in the methods section of this 
Chapter, the value for transvascular protein flux upon which these 
statistics are based, is derived from the slope of the corrected 
113mrn-transferrin lung:heart ratio (plotted versus time) and the 
intercept of this line. Both of these values are in turn derived from 
the computed linear regression equation. The linear correlation 
coefficients for the plots of the corrected lung:heart ratios versus 
time in those patients with positive results outside the control value 
99% confidence limits ranged from 0.50 to 0.94 (mean r = 0.74). These 
regression lines were in all cases statistically significant. 
Only 3 out of 14 patients studied (patients 7, 8 and 13) 
recovered from respiratory failure, and 1 of these died during the 
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same admission from an unrelated cause (patient 7). Autopsies were 
performed in 7 cases. Six showed diffuse alveolar damage but in 1 
case (patient 10) the features were consistent with desquamative 
interstitial pneumonia. 
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4.4 - Discussion 
The key features arising from the study are as follows: 
1) Pulmonary clearance of the aerosolised solute 99mTcDTPA is 
increased similarly in otherwise healthy smokers and critically ill 
ventilated patients with ARDS. 
2) Increased transvascular protein flux was demonstrated in the ARDS 
group but this was not, unlike increased DTPA clearance, an invariable 
finding. Three patients with classical ARDS by conventional criteria 
had values for · transvascular protein flux within the 95% confidence 
limits established in the combined control group. 
3) Close rank correlation was noted in the ARDS patients between the 
indices of lung injury used to assess lung microvascular and 
epithelial integrity. 
113m In-transferrin flux 
What is the explanation for the failure to detect increased 
protein flux in patients with classical ARDS? If this is a false 
negative finding, this reflects a lack of sensitivity of the 
technique. This is, however, contrary to the experimental findings of 
Dauber and associates (109) and to experimental work to be presented 
later in this thesis. The former study (109) showed, using a graded 
dose of thiourea, that a low dose caused increased protein flux 
without concomitant increase in extravascular lung water. This, 
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together with the similar finding to be reported here of increased 
protein flux in association with minimal morphological injury in one 
study and minimal increases in lung water in another, underlines the 
experimental sensitivity of this method of microvascular permeability 
assessment. It would be reasonable to assume that this applies also in 
the clinical situation. If, therefore, this is not a false negative 
finding, what alternative explanations exist for the normal prote1n 
flux in 3 of the ARDS patients. 
Since blood flow to the more injured areas is reduced (158),· 
normal flux data in these patients may represent more active 
derecruitment of these regions compared to the other patients. 
Brigham and associates have however, shown that a low 
permeability:surface area product for urea, implying active 
de recruitment · of injured areas, was associated with improved 
oxygenation and a more favourab.le prognosis (108). The 3 patients in 
this study all had severely impaired gas exchange and all died during 
the acute illness. This tends to negate derecruitment as a possible 
explanation for these findings. Alternatively and probably most 
likely, is the transient nature of transvascular protein leak in acute 
lung injury. Although this is not an aspect which has received much 
clinical or exper1mental attention, IIIOriJIIOioy1cal observations suyyest 
that pulmonary oedema formation (and presumably increased vascular 
permeability) usually reach a maximum within 24 hours of acute lung 
injury (31). Thereafter the oedema fluid is gradually resorbed and 
hyaline membranes and interstitial inflammation become more prominent 
histologically. Although all 3 patients were studied within 24 hours 
of fulfilment of ARDS criteria, increased protein flux may have been 
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too transient in these cases for detection with this technique. 
Notwithstanding the normal findings in 3 patients, the group as a 
whole differed significantly from the control subjects and this 
finding at present appears specific for the syndrome. Complete 
validation of this would require more systematic study in a group of 
patients with cardiogenic pulmonary oedema. Although Dauber•s study 
showed experimentally that the technique was unequivocally specific 
with normal findings in animals with increased left atrial pressure 
(109), I have subsequent to this initial clinical study assessed 4 
patients with cardiogenic pulmonary oedema. All patients had: 
1) Radiological evidence of pulmonary oedema. 
2) A known predisposing cause (in 2 patients myocardial infarction, 
and 2 patients acute renal failure with iatrogenic volume overload). 
3) Pulmonary capi 11 ary wedge pressure.s > 16 mmHg. 
In all 4 cases, pulmonary transvascular protein flux was within the 
95% confidence limits established in the combined smoking and 
non-smoking control group._ This finding supports the experimental 
data and underlines the specificity of the technique. 
Inhaled DTPA clearance 
In contrast to the data for protein flux, clearance of inhaled 
ggmTcDTPA was increased in every ARDS patient studied, but this 
finding was not specific to the syndrome. This study shows 
conclusively that as far as the extent of increased clearance is 
concerned, this technique cannot distinguish between ARDS patients and 
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otherwise normal smokers. This is an important finding, and makes 
data from the technique impossible to interpret in patients with acute 
lung injury who have a recent smoking history. A possible criticism 
relates to the relative paucity of subjects studied for this 
comparison. This reduces the power of the statistic and makes a 
statistical type 2 error (false ·acceptance of the null hypothesis that 
no difference exists between the 2 groups) more possible. It is 
however, unlikely in this. case that a type 2 error occurred as other 
larger studies in smokers have demonstrated similar means and 
variances for the DTPA clearance rate constant to that in the study 
(159,146). 
How can similar tracer solute clearances in the 2 groups be 
reconciled with their widely disparate clinical situations. The 
healthy smoking subjects must have nearly normal lung morphology in 
contrast to the severe diffuse lung injury of the ARDS patients. 
Similarly increased solute clearance in both groups may support 
previous suggestions that the site of increased solute flux in smokers 
is in respiratory bronchioles rather than in alveoli (160). As 
mentioned, the alveoli do not show inflammatory change in smokers 
(148). Implicit in these inferences from the DTPA clearance data is 
the actual deposition· of acrosolised tracer solute on peripheral 
non-ciliated epithelium including respiratory bronchioles and 
alveoli. Undoubtedly, there must have been some deposition of aerosol 
on more proximal airways; the relative surface areas of airspaces and 
airways, together with the DTPA particle size, must however, imply a 
contribution from the alveoli which is orders of magnitude greater 
than airways. It does therefore, seem reasonable to regard this 
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technique as an index of alveolar epithelial permeability. 
The DTPA clearance results show that in non-smoking patients a 
single study showing increased solute clearance implies an active 
inflammatory process while serial studies have been shown to provide 
useful information on recovery of alveolar-capillary barrier integrity 
(161). The use of PEEP in many of the ARDS patients introducing a 
possible source of error for the clearance data since PEEP increases 
the clearance of OTPA in normal non-smokers as will be outlined later 
in this thesis. However, as is discussed in Chapter 12, in the 
presence of acute lung injury clearance is unaffected by PEEP. This 
experimental data is consistent with that reported clinically by Mason 
and co-workers (143). They showed that ARDS patients with PEEP had 
similar DTPA clearance to ARDS patients not receiving PEEP. It, 
therefore, seems unlikely that in this study PEEP affected DTPA 
clearance in the ARDS patients. 
Correlation between indices of microvascular and epithelial 
permeability. 
The statistically significant rank correlation in the ARDS 
patients between DTPA clearance and transvascular protein flux was a 
surprising finding. These techniques not only employ solutes of very 
different molecular weights (transferrin approximately 76,000 daltons 
and DTPA approximately 500 daltons) but also assess discretely 
different components of the alveolar-capillary units. The 
microvascular permeability technique, being based purely on a 2 
compartment model of the lung (intra- and extravascular), is 
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independent of epithelial permeability. Clearance of OTPA, although 
indirectly assessing both epithelium and endothelium since the solute 
is cleared into blood, has the epithelium as its rate limiting step.· 
This is because the alveolar epithelium and pulmonary capillary 
endothelium have very different reflection coefficients for a 
substance of known molecular radius (128). This is particularly 
marked for small molecules like OTPA (molecular radius 0.6 nm) where 
the epithelium is virtually ten times less permeable than the 
endothelium. Thus most of the resistance to diffusion across the 
barrier of a hydrophilic solute like OTPA is in the epithelium rather 
than the endothelium. These relationships apply to normal rather than 
to injured lung. Nonetheless, the strong relationship found between 
the two indices of barrier integrity, despite the heterogeneity of 
predisposing conditions to lung injury, suggest that both epithelium 
and endothelium were damaged proportionately. Thus despite the 
relatively more severe epithelial rather than endothelial injury 
morphologically, the functional evidence would imply a positive 
correlative relationship between damage to each component of the 
barrier. This is in accord with a recent study of patients with acute 
alveolitis, where a significant correlation was shown between OTPA 
clearance and lung lavage albumin concentration (as an index of 
microvascular permeability) (162). 
In summary, although pulmonary 99mTcOTPA clearance is a 
sensitive technique in AROS, a ~ingle finding of increased clearance 
in a patient who smokes is non-specific. The use of this technique, 
therefore, in smokers with clinical acute lung injury . cannot be 
advocated. Transvascular protein flux is not affected by smoking and 
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appears at present specific for the syndrome. Although this was 
primarily a validating study and therefore assessed patients with 
established ARDS, the applicability for these techniques in future 
should include early or mild injury when lung water and the chest 
radiograph may be normal. The use of these techniques will hopefully 
focus attention on this early phase of acute lung injury when the 
potential benefit of appropriate therapy is greatest. In addition, in 
established disease and used appropriately, serial studies should aid 
management by providing more dynamic information about recovery of 
alveolar-capillary integrity. 
TABLE 1: Clinical details of ARDS patients 
No. Age Sex Precipitating event 
1. 27 M Post BMT 
2. 53 F Massive transfusion 
3. 22 F Post BMT 
4. 72 F Post cardiopulmonary bypass 
5. 26 F Post BMT 
6. 27 M Post BMT 
7. 48 M Post cardiopulmonary bypass 
8. 19 M Po.stoperat i ve as pi ration 
9. 28 M Post BMT 
10. 74 M Acute fibrosing alveolitis 
11. 70 M Sepsis 
12. 23 M Post BMT 
13. 47 M Acute pancreatitis 
14. 26 F Fulminant hepatic failure 
Abbreviations used: 
Background clinical information 
Associated GVHD; no pulmonary pathogen 
Laparotomies x 4 for uncontrolled GI bleeding 
Cytomegalovirus on open lung biopsy 
For closure of post infarct VSD 
Herpes simplex on sputum cytology 
No pulmonary pathogen found 
For replacement endocarditic mitral valve 
Major hepatic surgery 
No pulmonary pathogen found 
Known seropositive RA; DIP on autopsy biopsy 
Acute renal failure 
No pulmonary pathogen found 
Associated renal failure 
Associated raised intracranial pressure 
BMT = bone marrow transplant; GVHD = Graft-versus-host disease; GI = gastrointestinal 
RA = Rheumatoid arthritis; DIP = Desquamative interstitial pneumonia 
TABLE 2: Physiological and permeability data~ ARDS patients 
Physiological status at time of study Permeability indices 
No. Arterial/alveolar Total thoracic compliance PCWP Rate constant F1 ux units 
p02 ratio (ml/cm H20) (mmHg) (DTPA) (protein} 
1. 0.14 14 10 6.9 9.5 
2. 0.18 20 CVP 3cm 1.9 -0.9 
3. 0.15 17 12 3.8 3.2 
4. 0.23 22 15 2.6 1.6 
5. 0.19 24 11 3.7 0.2 
6. 0.18 17 CVP 4cm 3.3 -0.3 
7. 0.15 20 4 4.6 4.1 
8. 0.18 23 10 5.8 7.6 
9. 0.15 14 CVP 3cm 7.9 1.6 
10. 0.10 18 CVP 2cm 4.9 2.1 
ll. 0.09 29 10 3.9 1.6 
12. 0.10 20 CVP 6cm 13.3 8.5 
13. 0.18 22 14 3.4 2.8 
14. 0.24 26 7 14.0 10.2 ....... 
0 
Abbreviation: co 
CVP: Cental venous pressure (em water) taken from the mid-axi'llary line 
109 
14 • s:: 




< • 0:::: 8 • < UJ 
..J • :+ u • < 6 a.. :t 1-c 1- 4 I z < 
1-




smokers nonsmokers ARDS 
Figure i 
Clearance of DTPA in individual subjects and patients, expressed as the 
rate constant K (%/min). The means and standard errors are given by the 
crossed symbol alongside. Nonsmokers versus both smokers and ARDS 
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Figure 5 
Transvascular transferrin flux expressed as protein flux units (see 
text) in the 3 study groups. Smokers and nonsmokers do not differ, but 
































PROTEIN FLUX UNITS 
Protein flux units plotted against the rate constant K for DTPA 
clearance in each individual ARDS patient. Spearman's rank correlation, 
rs = 0.77 (p < 0.01). Vertical and horizontal lines dotted lines are 
the 95% confidence intervals in controls (see text). The diagonal lined 
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~· THE NEUTROPHIL AND ACUTE LUNG INJURY - A CRITICAL REVIEW 
In recent years, much attention has been focussed on the 
neutrophil as a key mediator of alveolar-capillary injury in AROS. 
This contention is based principally on extensive experimental work 
where the neutrophil and its toxic products have been shown to have 
the potential to cause lung tissue injury. Despite this, confirmatory 
evidence from clinical pathophysiological studies has been 
unconvincing. The issue remains controversial and presently 
constitutes one of the major challenges for workers in this field. 
Theoretical mechanisms of lung injury mediation by neutrophils were 
discussed in Chapter 2; therefore, this chapter will deal on.ly with a 
critical review of data implicating the cell in acute lung injury. 
The evidence can be summarised as follows: 
.lJ Neutrophil s sequestrate in the pulmonary microvasculature and 
migrate into the alveolar spaces in animal models and patients with 
ARDS. 
The role of complement as a major chemotactic factor for 
pulmonary neutrophil sequestration was discussed in Chapter 2. The 
importance of lung neutrophil sequestration to AROS-related research 
developed largely· from the observations of a group of workers at the 
University of Minnesota, USA. They were studying the phenomenon of 
haemodialysis-associated leucopaenia, an observation initially 
reported in 1968 (163). The Minnesota group showed conclusively that 
pulmonary vascular leucostasis in animals could be produced by 
infusion of plasma that had been incubated with a cellophane-membrane 
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dialyser (58). Additionally, their studies suggested that the 
dialyser cellophane activated complement and it was this plasma factor 
which was responsible for the profound pulmonary vascular 
leucostasis. Although this finding at the time appeared to have 
little clinical importance, their proposal (164) that an exaggerated 
version of these events - complement activation, intrapulmonary 
neutrophil aggregation and neutrophil-mediated pulmonary dysfunction -
could eventually produce ARDS, aroused much attention and 
fundamentally altered the thrust of research at the time. 
Over the last 6 years, two major research groups in the United 
States have addressed themselves to the relationship between 
complement activation, neutrophil intrapulmonary sequestration and 
lung injury. Ward and associates have consistently shown that 
complement activation by cobra venom factor produces lung injury with 
neutrophil accumulation in rats and mice (165-167). Shaw and his 
co-workers initially concurrred, showing that intra-tracheal 
installation of C5a produced intra-alveolar neutrophil accumulation 
with endothelial injury and oedema formation (168). This injury 
appeared neutrophil-dependent. Later studies from this latter group 
showed that neutrophil migration into the airspaces and microvascular 
injury only occurred when, in addition to complement activation, there 
were additional stresses including surgical manipulation, hypoxia or 
prostaglandin E2 infusion (169). The contrasting results may 
reflect species difference; nontheless the controversy of whether 
complement activation per se can produce neutrophil activation and 
lung injury co~tinues. The clinical finding of the Minnesota group 
that C5a concentrations in plasma predicted the subsequent onset of 
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ARDS appeared to give the hypothesis further scientific credibility 
(84). Although as outlined in Chapter 2, subsequent more sensitive 
measurements have shown no predictive value for intravascular 
complement activation in ARDS development, the work of the Minnesota 
group did focus attention on the aggregated, activated intravascular 
pulmonary leucocyte as a possible effector cell for lung injury. 
Histological evidence to support the hypothesis that pulmonary 
vascular leucostasis is an important feature in ARDS is limited. This 
is possibly because of the difficulty of accessibility to tissue early 
in the clinical course - this is usually limited to autopsy 
assessment. Existing electron micrographic studies performed early in 
the course of the syndrome do however, reveal increased numbers of 
neutrophils in lung capillaries, especially with sepsis-related ARDS 
(170). Experimental models of lung injury, especially endotoxin 
infusion, support the clinical evidence with marked neutrophil 
sequestration in the pulmonary microvasculature (171-173). Neutrophil 
sequestration has also been demonstrated with other experimental 
models of lung injury including haemorrhagic shock (174), pneumococcal 
bacteraemia (175) and inhalation injury (176). 
The accessibility of the airspaces for sampling of inflammatory 
cell populations has led to the popularising of broncho-alveolar 
lavage as a major tool in acute lung injury research. A recent 
clinical study indicated that neutrophils constituted the vast 
majority of the lavage cell population in ARDS compared to 
mechanically ventilated and normal volunteer subjects (177). This 
study also indicated that neutrophil recovery in lavage fluid 
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correlated with gas exchange abnormality and lung vascular 
permeability. Like previous workers (87 ,88), they demonstrated 
.neutrophil secretory products including collagenase and 
myeloperoxidase in ARDS lavage fluid. The major criticism of this 
work (177) relates to the lack of controls with at-risk factors for 
ARDS but without clinical features of the syndrome. Another group of 
workers indeed showed that neutrophils accumulate in the airspaces in 
patients predisposed to, but without clinical features of ARDS (178). 
A further recent study examined pulmonary neutrophil kinetics by 
assessing scintigraphically neutrophil-endothelial interaction in 
ARDS. Additionally they studied control groups which included 
patients with sepsis but without respiratory dysfunction and patients 
with cardiogenic pulmonary oedema (179). They demonstrated 
significantly greater pulmonary localisation of neutrophils in ARDS 
than in any of these control groups. This elegant scintigraphic study 
tended to confirm the work of Thommasen and associates (180) who 
showed that a fall in total white cell count was an early feature in 
AROS pathogenesis. Although it was inferred in the latter study that 
this transient leucopaenia reflected pulmonary sequestration, these 
workers produced no supportive data for this assumption. 
£) Neutrophils in the pulmonary and/or systemic circulation of ARDS 
patients exhibit abnormal functional activity. 
One of the first studies to address the issue of the functional 
activity of neutrophils from ARDS patients in vitro was published by 
Zimmermann and co-workers (181). They demonstrated enhanced 
chemotactic activity in neutrophils from patients with established 
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ARDS as compared to critically ill patients without AROS. They also 
studied the phenomenon of chemiluminescence; this accompanies the 
increased oxygen consumption resulting from stimulation of the 
neutrophi 1 plasma membrane. Increased resting and stimulated 
chemiluminescence responses were observed from neutrophils of ARDS 
patients, suggesting that the cell was primed and likely to generate 
enhanced quantities of oxygen-free radicals in response to membrane 
stimulation. Fowl.er and associates however, showed depressed 
neutrophil chemotactic activity in both AROS and at risk patients 
(182). They did show enhanced neutrophil secretory activity as judged 
by basal lysozymal enzyme release. Thus, although both studies implied 
enhanced functional activity of neutrophils from ARDS patients, the 
two studies produced conflicting results with regard to chemotactic 
activity. This is possibly because Zimmermann•s group examined blood 
from the pulmonary artery while the study of Fowler et al looked at 
peripheral blood neutrophils. Presumably in the latter situation, 
those neutrophils with enhanced chemotactic activity were not studied 
since they were preferentially already sequestrated in the pulmonary 
microvasculature. Both groups however, showed that chemotaxis of 
neutrophils from healthy control subjects was not enhanced by 
incubation with AROS plasma, tending to negate an important 
chemotactic role for complement components. 
A further study from Zimmermann•s group examined granulocyte 
adherence in AROS (183). They found interestingly that although 
plasma from ARDS patients enhanced in vitro adherence of granulocytes 
from healthy subjects, the AROS granulocytes themselves demonstrated 
'l reduced adherence. This suggested that ARDS granulocytes were 
' . 
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desensitized to a circulating adherence-promoting mediator. The 
apparent paradox of in vitro hypoadherence and in vivo scintigraphic 
white cell accumulation in the lung, implied that the determinants of 
pulmonary neutrophil accumulation were either inflammatory mediators 
or changes in endothelial cell characteristics. 
l) Neutrophil depletion or scavenging of neutrophil-generated 
oxygen-free radicals attenuates experimentally induced~ injury. 
Neutrophil depletion attenuates lung injury induced by hyperoxia 
(184), endotoxin (185) and microembolisation (186,187). Likewise, 
scavenging of neutrophil-derived oxygen-free radicals ameliorates 
injury in a number of experimental models (188-190). 
A retrospective clinical series has examined the contrary 
hypothesis; that increase in leucocyte numbers during remission of 
chemotherapy-induced leucopaenia accentuates pre-existing respiratory 
insufficiency (191). Although uncontrolled, the data appeared to 
confirm the hypothesis, with worsening oxygenation and increased 
microvascular permeability. 
Discussion of evidence presented. 
Despite the demonstration that neutrophils sequestrate in the 
pulmonary microvasculature and are recovered in abnormal numbers in 
the lavagable airspaces of ARDS patients, this by no means proves that 
the cell is causing the associated injury. It is well recognised 
experimentally that neutrophils accumulate in the lungs in response to 
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oleic acid administration··(192). Most studies suggest however, that 
neutropaenia does not protect against injury induced by this agent 
(193). This experimental finding may mirror the clinical situation in 
that the presence of the neutrophil reflects an inflammatory response 
to the tissue injury, rather than the cell being responsible for it. 
The neutrophil may be performing any of a number of functions inherent 
in the inflammatory response, including phagocytosing cellular debris 
or being involved in the process of tissue repair. Alternatively, its 
presence in ~he lung may be a non-specific epiphenomenon associated 
with the precipitating event rather than the lung injury itself. The 
finding of increased neutrophil activation in ARDS may also reflect a 
response to tissue i'njury rather than a causative relationship, since 
neutrophil activation has been demonstrated in a variety of 
inflammatory disorders (194). 
Evidence has recently been published suggesting that in. vitro 
findings of neutrophil-generated oxygen radical injury to endothelial 
cells may be modulated in vivo. The respiratory burst of activated 
neutrophils is inhibited by the presence of an endothelial monolayer 
("195), while the erythrocyte can act as a potent scavenger of 
superoxide anion (196). These protective factors which operate only 
in vivo would tend to influence or even negate many of the conclusions 
about neutrophil-mediated cytotoxicity derived from in vitro studies. 
Thus despite the intense interest that this cell has aroused in lung 
injury research, its precise role has yet to be completely defined. 
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CHAPTER 6 
EVIDENCE FOR A NEUTROPHIL-INDEPENDENT MECHANISM IN A SPECIFIC 
GROUP 
OF ADULT RESPIRATORY DISTRESS SYNDROME PATIENTS. 
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6. EVIDENCE FOR A NEUTROPHIL-INDEPENDENT MECHANISM Jli ~ SPECIFIC GROUP OF 
ADULT RESPIRATORY DISTRESS SYNDROME PATIENTS 
6.1 - Introduction 
The previous chapter reviewed critically the extensive evidence 
suggesting that neutrophils have a fundamental role in mediating acute 
lung injury in ARDS. Central to the question of whether or not the 
cell represents a common effector mechanism for lung injury 
development in ARDS, would be the demonstration that the classical 
syndrome can develop in certain situations by a neutrophil-independent 
mechanism. This clinical phenomenon would, if shown, contrast with 
the experimental observations previously reviewed, where neutrophil 
depletion protected against increased pulmonary vascular· permeability 
in several animal models of acute lung injury. Patients undergoing 
bone marrow transplantation (BMT) are rendered grossly neutropaenic 
routinely as part of the conditioning for grafting. After marrow 
transplantation, they remain neutropaeni.c until engraftment takes 
place, which, if successful, is usually within four weeks (197). 
Despite initial successf~l engraftment, subsequent neutropaenia may 
develop in association with acute or chronic graft-versus-host disease 
(GVHD) which directly impairs marrow granulocyte development (198). 
Careful study of respiratory complications developing in patients 
after BMT represents a natural clinical 
assessing the protective effect of 
neutropaenia. 
experiment similar to 
experimentally-induced 
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Pulmonary complications of BMT cause significant morbidity and 
mortality and occur in 40-60% of transplanted patients (199). The 
common syndrome within 100 days of BMT is interstitial pneumonitis 
which is often related to infection (199). Cytomegalovirus {CMV) is 
the most common organism associated with pneumonitis; it is extremely 
virulent with up to 90% mortality (200). The herpes virus, including 
simplex and zoster, is the other most important cause of pneumonitis 
(200). Bacterial pneumonitis, including gram-positive and negative, 
organisms occurs particularly in the context of neutropaenia, or with 
extensive chronic GVHD (201). Fungal pneumonitis is usually 
associated with systemic infection while pneumocystis is now much less 
of a problem as chemoprophylaxis is routine. In a significant 
percentage of patients, pneumonitis develops without a demonstrable 
infectious cause. Late chronic respiratory complications, including 
restrictive (202) and obstructive ventilatory defects (203), are not 
relevant to this discussion. 
A fulminant ARDS-type presentation has been described, 
particularly when donors and recipients have been mismatched for HLA 
antigens (204). In this chapter, 5 patients are described in whom 
acute respiratory failure developed after BMT for chronic myeloid 
leukaemia. All patients received fully matched sibling grafts and all 
were neutropaenic to varying degrees at the onset of respiratory 
symptoms. During their clinical course, all patients fulfilled the 
characteristic radiological, physiological and haemodynamic features 
of ARDS. An index of pulmonary epithelial permeability, clearance of 
99mTcDTPA, was examined in order to confirm alveolar-capillary 
barrier dysfunction, as all patients were non-smokers. Since 
peripheral 
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blood neutropaenia may be simply a reflection of 
intrapulmonary neutrophil sequestration, evidence for this feature was 
sought histologically. In addition, the general morphological lung 
features were assessed. Studies confirmed that: 
a) patients had classical ARDS with histological evidence in all cases 
of diffuse alveolar damage 
b) peripheral blood neutropaenia was not associated with 
intrapulmonary neutrophil sequestration 
This implies a neutrophil-independent mechanism and in the 
these findings the relationship between the neutrophil 




6.2 - Methods 
Patients 
Five patients, whose clinical features are summarised in Table 3, 
were studied. The diagnosis of chronic myeloid leukaemia had been 
made a median of 14 months before transplantation (range 9-42 months)~ 
at which time only patient 2 was in the accelerated phase of the 
disease. All patients had received intermittent busulphan therapy 
initially and only 2 patients (no 4 and no 5) had pre-transplant 
evidence of a mild reduction in gas transfer coefficient (KCO) of less 
than 10%. Pre-transplant conditioning consisted of daunorubicin 60 
mg/m2 on day -6 and cyclophosphamide 60 mg/kg on day -5 and day 
. -4. Total body irradiation was given as 5. fractionated doses of 200 
cGy at a dose rate of 15 cGy per minute, using a linear accelerator 
(days -3 to -1). Additional splenic irradiation was given at a dose 
of 500 cGy on two consecutive days. 
'All patients received marrow from HLA identical, mixed lymphocyte 
culture non-reactive siblings with no other evidence of 
histoincompatibility. Prophylaxis against GVHD consisted of T cell 
depletion with CAMPAT•l 1 (20S) in patients 1, 2 and 3 and a monoclonal 
anti-T antibodies RFT8 and MBG (206) in patient 4. Patient 4 received 
cyclosporin in addition. Patient 5 also received cyclosporin, in this 
case as the sole therapy. Definite GVHD developed in 4 patients (see 
Table xx) and.was graded by the criteria of Thomas and associates 
(207). It was treated with methylprednisolone except in the 2 




Alveolar-capillary barrier function was studied by examining 
clearance of aerosolised 99mTcDTPA as previously described. 
Pulmonary transvascular flux of 113min-transferrin was not 
assessed as these patients presented prior to proper validation of 
this technique. All patients were studied within 24 hours of 
fulfilling the identical criteria for ARDS that were outlined in 
Chapter 4. 
All patients studied were non-smokers. Since all patients were 
ventilated at the time of study, the aerosol was introduced by manual 
ventilation using the ventilation circuit described in Chapter 3. 
Radioactivity was again counted with 2 scintillation detectors placed 
over the right anterior upper chest and right thigh, providing a 
correction factor for tissue background. The placement of the probe 
detectors was made irrespective of the relative distribution of 
radiological abnormalities, although by definition all patients had 
diffuse infiltrates. Corrected lung counts were plotted 
semilogarithmically versus time and the computer fitted regression 
line was used to calculate the half-time clearance (Tl/2) and rate 
constant of DTPA clearance (K). Eight aged matched non-smoking adults 
were studied as control subjects • . 
Histology 
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Post mortem lung histology was available in all cases. The tissue 
was processed conventionally and examined under light microscopy. 
Statistical analysis. 
Where applicable results are expressed as mean ± standard 
deviation. The differences between groups were assessed with 
Student 1 S unpaired t test with p values· less than 0.05 deemed as 
significant. 
128 
6.3 - Results 
DTPA clearance 
Half-time clearance of the tracer solute was significantly less 
in the post BMT patients than in the control group, implying 
disordered alveolar-capillary barrier function (K values 4.3 ± 1.5 and 
1.1 ± 0.2 respectively, p < 0.001) (Table 4). Pulmonary clearance of 
DTPA was increased in each individual post BMT ARDS patient studied 
and all were outside the 99% confidence interval established iri the 
non-smoking control group. The correlation coefficients of the 
corrected DTPA disappearance curves, upon which calculation of the 
rate constant is based, was greater than -0.96 in all cases. 
Clinical outcome 
All patients died within 10 days of the start of artificial 
ventilation support. One patient had no evidence of pulmonary 
infection. All the other patients had ante or post mortem diagnoses 
of CMV or herpes simplex pneumonitis (see Table 4). 
Histology 
Autopsies were performed on all patients. All showed diffuse 
exudative alveolar damage with hyaline· membrane formation and 
intra-alveolar haemorrhage. There was no evidence of increased 
numbers of intracapillary neutrophils and the oedematous interstitium 
showed only a mild inflammatory infiltrate. CMV pneumonitis was 
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diagnosed histologically in 2 patients (see Table 4). 
Neutrophil counts 
The counts detailed in Table 4 refer to those obtained at the 
time of onset of respiratory symptoms. Subsequent counts during the 
clinical course were in all cases lower. 
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6.4 - Discussion 
Notwithstanding marked neutropaenia at the start of respiratory 
symptoms, all these patients went on to develop fatal acute 
respiratory insufficiency. Patients demonstrated accepted 
physiological and haemodynamic features consistent with the diagnosis 
of ARDS. This was further supported by the autopsy lung histological 
findings which showed diffuse alveolar damage with rare or absent 
neutrophils. Pulmonary clearance of 99mTcDTPA was vastly 
increased in all cases. This occurrence of ARDS in neutropaenic 
patients is of particular interest as it implies that the syndrome can 
in certain clinical situations develop independently of neutrophils. 
Although all patients had neutropaenia of varying severity at the 
onset of respiratory symptoms, this in itself might just be a 
reflection of the often precipitious fall in total white cells at the 
onset· of ARDS {180). The failure, however, to demonstrate 
histologically any evidence of intrapulmonary neutrophil aggregation 
and the minimal cellular infiltration observed, would appear to negate 
this possibility. 
Many possible precipitating factors, including total body 
irradiation, cytotoxic chemotherapy, infection and GVHD were present 
in these patients. Previous studies have suggested that the total dose 
of irradiation delivered to the lungs (208,209) and the dose rate 
(210) are both important in determining the incidence of interstitial 
pneumonitis after BMT. It does appear however, that the dose required 
to produce pathological and radiographic changes is appreciably higher 
than that administered to these patients as part of their 
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pre-transplant conditioning (211). Cyclophosphamide-related 
interstitial pneumonitis is well described (212) and thoracic 
irradiation appears to enhance the pulmonary toxicity of 
cyclophosphamide (213). Although lung injury has been demonstrated 
histologically (214) in experimental studies , clinical ARDS has only 
been reported on one occasion in association with cyclophosphamide 
(215). Thus neither radiation nor the cytotoxic chemotherapy appears 
likely to have played a role in mediating the pulmonary damage in 
these patients. GVHD itself produces defined abnormalities in humoral 
and cellular immunity (216). Its occurrence in 4 of the 5 patients 
described, in all of whom fatal respiratory failure subsequently 
developed, is in keeping with previous studies showing that the 
incidence and severity of pneumonia increases in association with the 
·incidence and severity of acute GVHD in other organs (217). 
The most common clinical syndrome after viral infection is 
interstitial pneumonitis and in 4 of these patients a viral pulmonary 
pathogen was demonstrated. Interstitial pneumonitis probably 
represents a less severe clinical and pathological expression of the 
same syndrome as post BMT ARDS. Furthermore, some of the cases 
described in the literature as interstitial pneumonitis probably had 
ARDS by standard criteria. Other workers have pointed to the 
association of high levels of cyclosporin and subsequent development 
of ARDS after BMT, particularly in view of a putative effect of 
cyclosporin on capillary permeability (218). This factor almost 
certainly had no bearing on this syndrome in this study. Only 2 
patients had cyclosporin as part of GVHD prophylaxis and in both 




the therapeutic range. 
The finding that the clearance of DTPA was significantly higher 
in the study group than in normal controls implies an impairment in 
alveolar-capillary barrier function. As all patients studied were 
non-smokers, this does seem a valid finding reflecting abnormal 
alveolar epithelial integrity. Is the finding specific to ARDS? As 
discussed in Chapter 4 and as will be outlined later in the thesis, 
increased clearance has been noted in a variety of clinical situations 
including chronic interstitial lung disease and ventilation at high 
lung volumes. Although none of these factors apply to these patients, 
the specificity of the data to 11 full-blown 11 ARDS is uncertain. Little 
data is available on the clearance of DTPA in the context of a 
localised pneumonic process. However, as an adjunct to this study, 2 
further patients with CMV pneumonitis were studied; these patients did 
not fulfil gas exchange or radiographic criteria for ARDS. The 
patients who were both non-smokers presented after renal and bone 
marrow transp 1 ants respectively. Clearance ·rate constants for i nha 1 ed 
DTPA over the area of maximum radiographic change were 3.85 and 3.15 
respectively, both well outside the 99% confidence limits established 
in normal non-smokers. These patients have by definition an 
inflammatory process in their peripheral airspaces and thus the result 
is hardly surprising. Abnormal DTPA clearance in a non-smoker, 
breathing at normal lung volumes (see Chapter 11), is thus indicative 
only of an inflammatory process. ARDS is defined by physiological 
criteria which may not necessarily reflect the intensity of 
inflammation or injury - highly abnormal gas exchange is more likely 
to be a reflection of gross ventilation:perfusion mismatch rather than 
-l ...... 
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11 alveolar-capillary block 11 • Thus as these two preliminary studies of 
a pneumonic area suggest, clearance in ARDS and in pneumonia· may not 
be dissimilar. Therefore, although this finding appears to reflect 
alveolar epithelial injury, the increased clearance suggests an 
inflammatory alveolitis rather than ARDS per se. 
What bearing does this finding of a neutrophil-independent 
mechanism have on our overall perception of ARDS pathogenesis? In 
Chapter 5, the clinical and experimental data suggesting an important 
effector role in lung injury for the neutrophil was reviewed. 
Although as discussed, there are numerous experimental models in which 
neutrophil depletion appears to attenuate injury, other investigators 
using different models have not shown similar protection with 
neutrophil depletion (219-221). This may be because of animal species 
differences or different mechanisms of· injury in the different 
experimental models used. In addition, even where attenuation of 
injury was shown with neutrophil depletion, this was always only 
partial. This experimental situation may well mirror that pertaining 
clinically, in that pathogenetic pathways of injury depend on the 
particular precipitating event and are not common to all cases of 
ARDS. This heterogeneity of AROS pathogenesis is in contrast to the 
concept that the neutrophil is a central component of the final common 
effector pathway in acute lung injury. 
The assumption that arises from this clinical study as well as 
from some of the experimental studies to be presented later in this 
, thesis is that the neutrophil is of importance in some models or with 
particular precipitating causes of lung injury. In view however, of 
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this neutrophil-independent mechanism, clearly other humoral and 
cellular factors are also playing an important role. The possible 
role of humoral factors in lung injury pathogenesis is addressed in 
Chapters 9 and 10. It has been shown experimentally that activated 
macrophages are capable of releasing toxic substances that can damage 
the alveolar-capillary barrier (222-224). Since alveolar macrophages 
appeared histologically to be present in normal numbers in these 
patients, it is thus possible that this cell had a role in mediating 
the lung tissue injury. 
In conclusion, this study demonstrates that classical AROS can in 
certain circumstances develop independently of neutrophils. This 
points to a more complex relationship between the neutrophil and lung 
injury development and suggests an important role for other humoral 
and cellular factors. 
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Acute GVHO Duration of clinical course 
(grade *) (from onset mechanical ventilation) 
III 9 days 
10 days 
II 4 days 
II 5 days 
II 6 days 



















CMV ~ Cytomegalovirus 
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CMV - Lung lavage 
and postmortem histology 
Herpes simplex- tracheal 
aspirate 
CMV - Lung lavage 
and postmortem histology 
CMV - lung tissue culture 
post mortem 
Mean= 4.3 ± 1.5 (standard deviation) 
(Controls = 1.1 ± 0.2, p < 0.01) 
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7. LUNG MICROVASCULAR INJURY AFTER CANINE CARDIOPULMONARY BYPASS: - -- _..;;...._~----~;;..._ 
PATHOPHYSIOLOGICAL IMPLICATIONS 
7.1 - Introduction 
Cardiopulmonary bypass (CPS) is associated with a small but 
signfficant incidence (2%) of severe alveolar-capillary injury 
presenting as the adult respiratory distress syndrome (post perfusion 
lung syndrome) ( 225). Since approximately 117000 operations for 
coronary artery bypass surgery were performed in the u.s. in 1980 
(226), post perfusion lung syndrome appears to represent an important 
clinical problem. Prospective ultrastructural studies suggest 
however, that minor degrees of cellular injury after CPS are virtually 
invariable, particularly with prolonged duration of bypass (227). In 
support of these morphological findings, physiological studies 
demonstrate increased pulmonary clearance of aerosolised 99mTcOTPA 
after CPS, implying impairment of alveolar-capillary barrier integrity 
(161). 
The pathophysiology of this injury is unknown, although evidence 
suggests a central role for complement activation and associated 
neutrophil sequestration (228). There is histological evidence for 
neutrophil sequestration in the pulmonary microvasculature after CPS 
and this phenomenon appears to correlate with evidence of cellular 
injury (229). As has been discussed, neutrophil accumulation in the 
lung microvasculature does not necessarily in itself, imply that these 
cells are responsible for the associated tissue damage. Neutrophils 
release at least three groups of products which could result in lung 
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tissue injury: proteolytic enzymes, oxygen free radicals and 
arachidonate derived products. Oxygen radicals cause tissue injury by 
amongst other mechanisms, peroxidizing cell membrane lipid (230). 
Products of this peroxidation, including principally malondialdehyde, 
can be quantitated using the thiobarbituric acid (TBA) reaction (231). 
Increased TBA reactivity, implying an oxygen free radical mechanism, 
has been demonstrated in experimental endotoxin-induced acute lung 
injury (232) and after experimental CPB (233). It has also been· 
demonstrated after human CPB, where the time sequence of rise in 
peroxidation products closely mirrored lung neutrophil sequestration 
(234). 
This model of lung injury was used as, not only did it have 
clinical relevance, but in addition it involved pathogenetic 
mechanisms that were of more general importance in ·lung injury 
• 
research. These factors represented advantages over chemical means of 
inducing lung injury (eg. alloxan, alpha-naphthylthiourea, oleic 
acid) which act by a direct toxic effect on lung microvascular 
endothelium. The objective of this study·was to determine whether 
accumulation of neutrophils in the lung was associated with egress 
from the lung of plasma peroxidation products (measured by TBA 
reactivity) and the development of increased pulmonary microvascular 
permeability. Egress from the lung of peroxidation products (measured 
by the left atrial : central venous gradient for TBA reactivity) was 
used in this study as the index of lung tissue peroxidation. These 
associations, if shown, would imply that the sequestered neutrophil 
was playing a role in mediating lung injury by release of oxygen free 
radicals. Such a relationship could be postulated on the basis of 
MO 
recent experimental work using a different model of lung injury (167). 
In that model neutrophil depletion significantly reduced plasma 
peroxidation products and a biochemical index of lung injury. In the 
present study these relationships were investigated in a canine model 
of CPS using the lung transvascular flux of 113mrn-transferrin as 
an index of pulmonary vascular permeability. 
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7.2 -Methods 
Animals and Anaesthesia 
Fourteen mongrel dogs (mean weight 27 Kg, range 18.5-37 Kg) were 
studied on two separate occasions. The first, seven days prior to the 
main study day, was used for control measurements of lung 
transvascular protein flux as described below. The animals were 
anaesthetized with intravenous thiopentone (10 mg/Kg) and intubated 
and ventilated using a Starling pump (rate 14/minute, tidal volume 10 
ml/Kg) with an inspired gas mixture of nitrous oxide in oxygen (1:1 by 
volume). This was supplemented by halothane (0.5-1%). 
Operative procedure and conduct of bypass 
Seven days after the control measurement the dogs were again 
anaesthetized and ventilated as described previously, with the 
addition of meperidine (2 mg/Kg) to provide analgesia. Eight dogs then 
underwent thoracotomy and a period of cardiopulmonary bypass, while in 
the remaining six control animals the effects of thoracotomy alone, 
with no diversion of pulmonary blood flow, hypothermia or 
anticoagulation, were investigated. In all dogs carotid arterial and 
internal jugular vein catheters were inserted to provide continuous 
monitoring of heart rate, systemic arterial blood pressure and central 
venous pressure. A right thoracotomy was performed and another 
catheter introduced into the left atrium for blood sampling and 
pressure recording. Following the administration of bovine lung 
heparin (300 units/Kg), the eight dogs allocated to the bypass group 
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underwent bypass according to the following schedule: cannulae were 
inserted directly into the ascending aorta and through the right 
atrium into the superior vena cava. Cardiopulmonary bypass was 
initiated with bubble oxygenators (BOS-5, Bentley Labs, Irvine, 
California) and non-pulsatile perfusion 'using Sarns roller pumps 
(Sarns, Ann Arbor, Michigan) at a flow of 100 ml/Kg/min. Hartmann•s 
solution (1,000-1 ,300 ml) was used to prime the oxygenator. When full 
flow was achieved, hypothermia (28-30°C) was induced, the aorta 
was cross-clamped and cardiac arrest produced by infusion of 30 ml/Kg 
of 4°C St. Thomas• cardiopiegic solution. This contained magnesium 
chloride 3.25 gm, potassium chloride 1.93 gm and procaine 
hydrochloride 272.8 gm in 1 litre of Hartmann•s solution. Mechanical 
ventilation of the lungs was then discontinued. After 45 minutes of 
total bypass, the aortic cross-clamp was removed and rewarming 
commenced. Restoration of sinus rhythm always required 10 J DC 
counter shock to the heart. 
,I 
Forty five minutes following cross-clamp removal and at an 
oesophageal temperature of 37°C, pulmonary ventilation was 
recommenced and the animals weaned from bypass. The aortic and caval 
catheters were removed and residual heparinisation reversed with 
protamine sulphate (1 mg/300 units heparin) administered via the left 
atrial line. During the bypass procedure, blood gas, electrolyte and 
acid base status were kept within normal limits with sodium 
bicarbonate and potassium supplementation if required. After 
haemostasis, the ribs were apposed and the thoracotomy closed. The 
animals continued to be ventilated for a further four hours until all 
studies were completed. The six remaining thoracotomy control dogs 
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were ventilated for 90 minutes open chested to simulate temporally the 
bypass procedure. As in the bypass animals, the chest wound was then 
closed and ventilation continued until all studies were completed. 
Studies 
White blood cell and neutrophil counts. 
Blood was diluted l :20 with 2% acetic acid and methylene blue and 
counts performed in duplicate in Neubauer chambers. Differential cell 
counts were performed on 200 consecutive cells on Wright•s stained 
blood films. The effect of hemodilution was corrected by simultaneous 
measurement of the packed cell volume. 
TBA reactive products. 
Separated plasma was assayed in duplicate using a modification of 
the thiobarbituric acid reaction (231). Briefly, thiobarbituric acid, 
freshly prepared as a 1% solution in 0.05 molar sodium hydroxide, was 
buffered with 4 molar potassium hydrogen phthalate in water and the pH 
adjusted to 3.5 with hydrochloric acid. Fifty microlitres of plasma 
and 2.4 ml of this buffered TBA reagent were heated to 95°C for 1 
hour. After cooling, the resultant thiobarbituric acid complex was 
extracted into 3 ml of Butan-1-ol (British Drug House, Poole, England) 
by whirly mixing for 10 seconds. Following centrifugation, the upper 
layer was transferred to polystyrene tubes containing.anhydrous sodium 
sulphate to dry the- Butan-1-ol. With excitation at 535 nM, the 
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fluorescent emission at 560 nM was then measured using a fluorimeter. 
Results were compared against a standard curve. The effect of 
hemodilution on plasma TBA concentration was corrected by simultaneous 
measurement of the total protein concentration. 
Measurement of lung transvascular protein flux. 
This technique, as described in previous chapters, examines 
dynamically the accumu.lation of 113min-transferrin in 
extravascular tissues of the lung. The technique used was identical 
to that already. outlined and only the essential features, relevant to 
this particular study are discussed. Autologous red cells labelled 
with ggmTc (lmCi, approximately= 37mBq) were injected along with 
0.5 mCi of 113min. Acrylamide gel electrophoresis of dog plasma 
after 113min injection and subsequent counting of sliced gel in a 
scintillation well counter confirmed binding to a protein with 
electrophoretic mobility consistent with transferrin (molecular weight 
76 ,000). 
After 15 minutes to allow for equilibration, scintillation 
detectors comprising 5. l em x 5.1 em collimated sodium iodide crystals 
were placed over the heart and right lung. The lung probe was placed 
over the midlung field and, since the dogs were studied open-chested, 
the heart probe was placed by direct visualisation. The latter 
probe•s position was further optimised by. ensuring that counts from it 
due to 99mTc red cells, as a reflection of the intravasular pool, 
were maximised. This method of assessing intravascular isotope 
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activity offers advantages over regular blood sampling as it allows 
continuous monitoring without blood loss; both features may be 
important in haemodynamically labile subjects. Additionally, 
continuous monitoring results in greater density of data points, 
reducing the time required for valid, accurate studies. A correction 
factor for influence of 113mrn on 99mTc counts (Compton 
scatter) was derived initially and applied to subsequent 99mTc 
counts. In all studies counts were recorded serially for at least 30 
minutes. The lung to heart ratio for 113mrn-transferrin for each 
minute was divided by the corresponding 99mTc ratio to correct 
pulmonary blood volume changes. The rate of change of this corrected 
113mrn-transferrin lung:heart ratio was quantitated by plotting 
the individual points versus time and fitting a computer-derived 
linear regression line. The regression equation derived slope was 
divided by the Y intercept at time 0 to correct for differences in 
physical factors between studies. This quotient was used as an index 
of vascular permeability and expressed as protein flux units 
(xl0-3/min). This method of data acquisition and analysis was 
identical to that employed in the human study reported in Chapter 4. 
Alveolar to arterial oxygen tension gradient 
The alveolar partial pressure of oxygen was calculated from the 
alveolar gas equation. Arterial oxygen and carbon dioxide tensions 
were determined on an automated analyser· and the inspired oxygen 
concentration (50%) was verified with a paramagnetic oxygen analyser. 
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Protocol 
Pre-anaesthesia blood was taken from a leg vein for measurement 
of neutrophil counts and TBA reactivity. After anaesthesia blood was 
taken from the central venous and left atrial lines at the following 
times: 
( 1) just after anaesthetic (arterial blood from carotid arterial 1 i ne) 
(2) 10 minutes into the bypass procedure 
(3) just prior to removal of aortic cross-clamp 
(4) 10 minutes after cross-clamp removal 
(5) 30 minutes after cross-clamp remova 1 
(6) 15 minutes after protamine administration 
In the control group, blood was taken at matched times. The 
samples were collected anaerobically into heparinzed, cooled 
syringes which were immediately capped and stored on ice. 
Separation of plasma was undertaken within 20 minutes of sampling. 
Transvascular protein flux was measured 3 hours after closing 
of the chest wound in both bypass and thoracotomy groups. The 
alveolar to arterial partial pressure of oxygen gradient was 




Lung biopsies from the right middle lobe were taken prior to 
bypass and just· before the protein flux study. They were inflated 
to lOcm H20 and ·the tissue divided for light and electron 
microscopy .. For 1 i ght microscopy the tissue was fixed in 10% 
neutral buffered formalin prior to being stained and examined. 
Tissue for-electron microscopy was fixed in phosphate buffered 2% 
glutaraldehyde and post-fixed in 1% osmium tetroxide. 
Statistical analysis 
When serial data were compared with one baseline sample, 
paired t tests were used with the critical p value corrected by the 
Bonferroni method (235). A p value of less than 0.01 was taken as 
si gni fi cant. for these data; otherwise a p va 1 ue of less than 0.05 
was taken as- significant. Because of large variances, Wilcoxon 
signed rank.. test was used to compare 1 ung protein flux on the 
control and study days. Correlation coefficients between variables 
were compared with Spearman's rank correlation coefficient. All 
results are expressed as mean ± standard error of the mean (SEM). 
148 
7.3 -Results 
Induction of anaesthesia caused no significant change in 
either neutrophil counts or concentration of TBA reactive products. 
Because of this, the first blood sample, just after induction of 
anaesthesia, was regarded as the baseline value for both neutrophil 
counts and TBA reactivity measurements. 
Neutrophil counts 
Left atrial and central venous neutrophil counts before, 
during, and after the bypass procedure are shown in Fig.?. Just 
prior to removal of the aortic cross clamp both left atrial (LA) 
and central venous (CV) neutrophil counts had fallen significantly 
in a parallel fashion from initial values of 5.3 ± 0.7 (x 109 
cells I l) and 5.3 ± 0.7 to 3.0 ± 0.5 and 2.9 ± 0.5 respectively (p 
< 0.001). This trend persisted after removal of the aortic cross 
clamp in the left atrial samples particularly, where it was still 
present 30 minutes later (3.T ± 1.1, p< 0.01). Significant 
gradients of neutrophil counts across the lung were demonstrated 
only in the samples taken 10 minutes (0.7 ± 0.2) and 30 minutes 
(1.2 ± 0.5) after cross clamp removal (p< 0.01 and p< 0.001 
respectively, versus baseline gradients). 
Neutrophil counts in the control thoracotomy dogs showed 
similar patterns in both CV and LA lines with a gradual rise during 
the course of thoracotomy from baseline values of 6.3 ± 1.6 (CV) 
and 6.6 ± 1.9 (LA) to respective values 90 minutes later of 8.3 ± 
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2.2 and 8.8 ± 2.6. This rise was not however statistically 
significant, and at no stage was a significant transpulmonary 
(CV-LA) gradient present. 
Trends in total white cell counts were mirrored closely by the 
neutrophil counts, and no significant changes were shown in other 
polymorphonuclear or in mononuclear cells. 
TBA reactive products 
There was a progressive rise in TBA reactivity in both CV and 
LA samples over the course of CPS (Fig.8). Baseline levels of 6.4 
± 0.5 nmol/l (CV) and 6.5 ± 0.5 nmol/1 (LA) rose 30 minutes after 
cross clamp removal to 8.6 ± 1.0 nmol/1 and 9.4 ± 1.0 nmol/1 
respectively (p < 0.01). Corresponding values after protamine 
administration (9.4 ± 1.6 nmol/1 and 9.8 ± 1.0 nmol/1) were 
likewise significantly different from baseline values. A 
significant transpulmonary gradient was shown only in the sample 
taken 30 minutes after cross clamp removal ( 0.8 ± 0.3 nmol/1, p < 
0.01 ) • 
The concentration of TBA reactive products tended to rise in 
the control thoracotomy dogs with baseline CV and LA levels of 5.9 
± 0.6 nmol/1 and 6.0 ± 0.7 nmol/1 rising at the end of the 
procedure to 7.7 ± 1.0 nmol/1 and 7.5 ± 1.0 nmol/1 respectively. 
This rise was not however, statistically significant. As with the 
neutrophil counts in the control thoracotomy dogs, LA and CV 
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concentrations were similar throughout and at no time did a 
significant transpulmonary gradient exist. 
Lung transvascular protein flux 
Individual results of lung 113min-transferrin flux studies 
are represented in Fig.9. In the CPS dogs the mean baseline flux 
was -0.2 ± 0.3 units and after bypass there was a significant 
increase to 3.3 ± 1.0 units (p < 0.01). Five out of eight dogs 
showed protein flux outside the normal range (defined by the 95% 
confidence limits in all 14 dogs on their baseline study day, 0.0.± 
0.2). The control thoracotomy dogs had protein flux results 
similar to baseline studies of the CPS group (0.2 ± 0.3) but no 
significant increase was seen after thoracotomy (0.2 ± 0.2). No 
individual animal in this control group had a value for protein 
flux outside the normal range. 
Alveolar to arterial oxygen tension gradient 
The gradient rose from 154 ± 12 mmHg before bypass to 296 ± 6 
mmHg three hours after bypass (p < 0.001). The control animals did 
not show a significant increase in gradient-with respective values 
of 140 ± 17 mmHg and 152 ± 11 mmHg. 
Correlation between variables 
Significant neutrophil and TSA reactive product concentration 
transpulmonary gradients were demonstrated only in the bypass 
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animals after removal of the aortic cross clamp, when coronary and 
pulmonary perfusion were restored. after a period of asystole. 
Fig.10 shows the transvascular protein flux results after bypass 
for individual animals, plotted against the difference in LA-CV TBA 
concentration gradients 30 minutes after and just prior to cross 
clamp removal. This transpulmonary gradient was used as an index of 
net lung lipid peroxidation when pulmonary perfusion recommenced. 
There was a significant Spearman•s rank correlation coefficient 
between these variables (rs = 0.81, p < 0.05). Similarly Fig.11 
shows individual values for net pulmonary neutrophil sequestration 
after cross clamp removal (gradient 30 minutes after - gradient 
just prior to clamp removal) plotted against the gradient 
difference for TBA reactivity ~oncentrations over this same time 
' period. Spearman•s rank correlation for these two variables was 
again significant (rs = 0.76, p < 0.05). In individual animals 
this index of neutrophil sequestration also correlated with 
transvascular protein flux after bypass (rs = 0.66, p < 0.05). 
No relationship existed between each animal •s 
alveolar:arterial oxygen tension gradient and value for lung 
protein flux. 
Histology 
Examination of biopsied lung tissue under light microscopy · 
showed accumulation of granulocytes in alveolar capillaries after 
bypass only. No intra-alveolar granulocytes were seen. In addition, 
no perivascular or intra-alveolar edema and no interstitial 
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inflammatory cell infiltrate were noted. Electron microscopy did 
however show signs of cellular injury after bypass with endothelial 
swelling, disruption of the basement membrane, and neutrophils 
tightly apposed to endothelial cells. In addition mild interstitial 




This study demonstrates that CPS in dogs is associated with 
significantly increased lung transvascular protein flux, neutrophil 
sequestration and egress from the lung of products of lipid 
peroxidation. Significant correlations were demonstrated between 
peroxidation product egress from the lung and both increased 
vascular permeability and pulmonary neutrophil sequestration. 
The finding of abnormal protein flux in five out of the eight 
bypass dogs, but in none of the six dogs subjected to thoracotomy 
alone, suggests that this feature was not a non-specific response 
to anaesthesia and major thoracic 
related to CPS or it•s specific 
surgery, -but was a feature 
associated perturbations 
(extra-corporeal circulation and pulmonary blood flow diversion, 
hypothermia and protamine administration). Since none of the 
bypass dogs showed morphological evidence on light microscopy of 
parenchymal damage after bypass, this increased protein flux_ 
probably reflects a mild injury. This was confirmed by electron 
microscopy which also revealed interstitial edema. Presumably this 
finding reflects a less severe microvascular injury where lung 
lymphatic clearance is still able to deal with increased fluid and 
solute flux. The animals in this study thus avoided frank 
intra-alveolar edema as in the post-perfusion lung syndrome. 
Nontheless these data represent one end of the spectrum of lung 
injury after CPB; this may have been either a transient abnormality 
or alternatively there may have been, in time, progression to frank 
pulmonary edema·. The bypass dogs showed a significant increase in 
154 
alveolar:arterial oxygen tension gradient after the procedure; the 
lack of relationship between this variable and lung protein flux, 
together with the absence of intra-alveolar edema histologically, 
would suggest that the main determinant of the profound hypoxemia 
after bypass was ventilation:perfusion inequality. 
Neutrophil counts in the bypass group showed a different 
pattern to those dogs who underwent thoracotomy alone. The initial 
parallel fall in both CV and LA neutrophil counts early in the 
bypass procedure, without a transpulmonary gradient, implies 
sequestration of cells outside the lungs, probably in the 
splanchnic or mesenteric vascular beds. This fall cannot be 
ascribed to haemodilution as this was specifically corrected for in 
all samples. After release of the aortic cross-clamp and reversal 
of complete cardiac asystole, a significant neutrophil gradient 
across the lungs was noted, implying intrapulmonary sequestration. 
Failure to establish a transpulmonary gradient for neutrophils or 
TBA reactivity in those dogs not undergoing CPB, suggests that 
bypass itself is necessary for significant cell sequestration and 
peroxidation product egress from the lung. The temporal 
relationship between aortic cross clamp removal and lung neutrophil 
sequestration and peroxidation product egress is similar to that 
reported after human CPB (234). In contrast to the findings in that 
study however, is the observation that dogs show progessive falls 
in neutrophil counts in the pre-cross clamp removal phase of 
bypass. Similar falls in neutrophil counts have however, been 
reported in another human bypass study, although transpulmonary 
counts were not obtained and neutropaenia was only a transient 
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phenomenon (236). An additional contrast to the previously 
reported human CPS study (234), is the timing in dogs of lung 
neutrophil sequestration and oxidant production. In humans both 
features were present five minutes after cross clamp release. In 
this study although significant neutrophil sequestration was noted 
within 10 minutes, a transpulmonary gradient for TSA reactivity was 
shown only in the sample obtained 30 minutes after cross clamp 
removal. 
Notwithstanding these differences between human and dog 
studies, this study supports the concept that resumption of 
pulmonary vascular perfusion, after the period of total pulmonary 
blood diversion, is crucial in the mediation of lung neutrophil 
trapping, tissue peroxidation and increased pulmonary vascular 
penneability. Complement activation and pulmonary leucostasis have 
been demonstrated in extracorporeal systems (237) including CPS 
(228,236). Polymorphonuclear leucocytes when exposed to activated 
complement, aggregate (238) and release oxygen radicals which in 
vitro damage endothelial cells (190). After cross clamp release, 
rewanning and reversal of asystole, complement activated 
neutrophils perfuse the pulmonary vascular bed for the first time. 
This could account for neutrophils sequestrating in the lungs at 
this particular phase of the bypass procedure. Alternatively, 
reperfusion of the relatively ischaemic coronary and pulmonary 
vasculature could result in a burst of oxygen free radical 
production (239) and pulmonary endothelial cell injury. 
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Since protamine administration has been associated with 
transient neutropaenia (240) and increase in pulmonary vascular 
permeability both clinically (241) and experimentally (242), it•s 
possible role in this study should be addressed. As the effect of 
CPB and its associated perturbations were examined, only the bypass 
group received protamine. No exacerbation of neutropaenia was noted 
in the blood sample taken after protamine (point 6) and the role of 
the drug in influencing this variable can thus be disregarded. The 
role of protamine in mediating the alteration in pulmonary 
microvascular integrity remains speculative however. Frater and his 
associates showed that clinically, protamine administration via the 
left atrial line minimised the associated haemodynamic effects of 
systemic arterial hypotension and decrease in systemic vascular 
resistance (243). Accordingly in this study protamine was given via 
the left atrial line and no significant change in haemodynamic 
variables resulted. Clinical descriptions of protamine-associated 
non-cardiogenic pulmonary edema featured marked peripheral vascular 
collapse within an hour of administration (241); our finding of 
less severe pulmonary vascular injury at three hours without 
significant haemodynamic alterations, would tend to negate, 
although not totally rule out, a role for the drug in the pulmonary 
vascular permeability changes observed. 
Does measurement of plasma TBA reactivity reflect lung tissue 
peroxidation. Considerable theoretical and practical difficulties 
exist in attempting to demonstrate tissue lipid peroxidation using 
the thiobarbituric acid technique. Peroxidised cell membrane lipids 
are rapidly lost from the cell into the plasma as has been 
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demonstrated in vitro (244). These workers showed that tissue lipid 
peroxidation induced hydrolytic enzyme activity which could 
profoundly alter analysis of tissue for TBA reactivity. These 
considerations were probably responsible for the inability of Ward 
and colleagues (167} to demonstrate lung tissue peroxidation using 
this technique. Because of the rapid loss of TBA reactive products 
into the plasma, it was reasoned that measurement of plasma 
reactivity across the lung would better reflect lung tissue 
peroxidation. Accordingly, the left atrial :central venous gradient 
was used as an index of egress from the lung of tissue oxidants and 
this was interpreted as an indirect measurement of lung lipid 
peroxidation. 
The strong rank correlation demonstrated between lung 
neutrophil accumulation and peroxidation egress from the lung, as 
well as the temporal relationship between these two phenomena, 
suggests that the neutrophil was in part responsible for. production 
of the tissue oxidants. Similarly, the significant association 
between peroxidation egress, as measured by the difference in 
transpulmonary gradients before and after cross clamp removal, and 
lung protein flux suggests that oxidants were, at least in part, 
responsible for this increase in pulmonary vascular permeability. 
It is unlikely however, that oxidant release was the sole mechanism 
responsible for this finding, although other potential toxic 
substances were not .specifically investigated. Neutrophil 
·proteolytic enzymes have been implicated in the pathogenesis of the 
adult respiratory distress syndrome (88). This may involve 
directly, digestion of lung elastin, or indirectly, amplification 
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of the inflammatory process (245). Activated neutrophils may also 
release arachidonate derived products with potential deleterious 
effects on vascular and airway smooth muscle tone and vascular 
permeability. The probable interrelations-hip of all these potential 
mechanisms of tissue injury is underlined by the observation that 
arachidonic acid metabolism in macrophages or neutrophils is 
associated with oxygen radical production (246). 
In conclusion, this study suggests that neutrophils 
sequestered in the lung play a role in the development of pulmonary 
micovascular injury, which occasionally presents clinically as 
the•post-perfusion lung syndrome•. Although these data imply that 
release of tissue oxidants is one of the mechanisms that may be 
responsible for these findings, firm conclusions cannot be drawn 
until the findings are verified in a study where appropriate 
protective interventions are introduced. Nonetheless, the data 
support the concept outlined in Chapter 6 that the neutrophil is 
important in particular models of lung injury. 
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Figure l 
Neutrophil counts (x 10911, mean± SEM) in central venous (filled 
circles) and left atrial (open circles) samples for the dogs that 
underwent cardiopulmonary bypass. Numbers· on the x axis refer to 
standard times of sampling, as described on Page 146. * p< 0.01; ** p< 
0.001; versus respective central· venous or left atrial values at 
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4 5 6 
Concentration of thiobarbituric acid (TBA) reactive substances (mean ± 
SEM) in central venous (filled circles) and left atrial samples for 
bypass dogs (n=B). Numbers on the x axis refer to the standard times of 
sampling outlined on Page 146. * p< 0.01 versus respective central 
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Fisure 1 
The rates of transvascular.flux of 113min-transferrin expressed as 
protein flux units are shown in individual bypass dogs ( n=8, filled 
circles) and control thoracotomy animals (n=6, open ci rc 1 es) • Both 
groups · have values shown for the baseline study one week before ( 1 eft) 
as well as the study 3 hours after thoracotomy closure (right). * p< 
0.01 versus baseline study 1 week prior to bypass. 
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Ll TBA transpulmonary gradient 
Figure 1Q 
Protein flux units for each individual dog after bypass (n=8) plotted 
·against the difference in transpulmonary gradient (LA-CV) 30 minutes 
after and just prior to removal of the aortic cross-clamp. Spearman•s 
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Ll TBA transpulmonary gradient 
The difference in transpulmonary neutrophil gradient (CV-LA) for each 
individual bypass dog (n=8) 30 minutes after and just prior to removal 
of the aortic cross-clamp, plotted against the transpulmonary gradient 
over the same time period for TBA reactivity. rs = 0.76, p< 0.05. 
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F iyure g 
Electron micrograph (x 20,000) showing the relationship between the 
neutrophil (1) and the endothelial cell lining (3) before institution of 
cardiopulmonary bypass. Important is the clear space visible between the 
neutrophil and the endothelial lining, demonstrating that the cell is 
not apposed to the endothelial surface. Of note also is the multi-lobed 
neutrophil nucleus (2), and alongside the neutrophil is a red cell (6), 
both lying within the capillary lumen. Also visib l e, apparently 
protruding into the alveolar space, is a Type 2 pneumocyte (4) with its 
lamellar cytoplasmic bodies and microvilli (5). 
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FigureD.. 
Further detail on a higher power electron micrograph (x 50,000) taken 
again before institution of cardiopulmonary bypass. The demarcation 
between the neutrophil (1) and the endothelial cell lining (2) is 
clearly visible. Of interest are the neutrophilic granules 
(electron-dense bodies in the neutrophil cytoplasm) and the endothelial 
caveolae (pinocytic vesicles) adjacent to the symbol (2). 
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Figure _!i 
Electron micrograph (x 20,000) from a l ung biopsy taken just after 
coming off bypass. This shows the neutrophil with its multilobed nucleus 
(1) tightly apposed to the endothelial lining. This latter feature can 
be appreciated by the position of the elongated endothelial cell nucleus 
( 2) • 
1 6 7 
Figure ~ 
High power electron m1crograph (x 50,000) from a lung biopsy 2 hours 
after corning off cardiopulmonary bypass. The important feature is the 
gross endothelial swe lli ng (1); orientation is facilitated by the red 
cell lying within the capillary lumen (3) and the alveolar space (2) . 
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CHAPTER 8 
ENDOTOXIN INFUSION __ IN _DO_G_S: DICHOTOMY BETWEEN LUNG ~NE~U~TR~O~P~HI~L 
SEQUESTRATION AND LUNG INJURY DEVELOPMENT. 
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8. ENDOTOXIN INFUSION lli DOGS: DICHOTOMY BETWEEN LUNG NEUTROPHIL 
SEQUESTRATION 
AND LUNG INJURY DEVELOPMENT 
8.1 - Introduction 
Gram-negative sepsis represents one of the most common 
precipitating events for lung injury development. Because of this 
many investigators have used endotoxaemia as a convenient, 
clinically relevant model, to study the pathophysiology of the 
associated lung injury. This model has been particularly 
extensively studied in sheep where the pulmonary functional 
abnormalities mimic many of the features of human ARDS (32). A 
2-phase response is classically described with rise in pulmonary 
artery pressure and alterations in lung mechanics oc·curring within 
the first hour. From 2 hours onward, increase in lung vascular 
penneability is noted in association with lung endothelial cell 
injury. The relative sensitivity of the sheep to endotoxin is not, 
howeve·r, common to all animal species. The rat is able to tolerate 
enormous doses of endotoxin without obvious evidence of lung injury 
(247), while the dog similarly requires large doses to produce 
significant haemodynamic effects (248). Even with large doses of 
endotoxin in the dog, the cardiovascular effects outweigh the 
relatively mild lung injury; this is in contrast to the she.ep where 
severe lung injury can occur in the absence of shock (249). 
The original motivation for this study was to attempt to 





pulmonary transvascular flux 
intention was to develop a model of 
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of 
lung injury that would result in loss of endothelial cell integrity 
similar to that induced by cardiopulmonary bypass, which was 
outlined in the last chapter. The particular reason for choosing 
endotoxin was that it was known to involve similar pathogenetic 
pathways to bypass. Endotoxin infusion produces complement 
activation and the subsequent intrapulmonary neutrophil 
sequestration and activation is thought to be a putative mechanism 
for the effect of endotoxin on the lungs. 
If endotoxin did produce consistent lung injury in dogs, it 
would represent a simple, relatively non-invasive model for further 
investigation. 
significant 
Despite however, producing persistent and 
neutropaenia suggestive of intrapulmonary 
sequestration, the dogs studied showed no evidence of acute lung 
injury. The relevance of this finding to current concepts of lung 
injury pathophysiology is further addressed in section 8.4. 
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8.2 - Methods 
Six mongrel dogs (mean weight 23 Kg, range 18-27 Kg) were 
studied. The animals were anaesthetized with intravenous 
thiopentone (10 mg/Kg) and intubated anp ventilated using a 
Starling pump (rate 14/minute, tidal volume 10 ml/Kg) with an 
inspired gas mixture of nitrous oxide in oxygen (1:1 by volume). 
This was supplemented by halothane 0.5-1.0%. 
The initial preparation included catheterisation of - the 
carotid artery to produce continuous monitoring of systemic 
arterial blood pressure. The internal jugular vein was 
catheterised with a Swan Ganz flow directed catheter so that the 
catheter tip was in the pulmonary artery and a satisfactory trace 
verifying wedging of the catheter obtained. Cardiac output was 
determined by thermal dilution using a cardiac output computer. 
After preparation, each dog was allowed to stablilise for 20 
minutes before baseline transferrin transvascular flux was 
determined. In addition, baseline haemodynamic and arterial blood 
gas data was acquired and blood taken for white cell and 
differential counts from the pulmonary artery and carotid artery 
lines. 
Experimental protocol. 
After 30 minutes baseline measurement of transvascular 
transferrin flux, 4 dogs received an infusion of E. Coli endotoxin 
(serotype 055:85, Sigma Ltd, Dorset, UK) 2 mg/Kg given at a dose 
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rate of 2 mg/minute. After endotoxin infusion, cardiovascular 
measurements and arterial blood gas estimations were performed 
every half hour until completion of the study. The 2 remaining 
dogs were studied in a similar fashion but did not receive 
endotoxin and acted as time course controls. All animals were 
studied for two and a half hours after endotoxin infusion. During 
this time period, ventilation settings were held constant. 
Studies. 
Transvascular 113min-transferrin flux. 
This was performed in a similar fashion to that used in the 
bypass ·study described in Chapter 7. In this study, however, all 
animals were studied closed-chested. Accordingly. the heart 
scintillation probe was placed initially to be just over the 
observed cardiac impulse. ·As before, this position was optimised 
by movements. aimed to maximise counts resulting from 
99mTc-labelled red cells. The lung probe was placed over the 
right mid lung field in all studies.. Once the initial probe 
positions had been determined, they were not moved until all 
studies had been completed. Baseline data pre-endotoxin was 
collected for 30min and after endotoxin infusion counts due to both 
isotopes were monitored continuously for two and a half hours. The 
data was analysed in 30 minute time periods and as previously the 
data for each time period was expressed as protein flux units (x 
10-3 /minute). 
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Assessment of oxygenation defect. 
This was assessed by calculating the arterial to alveolar 
partial pressure of oxygen ratio before endotoxin and at half hour 
intervals thereafter. The alveolar partial pressure of oxygen was 
calculated from the alveolar gas equation as described in Chapter 
4. Arterial oxygen and carbon dioxide tensions were determined on 
an automated analyser and the inspired oxygen concentration (50%) 
verified with a paramagnetic oxygen analyser. 
White blood cell and neutrophil counts. 
White cell counts were performed in duplicate in Neubauer 
chambers and differential counts assessed using Wright's stained 
blood films. Blood samples were taken before endotoxin and at 5, 
30 and 150 minutes after endotoxin. 
Haemodynamics. 
Heart rate, systemic and pulmonary arterial blood pressures 
were monitored continuously. Cardiac output estimations were 
performed in triplicate before endotoxin and at half hourly 
intervals thereafter. The mean of these 3 estimations was used as 
the value for that time period. Pulmonary vascular resistance was 
calculated by the use of the following formula:-
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Mean pulmonary artery pressure - pulmonary capillary" wedge pressure 
cardiac output 
and was expressed in arbitrary units. 
Statistics 
All data is· expressed as mean ± standard error of the mean. 
When serial data was compared with one baseline sample, paired t 
tests were used with the critical p value corrected by the 
Bonferroni method (235). Otherwise the .p value of< 0.05 was taken 
as significant. 
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8.3 - Results 
Neutrophil counts 
Counts taken after endotoxin were expressed as a percentage of 
the baseline pre-endotoxin sample. Values 5, 30 and 150 minutes 
after endotoxin were 29.8 ± 3.2, 18.4 ± 5.8 and 10.8 ± 4.9% 
respectively of the baseline count (p < 0.001). This . indicates a 
severe and persistent neutropaenia over the whole course of the 
study. Trends in total white cell counts were mirrored closely by 
the neutrophil counts, and no significant changes were shown in 
other polymorphonuclear or in other mononuclear cells. Although in 
all cases mean pulmonary artery counts were greater than mean 
systemic arterial counts, this did not at any of the time periods 
reach statistical significance. 
Haemodynamics and oxygenation data. 
This is summarised in Table 5. Persistent significant falls 
in mean artetial systemic blood pressure were noted (p < 0.01) 
which were maximal half an hour after endotoxin infusion (68.3 ± 
5.8 mmHg). Cardiac output fell after endotoxin infusion from 3.1 ± 
0.3 litres/minute pre-endotoxin to 2.3 ± 0.3 litres/minute half an 
hour after endotoxin infusion (p < 0.01). Although the other mean 
values for cardiac output were less than the mean baseline value, 
they did not reach statistical significance. Pulmonary vascular 
resistance increased from 2.7 ± 0.1 units pre-endotoxin to 4.0 ± 




hours after endotoxin, respectively. The value at two and a half 
hours (2.9 ± 0.2 units) was no longer statistically significant. 
Arterial o~ygenation deficit expressed as the partial pressure 
of arterial oxygen to the partial pressure of alveolar oxygen ratio 
was within normal limits and did not differ from the baseline value 
significantly throughut the study. 
Pulmonary transvascular protein flux. 
No mean value for any of the 5 half hour time periods after 
endotoxin differed significantly from the baseline value (0.01 ± 
0.1, 0.07 ± 0.1, 0.2 ± 0.1, 0.1 ± 0.2 and 0.4 ± 0.2 protein flux 
units). Indeed no individual animal had a single value after 
endotoxin that was outside the 99% confidence limits derived from 
the 14 dogs studied on the baseline day in the bypass project 
described in Chapter 7. 
Control studies. 
The 2 control dogs demonstrated no significant change in 
neutrophil counts, haemodynamics, oxygenation or transvascular 
protein flux over the temporally matched period of study. 
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8.4 - Discussion 
These data demonstrate that infusion into dogs of 2mg/kg of 
E.coli endotoxin produces significant haemodynamic effects, severe 
persistent neutropaenia indicative of sequestration within the 
pulmonary vasculature, but no evidence of microvascular injury. 
These findings are of principal interest since they provide 
evidence for a more complex relationship between intrapulmonary 
neutrophil sequestration and lung injury development. 
This study did not include histological assessment; therefore 
conclusions about two of the major experimental variables - lung 
injury and i ntrapul mcnary neutrophi 1 sequestration - are based on 
functional information. The data do show profound and persistent 
neutropaenia after endotoxin infusion but this per se does not· 
necessarily indicate neutrophil sequestration within the lungs. 
Although the gradient of cells across the lungs was at no stage 
significant, this factor does not in itself mean that neutrophils 
didn•t sequestrate within the lungs. If, as seems likely, 
neutrophils sequestered not only within the lungs but also within 
extra-pulmonary tissue 'including the· mesenteric and splanchnic 
vascular beds, any gradient across the lungs would be lost. In 
support of this interpretation is previous histological assessment 
after endotoxin infusion in dogs clearly showing marked pulmonary 
leucostasis (250). 
The finding of an absence of microvascular injury, based on no 
change in pulmonary transvascular protein flux, emphasises the 
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species-specific nature of the response to endotoxin. The lack of 
change in the microvascular permeability index does it seems, 
provide valid evidence for a lack of significant lung injury 
despite the absence of confirmatory morphological assessment. This 
contention is supported by: 
i) the work reported in this thesis. In the cardiopulmonary bypass 
studies pulmonary transvascular protein flux was increased despite 
relatively subtle changes morphologically. This is similar to the 
findings reported in Chapter 10 in the study of platelet activating 
factor. 
ii) the finding of Dauber et al, previously alluded to (109), 
showing that transvascular protein flux is increased before 
increase in extravasacular lung water occurs. 
Both these aspects point to the extreme sensitivity of this 
microvascular permeability technique, and tend to rule out the 
possibility of a false negative finding. Further evidence of the 
.minimal nature of the respiratory dysfunction associated with this 
model, is the lack of significant deterioration in arterial 
oxygenation over the course of this study. Although no previous 
study has examined a similar microvascular permeability index after 
canine endotoxin infusion, McCaffree and colleagues reported a lack 
of change in gravimetric lung water with this model (250). They 
also noted a discrepancy between the lack of lung injury and a 
significant haemodynamic response as in the present study. These 
workers did however, as mentioned, use extravascular lung water 
accumulation as their index of lung injury. 
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Workers at Vanderbilt University, Nashville U.S.A, have 
clearly shown that endotoxin produces significant intrapulmonary 
neutrophil sequestration in the sheep with evidence of lung injury 
(251). In contrast they have demonstrated that infusion of 
zymosan-activated plasma (ZAP) produces similar cellular 
sequestration but minimal lung injury (252). This ZAP-related 
phenomenon appears similar to the results of this study. The 
difference between the neutrophil-endothelial cell interactions in 
these two situations is crucial to future understanding of lung 
injury pathogenesis. Brigham and Meyrick have pointed to the 
difference not being explainable simply by a quantitative 
difference in the numbers of granulocytes sequestered (253). These 
data would support their contention, although based indirectly only 
on the profound and persistent neutropaenia observed. It is more 
likely that there is a qualitative difference, with actual injury 
only being produced in specific circumstances. Henson and 
colleagues have shown accentuation of lung injury resulting from 
intratracheal instillation of chemotactic stimuli, with hypoxaemia 
or infusions of vasodilator prostaglandins (169). A further 
possibility is that injury only occurs when either neutrophils 
produce a specific toxic product (possibly a protease or oxygen 
free radical) or in the presence of a specific humoral mediator 
(possibly platelet-activating factor or an arachidonate 
metabolite). At present these are merely speculations, but 
undoubtedly in future the dichotomy pointed to by this study will 
be the subject of much research. 
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In summary, endotoxin infusion in dogs produced no evidence of 
transferrin accumulation as a measure of lung microvascular injury, 
despite indirect evidence for intrapulmonary neutrophil 
sequestration. These features point to a more complex relationship 
between the latter finding and the development of acute lung 
injury. 












117 ± 3.4 
108.8 ± 6.3 
2.7 ± 0.1 
! 
3.1 ± 0.3 
0.66 ± 0.03 
Time (hours) after endotoxin 
0.5 1.5 
130 ± 4.8 132.8 ± 3.2 
68.3 ± 5.8* 59.5 ± 4.3* 
4.0 ± 0.3* 3.5 ± 0.2 
2.3 ± 0.3* 2.8 ± 0.5 
0.61 ± 0.07 0.63 ± 0.04 
PVR = Pulmonary vascular resistance; MABP = Mean arterial blood pressure; 
HR = Heart rate. 
Results expressed as mean± standard error. * = p < 0.01, versus baseline sample 
2.5 
139.3 ± 3.2 
83.5 ± 4.9* 
2.9 ± 0.2 
3.2 ± 0.4 
0.59 ± 0.09 
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9. HISTAMINE AND BRADYKININ: THEIR EFFECT ON AN INDEX OF ALVEOLAR EPITHELIAL 
PERMEABILITY Jli HUMANS 
9.1 - Histamine 
9.1.1 - Introduction 
The role of histamine as a mediator of altered 
alveolar-capillary permeability in acute lung injury is 
controversial. Its potential role as a mediator was initially 
suggested by the studies of Brigham and Owen in 1975 (254). They 
showed in the sheep that histamine infusion caused a 2-6 fold 
increase in lung transvascular protein clearance as assessed by the 
product of lung lymph flow and lung lymph:plasma protein ratio. 
This implied an increase in pulmonary microvascular permeability, 
suggesting a possible role for histamine in clinical lung injury. 
Later more detailed studies from Brigham•s group implied that any 
permeability response was only transient and that the sustained 
response seen was explainable by an increase in exchanging vessel 
surface area rather than microvascular permeability (255). 
These studies from Brigham•s group were in contrast to other 
studies which did not show a permeability enhancing effect of 
histamine on the pulmonary microcirculation (256,257). The 
conflicting data may be a reflection of the different molecular 
size substances studied and also the different component of the 
alveolar-capillary unit assessed; Pietra and. associates used a 
static model with a large molecular weight probe (256) while 
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Goetzman's and Visscher's study examined alveolar epithelial 
permeability to albumin {257). Propst and associates extended this 
latter study by examining the effect of histamine on alveolar 
epithelial permeability to different molecular weight substances, 
using the in vivo saline-filled dog lung model {258). They showed 
that histamine increased permeability to substances of molecular 
weight up to 10,000 daltons, but like the study of Goetzman, 
permeability to albumin was unaffected. The exact site however, of 
any permeability-increasing effect of histamine is uncertain. 
Pietra and co-workers injected colloidal carbon intravenously to 
delineate the site of vascular leakage after histamine infusion 
(256). They found the marker to be confined to the cellular 
junctions of the bronchial circulation. This was in contrast to 
the original Brigham study {254) which showed an increased effect 
of histamine on lung lymph protein clearance when it was infused 
into the pulmonary circulation rather than the left atrium. The 
role of histamine in effecting an increase in bronchial vascular 
permeability was further assessed by Hutchison and colleagues, 
again using the sheep lung lymph model (259). They showed that 
aerosol histamine increased lung lymph flow with a higher protein 
concentration than under baseline conditions. These findings were 
interpreted as being consistent with an increase in bronchial 
rather than pulmonary vascular permeability. 
This study sought to examine further the effect of histamine 
on lung permeability characteristics by assessing the r~sponse of 
pulmonary 99mTcDTPA clearance to inhalation of a histamine 
aerosol in humans. A preliminary study by other workers showed an 
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apparent increase in lung DTPA clearance in response to histamine 
inhalation (Z60) but the time course of this response and the 
histamine receptor subtype response for mediating this effect had 
not been studied. Assessment of cutaneous vascular permeability 
showed that both H1 and Hz antagonists reduced 
histamine-induced skin weals in man, indicating a possible role for 
both receptor subtypes in vascular permeability (Z61). The Hz 
antagonist cimetidine however, had little or no effect on resting 
bronchial tone or on histamine-induced bronchospasm which was 
exclusively H1 mediated (Z6Z-Z64). This study examined the 
effects of inhaled histamine on the lung epithelial permeability 
index and determined the histamine receptor responsible for this by 
prior H1 or Hz blockade in a double blind randomized 
cross-over fashion. In addition, in the same subjects the effect 
of receptor blockade on histamine-induced bronchoconstriction was 
assessed. 
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9.1.2 - Methods 
Subjects 
Seven healthy non-smoking men (age range 24-36 years) were 
studied. Although not clinically asthmatic, all were atopic and 
had previously demonstrated bronchial reactivity to histamine. 
None had a history of recent upper respiratory tract infection ·and 
none was on medication. The study was approved by the hospital 
Ethical Committee and all subjects gave informed consent. 
Lung epithelial permeability 
Pulmonary clearance of inhaled 99mTcDTPA was measured 
using identical equipment and technique to ·that previously 
described. Throughout this study DTPA clearance was expressed as ~ 
the half-time clearance (T112 ) rather than the rate constant of 
clearance as in previous chapters. Each subject had the clearance 
study performed on six separate occasions; the total dose of 
radioactivity inhaled by each subject was calculated to be less 
than l mCi. The respone to histamine (inhaled concentration 
described under Experimental Protocol) was verified on two separate 
occasions. Subsequently the effect of saline on DTPA clearance was 
assessed before entry into the placebo controlled study of H1 
and H2 receptor antagonists. In the 2 initial histamine 
permeability studies, it was apparent that after histamine 
inhalation the radioactivity clearance was biexponential with an 
initial period of relatively steep fall, which in all subjects was 
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complete by 7 minutes. Thereafter the slope approximated closely 
to the pre-histamine challenge clearance slope. Because of this 
biexponential slope, data from the first 5 minutes was analysed 
separately. 
Bronchial reactivity. 
This was measured by determining the concentration of inhaled 
histamine which produced a 40% fall in expiratory flow at 70% 
expired vital capacity from a partial flow volume manoeuvre. This 
was expressed as the provocation concentration (Pc40 ). The 
partial flow volume technique is a sensitive measurement of small 
airway calibre and avoids possible changes in bronchomotor tone 
produced by a full inflation (265). A rolling-seal dry spirometer 
(P.K. Morgan, Ltd., Gillingham, Kent) was interfaced to a Hewlett 
Packard 85B dedicated minicomputer (Collingwood Measurement, 
Leicester, UK). Histamine was inhaled from a Wright nebulizer 
driven by air at 8 litres/minute for 2 minutes at doubling 
concentrations every 5 minutes from 2 mg/ml until the required 
bronchoconstriction. 
Experimental Protocol 
In 2 of the 7 subjects, inhalation of a concentration of 
histamine one multiple above the PC40 for 2 minutes either 
produced an insigificant increase in DTPA clearance or a 
significant increase that was not reproducible. Five subjects had 
a significant reproducible permeability increase in response to 
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histamine and they were studied further in a double blind 
randomized manner at weekly intervals. Subjects were pre-treated 
orally with either an H1 blocker (terfenadine 60 mg), H2 
blocker (ranitidine 150 mg) or matched placebo at the same time on 
each of the three study day·s. Baseline airway calibre was assessed 
just before ingestion of the matched capsule and 2 hours later. 
This was to exclude an effect of either ranitidine or terfenadine 
itself on airway calibre. Immediately thereafter (2 hours after 
ingestion of the matched capsule) subjects inhaled via the 
ventilator circuit previously described, a nebulized solution of 
99mTcDTPA. After satisfactory counts of 99mTc over the 
lung was achieved (20-30,000/minute) baseline assessment of 
99mDTPA - clearance was performed. After 15 minutes data 
collection, subjects inhaled a histamine aerosol generated by a 
Wright nebulizer at a concentration 1 multiple above the Pc40 
for 2 minutes. While subjects maintained the exact position 
relative to the scintillation counters they held previously, lung 
and thigh radioactivity counts were recorded for a further 25 
minutes. Thereafter, bronchial reactivity was again measured with 
a histamine challenge as described above. This was designed to 
test the effect of pre-existing H1 or H2 blockade or 
placebo on histamine bronchial responsiveness. 
Stastistical Analysis 
Results were expressed as mean ± standard error of the mean. 
Differences between the groups were analysed using analysis of 
variance and paired student•s t tests. 
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9.1.3 - Results 
Lung epithelial permeability response to histamine. 
Mean baseline half-time of clearance was 72.4 ± 5.4 minutes 
which did not fall significantly after saline inhalation (66.8 ± 
9.9 minutes). Histamine caused a pronounced increase in clearance 
in the first 5 minutes after inhalation. In the 2 preliminary 
measurements, the half-time for this initial period fell by 64.6 ± 
2.8% compared to the pre-histamine half-time (p < 0.01). The mean 
fall in half-time for the remaining 20 minutes of the study was 
22.7 ± 8.5% and this fall did not reach statistical significance. 
Neither placebo nor terfenadine pre-treatment had any effect on the 
initial 5 minute permeability increase to histamine with respective 
falls in half-time of 62.6 ± 3.9% and 52.6 ± 6.0% (see Fig.16). 
Rantidine pre-treatment however, conferred significant protection 
with the half-time falling only 27.6 ± 4.9% in the first 5 minutes 
(p < 0.01 compared to terfenadine and placebo pre-treatment). On 
the 3 study days, mean pre-histamine half-time did not differ 
significantly. 
Airway response to histamine 
Terfenadine and ranitidine produced a mean change on baseline 
expiratory flow of 6.6 ± 3.6% and -4.9 ± 1.5% respectively. 
Neither change was significant and neither differed from that 
produced by placebo. Pc40 values were derived for each subject 
on each of the 3 study days. With placebo pre-treatment mean 
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PC40 was not significantly different from the value obtained 
when bronchial reactivity was defined before entry into the study. 
Pc40 rose from 5.1 ± 0.8 mg/ml (geometric mean ± SEM) after 
placebo to 38.0 ± 1.9 mg/ml after terfenadine pre-treatment (p < 
0.001) - see Fig.17. These values underestimate the degree of 
protection conferred by terfenadine on histamine-induced 
bronchoconstriction since 2 subjects had to discontinue the 
histamine challenge at 64 mg/ml because of unacceptable systemic 
side-effects before the required change in lung function. These 
subjects were arbitrarily assigned 64 mg/ml as their PC40 to 
facilitate statistical analysis. After rantidine pre-treatment the 
mean Pc40 (5.5 ± 1.5 mg/ml) did not differ significantly from 
that after placebo pre-treatment. 
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9.1.4 - Discussion 
This study demonstrates that histamine inhalation, at a dose 
that caused significant changes in airway calibre, produced 
profound but transient increase in 99mTcDTPA clearance. Prior 
H1 receptor blockade ·had no significant effect on this 
histamine-induced response. In contrast however, H2 receptor 
blockade did result in marked protection of the initial DTPA 
clearance increase. Assessment of bronchial responsiveness to 
histamine revealed that terfenadine pre-treatment significantly 
increased Pc40 while ranitidine had no effect. This confirms 
the sole role of the H1 receptor in mediating histamine-induced 
bronchoconstriction. 
The failure of H1 receptor blockade and the ability of 
H2 receptor blockade to ameliorate histamine-induced DTPA 
clearance increase was a surprising finding. This discussion will 
therefore, focus on possible reasons to explain the result as well 
as its likely significance. The lack of response to the H1 
blocker could. Qe due to inadequate receptor blockade. This 
however, appears unlikely as terfenadine resulted in significant 
shift to the right of the dose-response curve of bronchial 
responsiveness to histamine. Terfenadine is a specific H1 
antagonist whose plasma concentration peaks 1-2 hours after oral 
ingestion (266). Thus the lack of effect of this drug on the 
alveolar epithelial permeability ·index appears to be a true 
finding, as receptor blockade was theoretically and practically 
adequate. The apparent H2 receptor mediation of increased 
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pulmonary solute clearance may reflect a role for this receptor in 
modulating pulmonary or bronchial blood flow. In vitro studies on 
human pulmonary arteries show that the H2 receptor mediates 
pulmonary dilatation (267). Therefore, this ranitidine-mediated 
effect may be due to an increase in microvascular surface area due 
to recruitment of alveolar capillaries. The transient nature of 
the increased DTPA clearance after histamine would tend to support 
an H2 .. vascular blush
11 with resultant capillary recruitment as 
a possible mechanism. Interestingly, a recent study in sheep 
showed that increased bronchial arterial blood flow after histamine 
is mediated predominantly by H2 receptors (268). This could 
promote airway mucosal oedema ·and the resultant change in 
epithelial cell configuration increase epithelial permeability 
(269). The relative importance of bronchial and pulmonary blood 
flow in influencing 99mTcOTPA clearance in humans is difficult 
to assess precisely. In animal studies, solute clearance appears 
to be dependent on pulmonary rather than bronchial blood flow 
(134); this is in keeping with the known predominant periph~ral 
deposition of the 99mTcDTPA aerosol. 
In further support of these data is the finding that H2 
receptor-blocking drugs have apparent anti-permeability effects in 
other models of lung injury. This raises the speculative 
possibility that this effect is independent of its ability to 
competitively antagonize histamine at H2 receptor sites. This 
notion is supported by 3 diverse experimental findings: 
(1) Cimetidine, a selective H2 antagonist, when infused 
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intravenously, is a pulmonary vasodilator (270). The mechanism for 
this is unknown. 
(2) In mice with acute lung injury induced by cobra venom factor (a 
complement activator), cimetidine produced a 44% reduction in an 
index of lung vascular permeability (166). In contrast, an H1 
antagonist had no protective effect. 
(3) In an acid aspiration model of lung injury in rats, ranitidine 
produced significant reduction in the increased pulmonary 
99mTcDTPA clearance and lung water accumulation which occurred 
in association with the lung.damage (271). · 
Although it is conceivable that histamine release is a component of 
both of the above models of lung injury, it is unlikely that its 
antagonism alone would produce the significant protection observed. 
If the mechanism of these findings is related to histamine 
antagonism, the important physiological effect blocked is likely to 
be pulmonary vasodilatation; otherwise the drug must possess some 
other unknown protective effect unassociated with histamine 
blockade. 
In summary, histamine produced only a short-lived increase in 
pulmonary solute clearance which appeared to be H2 receptor 
mediated. This is probably a haemodynamic effect related to 
pulmonary or bronchial vasodilatation. These data do not appear to 
support the notion that histamine plays an important role in 
mediating acute lung injury. In vivo endogenous histamine release 
may however, result in much higher tissue concentrations. Caution 




9.2 - Bradykinin 
9.2.1 - Introduction 
Like histamine, bradykinin is unequivocally a potent mediator 
of vascular permeability in the systemic microcirculation 
(272,273). Its effect however, on the pulmonary circulation is 
less well defined. In sheep in the presence of hypoxia, bradykinin 
induced an increase in lung lymph flow and lung lymph protein 
clearance (274). The authors ascribed this increase in. 
microvascular permeability to hypoxia-mediated depression of 
angiotensin converting enzyme, which normally degrades bradykinin. 
Subsequent studies have not confirmed these data; using the same 
sheep lung lymph model, bradykinin, with or without angiotensin 
converting enzyme inhibition, had no effect on microvascular 
permeability (275). More recently, other workers have examined the 
effect of bradykinin infusion, with or without simultaneous 
hypoxia, on sheep pulmonary clearance of 99mTcDTPA (276). 
Bradykinin did not increase lung solute clearance either with or 
without coexistent alveolar hypoxia. Additionally, they showed no 
impairment in the ability of the lungs to clear bradykinin despite 
profound alveolar hypoxia. 
This study assessed in humans the effect of bradykinin 
inhalation - at a dose that had previously caused significant 
bronchoconstriction - on pulmonary 99mTcDTPA clearance. This 
represented the first attempt to extend previous animal studies of 




9.2.2 - Methods 
Four healthy non-smoking subjects (age range 22-36 years) were 
studied. All subjects were atopic and mildly asthmatic. None had 
a history of recent upper respiratory tract infection and none was 
on medication. The study was approved by the hospital Ethical 
Committee and all subjects gave informed consent. The subjects had 
previously taken part in another study which assessed bronchial 
responsiveness to bradykinin. In that study, the provocative 
concentration required to cause a 35% fall in specific airways 
conductance (PC35 ) using a computeri~ed body plethysmograph had 
been assessed. Bradykinin had been delivered via a compressed air 
nebuliser controlled by a breath-actuated dosimeter. Each dose 
consisted of 5 slow vital capacity breaths from the nebuliser. 
Full details of this protocol are described elsewhere (277). The 
required fall in airways conductance was reached in the subjects at 
bradykinin concentrations ranging from 0.03 to 16 mg/ml. For the 
assessment of 99mTcDTPA clearance, each subject inhaled their 
PC35 dose in an identical manner to that described above. 
Lung epithelial permeability. 
This was performed as previously described in this thesis. 
After collection of baseline DTPA clearance data, subjects inhaled 
their own Pc35 dose while reclining semi-supine. As with the 
histamine study, this inhalation was accomplished without moving 
from the position held during the DTPA clearance study. The dose 
of bradykinin was delivered by 5 slow vital capacity breaths from 
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the . dosimeter-controlled nebuliser. Immediately thereafter 
clearance data of DTPA was collected for a further 20 minutes. The 
half-time of clearance for each of the 4 subjects was calculated 
both before and after bradykinin inhalation. 
Statistics 
Results are presented as mean ± standard error of the mean. 
The paired student•s t test was used to compare half-times before 
and after bradykinin inhalations. 
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9.2.3 - Results 
The linear correlation coefficients of the corrected 
99mTcDTPA clearance data plotted again~t time, from which the 
clearance half-time is derived, ranged between -0.95 and -1.0 in 
the 8 DTPA clearance slopes analysed. Half-time clearance before 
bradykinin was 66.4 ± 5.8 minutes and after bradykinin was 60.8 ± 
7.9 minutes (non-significant difference). No individual subject 
had a significant fall in DTPA clearance half-time after 
bradykinin. 
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9.2.4 - Discussion 
These data indicate that bradykinin inhalation does not 
increase pulmonary epithelial permeability to a small molecular 
weight solute in humans. This finding is compatible with that of 
o•srodovich and colleagues who studied the effect of bradykinin 
infusion on the pulmonary clearance of 99mTcDTPA in sheep 
(276). Clearance from the lung of this solute is, as previously 
discussed, largely diffusion-dependent with the airway epithelium 
rather than the microvascular endothelium, the rate-limiting step. 
Thus it is possible that bradykinin had a small effect on 
endothelial permeability which is not reflected in these data. 
This is however, unlikely in view of the equivocal, largely 
negative, previous experimental studies of bradykinin and pulmonary 
vascular permeability. 
Thus notwithstanding the potent effects of bradykinin on the 
systemic microcirculation, this study supports the concept that 
this mediator is unlikely to play a role in the increased alveolar 












































The effect of pretreatment with placebo, H1-antagonist (terfenadine) 
or H
2
-antagonist (ranitidine) on the pulmonary clearance of 
ggmTcDTPA after inhaled histamine. The figure shows the mean ± SEM 
percentage fall in the half-time of clearance in the first five minutes 




















The effect of pretreatment with placebo, H1-antagonist (terfenadine) 
or H2-antagonist (ranitidine) on bronchial responsiveness to 
histamine. Values shown are the geometric mean PC40 for all 
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10. PLATELET ACTIVATING FACTOR INFUSION~ DOGS: ASSESSMENT OF LUNG 
TRANSVASCULAR PROTEIN FLUX 
AND RELATED CARDIORESPIRATORY VARIABLES 
10.1 - Introduction 
Platelet activating factor (PAF) is one of the most potent 
inflalllTlatory mediators to be recently identified. Henson reported 
originally the isolation of a soluble factor from 
antigen-sensitized basophils, that induced histamine release from 
platelets (278). Subsequently, it has been shown to be released by 
a variety of inflammatory cells including neutrophils, platelets, 
macrophages and monocytes (279,280). The mediator has been 
identified as a low molecular weight phospholipid, acetyl glyceryl 
ether phosphorylcholine (281), and is usually referred to as AGEPC 
in the American literature. It has a wide spectrum of biological 
activities including in vitro platelet and neutrophil aggregation 
and stimulation (281-283). Intravenous infusion of PAF into 
rabbits produces acute neutropaenia and thrombocytopaenia together 
with profound cardiopulmonary changes, including systemic 
hypotension, increased pulmonary artery pressures and increased 
airway resistance (284,285). These latter changes are typical of 
those which develop during IgE-induced systemic anaphylaxis in the 
rabbit and suggest that this phospholipid is an extremely important 
mediator of allergic and inflammatory responses. 
An additional important proinflammatory property of PAF is its 
ability to increase vascular permeability. This was first alluded 
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to by McManus and co-workers in 1981 (286); they showed that PAF 
infusion into baboons caused a dramatic increase in haematocrit. 
They interpreted this increase as being due to loss of 
intravascular fluid due to altered vascular permeability, although 
the sites of extravascular water accumulation were not further 
investigated. In subsequent work from this group, they 
investigated a morphological correlate of increased vascular 
permeability in extrapulmonary tissue (287). In this study, PAF 
was potent in inducing Evans blue dye extravasation in skin and 
cremaster muscle. Concomitant with the vascular permeability 
changes, leucocyte emigration from venules was noted. These 
findings have been confirmed and extended by other groups focussing 
on the systemic microcirculation. Using the hamster cheek pouch, 
PAF was shown to induce macromolecular extravasation from venules 
as well as polymorphonuclear leucocyte adherence and emigration 
(288). 
Few studies have assessed the effect of PAF on the 
permeability characteristics of the pulmonary microcirculation in 
vivo. Available evidence suggests that exogenous PAF can induce 
pulmonary oedema in an isolated perfused guinea pig lung system and 
this is associated with increased levels of metabolites of 
prostacyclin and thromboxane in the perfusate (289). This effect 
of PAF was platelet-independent in contrast to earlier work in 
isolated rabbit lungs where the PAF-induced pulmonary oedema was 
dependent on the presence of human platelets (290). Mojarad and 
co-workers did examine the effect of PAF in vivo using a dose that 
did not change pulmonary haemodynamics or platelet and neutrophil 
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counts (66). In this canine study, microvascular permeability was 
assessed by lung lymph protein clearance. Small but significant 
increases were noted in this index but these were unassociated with 
obvious morphological injury. 
Prompted by the paucity of data available on the effect of PAF 
in vivo, this study aimed to assess this putative mediator further 
by examining in dogs its effect on a dynamic index of pulmonary 
microvascular integrity. The transvascular protein flux of 
113min-transferri n was studied rather than the pulmonary 
clearance of 99mTcDPTA as the former index alone could provide 
a dynamic, continuous assessment. In order to mirror the clinical 
situation, a dose of PAF was selected which, based on previous 
canine studies, was likely to elicit major but non-lethal 
haemodynamic effects. 
assessed by: 
In this study, acute lung injury was 
(1) Examining continuously the pulmonary transvascular flux of 
113m I t f · t · d n- rans err1n o prov1 e a dynamic index of pulmonary 
microvascular permeability. 
(2) Measurement of gravimetric lung water before and after PAF 
infusion to provide an index of extravascular lung water 
accumulation. 
(3) Histological (including electron microscopic) evaluation of 
lung biopsies to provide a morphological correlate for the above 
functional indices. In addition to assessment of alveolar 
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capillary injury, histological evidence for platelet and neutrophil 
sequestration within the pulmonary microvasculature was sought. 
The results of the study demonstrate that PAF induces acute 
lung injury in vivo, supporting a role for the mediator clinically 
in ARDS. 
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10.2 - Methods 
Animals and anaesthesia. 
Ten greyhound dogs (mean weight 26 Kg, range 22 to 33 Kg) were 
studied. The animals were anaesthetized with intravenous 
thiopentone (10 mg/Kg) and intubated and ventilated using a 
Starling pump (rate 14/minute, tidal volume 12 ml/Kg) with an 
inspired gas mixture of nitrous oxide in oxygen (1:1 by volume). 
This was supplemented by 0.5-1.0% halothane. 
Operative procedure and instrumentation. 
After induction of anesthesia, femoral arterial and internal 
jugular vein catheters were inserted to provide continuous 
monitoring of heart rate, systemic arterial blood pressure and 
central venous pressure. A right thoracotomy was performed and 
another catheter introduced directly into the left atrium for blood 
sampling and pressure recording. A 7 French thermistor tipped, 
flow directed Swan Ganz catheter was inserted through the right 
atrium and right ventricle into the pulmonary artery, where its 
position was verified by the appropriate pressure tracing. The tip 
of the catheter was not wedged as left atrial pressure was 
monitored directly. Through this catheter cardiac output was 
determined by thermal dilution using a cardiac output computer. 
Drug administration. 
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Known amounts of PAF aliquots, prepared from bovine heart 
lecithin by a modification of a previously described method (281), 
(Sigma Ltd, Dorset, UK) were stored at -20°C having been 
dissolved in chloroform. On the day of study, the solvent was 
evaporated and the PAF redissolved in saline containing 2 mg bovine 
serum albumin/ml. Each dog received 1 ug/Kg PAF (usual volume of 
injectate 6-7 ml) as a bolus injection over 2 minutes directly into 
the pulmonary artery line. 
Studies performed. 
(1) Measurement of transvascular lung protein flux • 
. The technique used here was identical to that described in the 
canine bypass study which was outlined in Chapter 7. Briefly, 
autologous 99mTc labelled red cells were injected along with 
113mrn which had been demonstrated to bind to transferrin in 
vivo (approximately 1 and 0.5 mCi of isotope activity 
respectively). Scintillation detectors (5.1 x 5.1 em sodium iodide 
crystals) were placed over the heart and right mid lung field. The 
probe over the heart was placed by direct vision and its positjon 
optimized as previously by ensuring that counts due to 99mTc 
red cells, as a reflection of the intravascular pool, were 
maximized. The isotopes were injected 30 minutes after thoracotomy 
and instrumentation were completed. Subsequently, data was 
acquired continuously until completion of the study. Initial data 
was collected for 30 minutes prior to injection of platelet 
activating factor (n=6) or equivalent volumes of diluent (n=4) and 
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for three and a half hours after injection. All data was analysed 
in 30 minute time periods. Thus, a value of protein flux units (x 
10-3/minute) was derived from the pre-PAF or control injection 
periods as well as 7 values to represent the 210 minutes of study 
after injection. The method of data acquisition and analysis was 
identical to that already described in Chapters 4 and 7. 
(2) Haemodynamic Studies 
Heart rate, mean systemic arterial blood pressure, mean pulmonary 
artery and left atrial pressures were recorded and displayed 
continuously. Cardiac output measurements were performed before 
PAF or control administration and at 1, 5, 10, 15, 30 minutes 
afterwards and thereafter at half hourly intervals until 210 
minutes when all studies were completed. On each occasion, cardiac 
output measurements were performed in triplicate and a mean value 
taken. Pulmonary vascular resistance was calculated as the -
mean pulmonary arterial pressure - mean left atrial pressure 
cardiac output 
and expressed in arbitrary units. 
(3) White cell and platelet counts. 
These were performed manually using Neubauer chambers. 
Differential cell counts were performed on 200 consecutive cells 
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using Wright•s stained blood film. The effect of haemodilution was 
corrected for by simultaneous measurement of the packed cell 
volume. Blood samples were taken at each time point (pre-PAF or 
control) and thereafter at 5, 15, 30, 60 and 210 minutes, from both 
the left atrial and central venous lines. 
(4) Alveolar to arterial oxygen tension gradient. 
The alveolar partial pressure of oxygen was calculated from the 
alveolar gas equation described in Chapter 4. Arterial oxygen and 
carbon dioxide tensions were determined on an automated analyser 
and the inspired oxygen concentration was verified with a 
paramagnetic oxygen analyser. Arterial blood was sampled before 
and immediately after PAF or control injection and at half hourly 
intervals thereafter until all studies were completed. 
(5) Peak inflation pressure. 
This was monitored before PAF or control injection, immediately 
thereafter and at 5,15,30 minutes and then at 30 minute intervals 
until completion of the study. This was used as an indirect index 
of airway calibre. 
(6) Gravimetric lung water. 
Biopsies were taken from the right middle lobe before drug or 
control administration and at the end of the study. Gravimetric 
lung water was calculated by a modification of the method of Pearce 
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et al (99). Correction for residual blood in tissue was 
facilitated by counting known weights of blood and lung tissue for 
99mTc labelled red cells which had already been introduced for 
the study of transvascular protein flux. An example of the 
calculation involved in deriving the baseline wet to dry weight 
ratio in one of the PAF studies is outlined here: 
wet weight (~) .9.!x weight (~) 
Lung tissue 1.4297 0.3031 
Blood 1.0782 0.2682 
Calculation of correction for residua 1 blood: 
a) 1.0392 gm tissue homogenized in 9 ml saline 
1 ml of homogenate yields 427 counts/minute (cpm) 
Therefore total count in tissue = 427 x 9 = 3847 cpm 
b) 1.0134 gm of blood gave 16,725 cpm 
c) Weight of blood in tissue= (3847 + 16,725) x 1.0134 
= 0.233 gm/1.0392 gm tissue 
d) True wet weight of tissue = 1.4297 - (0.233 x 1.4297 t 1.0392) 
= 1.4297 - 0.3206 
= 1.109 gm 
e) Dry weight of same tissue = 0.3031 - (0.3206 x 0.2682 + 1.0782) 
= 0.2242 gm 
f) Corrected wet/dry weight ratio= 1.109 t 0.2242 = 4.946 
(7) Lung histology 
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Lung biopsies from the right middle lobe were taken before PAF or 
control administration and at the end of the study. The tissue was 
divided immediately for light and electron microscopic study. For 
light microscopy the tissue was fixed in 10% neutral buffered 
fonnalin prior to being stained and examined. Tissue for electron 
microscopy was fixed in phosphate buffered 2% glutaraldehyde and 
post-fixed in 1% osmium tetroxide. The histologist was unaware 
whether a particular dog had been given PAF or control solution. 
Summary of protocol. 
After initial instrumentation and equilibration, baseline 
measurement of transvascular protein flux was performed. 
Thereafter blood samples were drawn and a lung biopsy performed for 
baseline histology and weight:dry weight ratio estimati·ons. In 6 
dogs, PAF was then administered over 2 minutes as described above, 
while in the remaining 4 dogs the diluent was given in an identical 
volume. Both groups were then studied in identical fashion with 
continuous transvascular protein flux, haemodynamic monitoring and 
intennittent blood sampling from the left atrial and pulmonary 
artery lines as described. At 210.minutes after PAF'or control 
solution, a further lung biopsy was performed for histology and 
lung water estimation and the study completed. In all animals, 
only intravenous normal saline was infused during the study 




All results are expressed as mean ± standard error of the 
mean. All haemodynamic data is expressed as a percentage of the 
baseline value. When serial data were compared with one baseline 
sample, paired t tests were used with the critical p value (0.05) 
corrected by the Bonferroni method (235). 
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10.3 - Results 
Pulmonary transvascular protein flux. 
A value for protein flux units was derived for each 30 minute 
study period - 1 before PAF or control administration and 7 
thereafter. The results in the PAF groups are represented 
graphically in Fig 18. Baseline pre-PAF protein flux was 0.4 ± 0.1 
units and in the first half hour time period after PAF 
administration only 1 of the 6 dogs had a value (6.3) that was 
outside the 95% confidence limits derived. from the baseline 
studies. As a group, protein flux was significantly increased from 
baseline values from the 4th period (60-90 minutes, 1.7 ± 0.5) 
through the remaining 2 hours of the study (2.5 ± 0.5, 2.5 ± 0.6, 
2.3 ± 0.6, 2.4 ± 0.6 respectively, p < 0.01 for all these periods 
compared to baseline). Despite the PAF group as a whole showing 
increased transvascular protein flux from 60 minutes to the end of 
the study, this response was not uniform as 1 animal had a normal 
value for each post-PAF time period. None of the 4 control dogs 
who were subjected to the same protocol had a single value for any 
of the time periods that was outside the 95% confidence limits 
established from their baseline study (0.2 ± 0.2 units). Baseline 
values in the 2 groups did not differ significantly. 
Gravimetric lung water. 
This was examined in 4 of the 6 PAF dogs and all of the 4 
control animals. In the PAF group, wet:dry weight ratios increased 
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from 4.60 ± 0.2 to 5.75 ± 0.3 (p < 0.01). This constitutes a 25% 
increase in an index of extravascular lung water accumulation. In 
the control group, no significant difference existed between the 
initial and final wet:dry weight ratio (4.73 ± 0.1 and 4.66 ± 0.1 
respectively). 
Lung histology. 
Light microscopic appearances were in all cases within normal 
limits. Only the electron microscopy studies in the PAF group 
revealed significant abnormalities. Gross endothelial cell swelling 
was noted in all PAF animals (see Fig.l9) and in some cases clear 
disruption of the endothelial cell layer was seen (Fig.20). There 
was marked accumulation of granulocytes in alveolar capillaries and 
many of these cells were tightly apposed to the endothelial cell 
(Fig.21). Some granulocytes appeared to be disintegrating 
(Fig.22). No structural abnormalities in or accumulation of 
platelets in the pulmonary microvasculature was noted. 
Haemodynamic studies 
Mean systemic arterial blood pressure (MABP) fell to 42.0 ± 
3.5% of the baseline value 1 minute after completion of PAF 
administration (p < 0.001). A significant fall in MABP persisted 
until 15 minutes after PAF administration (Fig.23) at which point 
it was 67.2 ± 5.8% of the baseline value (p < 0.01). Thereafter 
MABP gradually recovered towards the normal range and at completion 
of the study was 94.0 ± 0.8% of its baseline value. Fall in MABP 
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was accompanied by an initial dramatic fall in cardiac output to 
36.0 ± 4.9% of baseline value 1 minute after PAF administration. 
This fall persisted at 5, 10 and 15 minutes (47.1 ± 7.3, 57.6 ± 6.0 
and 63.8 ± 4.4% of baseline value respectively, p < 0.01). 
Thereafter like MABP, cardiac output gradually returned towards 
baseline values and at completion of the study at 210 minutes after 
PAF was 81.6 ± 1.9 of the baseline value. Pulmonary vascular 
resistance (PVR) was, as outlined, derived from the mean pulmonary 
arterial and left atrial pressures and the cardiac output. 
Immediately after PAF administration (Fig.24) there was a marked 
increase in PVR to 273.8 ± 57.9% of the baseline pre-PAF value (p 
< 0.01). This significant PVR increase persisted at 5 and 10 
minutes (188.2 ± 22.7 and 187.1 ± 16.5% of baseline value 
respectively, p < 0.01 ). Thereafter, although mean PVR remained 
above baseline value, the p value was above the significant 
threshold taking Bonferroni•s correction for multiple comparisons 
into account. At study completion, the PVR was 132.0 ± 13.0% of 
baseline value (p = 0.047). Control animals showed no signficant 
variation in any haemodynamic parameter throughout the experiment. 
Neutrophil and platelet counts. 
These are displayed in Tables 6 and 7. Neutrophil counts 
(Table 7) before PAF administration in central venous and left 
atrial blood were 2.1 ± 0.5 and 2.1 ± 0.4 x 1031mm3 
respectively. After PAF significant falls were noted (p < 0.01) 
which persisted to the 15 minute sample (Fig.25). Only in the 15 
minute sample did a significant transpulmonary gradient (central 
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venous- left atrial) exist. A significant rebound neutrophilia was 
noted in the final sample at 210 min (5.3 ± 1.3 and 5.0 ± 1.0 
respectively). Platelet counts (Table 7) followed a similar 
pattern with initial central venous and left atrial counts of 103.9 
± 19.6 and 98.4 ± 15.1 falling to 54.7 ± 3.5 and 46.2 ± 5.3 x 
lo3;mm3 respectively 5 minutes after PAF (p < 0.001). 
Platelet counts remained significantly depressed until the 15 
minutes (64.4 ± 4.0 and 70.5 ± 8.8 respectively, p < 0.01) but by 
30 minutes were similar to baseline levels. At no stage was there 
a significant transpulmonary gradient for platelet counts. No 
significant alteration in platelet or neutrophil counts were noted 
in the control animals. 
Peak inflation pressure. 
This increased from 18.0 ± 2.0cm H2o before PAF 
administration to 23.8 ± 2.3 em H2o immediately thereafter (p 
< 0.01). This rise was transient and by 5 minutes peak inflation 
pressure was similar to baseline levels (19.2 ± 1.7 em H2o) 
where it remained for the rest of the study. No significant change 
was noted in this variable in the control group over the course of 
the study. 
Alveolar-arterial oxygen difference. 
This gradient increased from 152.4 ± 15.2 mmHg at baseline to 
307 ± 35.4 mmHg at the end of the study in the PAF group (p < 
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0.001). No significant increase occurred in the control group. 
I 
' 220 
10.4 - Discussion 
This study emphasises both the wide range of biological actions, 
and potential importance as a inflammatory mediator of PAF. A single 
infusion of lug/kg of PAF in dogs produced important haemodynamic 
effects with systemic hypotension, reduction in cardiac output and 
increased pulmonary vascular resistance. Most significantly from the 
viewpoint of this study, was the demonstration that in vivo, infusion 
of the mediator produced unequivocal evidence of acute lung injury. 
Functionally, increased microvascular permeability was noted with 
abnormal pulmonary transvascular protein flux; additional evidence for 
loss of microvascular integrity came from the 25% increase in 
extravascular lung water. These findings were extended by the 
morphological demonstration of endothelial cell injury on electron 
microscopy which also showed intrapulmonary neutrophil sequestration. 
Using an indirect index, PAF infusion resulted in only a transient 
airway calibre decrease, but widening of the alveolar-arterial oxygen 
gradient was noted. All these changes appeared specific to PAF, since 
these features were not noted in the control group who were treated in 
all other respects similarly. 
The finding of acute lung injury, supported by both functional 
and morphological evidence, developing after in vivo canine PAF 
infusion is novel, and supports the 2 previously published preliminary 
studies of PAF infusion in sheep (291,292). These studies however, 
only examined lung microvascular permeability, by assessing 
transvascular lung lymph protein clearance, and did not assess 
extravascular lung water or lung morphology. In this study 
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transvascular protein flux in the group as a whole only became 
abnormal 60 min after PAF infusion. This is in contrast to the above 
sheep studies (291,292), where lung lymph flow appeared to increase 
immediately after PAF infusion. While this may reflect genuine species 
differences, another interpretation is the increased sensitivity of 
the lymph protein clearance technique. This was not the case however, 
when Gorin and colleagues compared the two techniques and found a 
close correlation between them (123). If the temporal .findings in this 
study are valid, it would resemble closely the sheep endotoxin model, 
where peak rises in pulmonary artery pressure are seen early and an 
increase in lung vasacular permeability occurs only from 2 hours 
onward (251). Interestingly, the similarity to the endotoxin model 
extends both to the haemodynamic findings and the apparent involvement 
of neutrophils in the production of lung injury. 
Morphologically, intrapulmonary neutrophil sequestration was a 
prominent feature and this was associated with a profound early 
neutropaenia and the demonstration of a transpulmonary gradient. 
Although thrombocytopaenia was also noted in the first hour after PAF 
infusion, this was unassociated with a transpulmonary gradient and no 
increase in pulmonary capillary numbers was noted histologically. This 
would imply that the development of lung injury was independent of the 
platelet. This is consistent with Christman and associates who showed 
that platelet depletion did not attenuate lung injury, (292) and an in 
vitro study where PAF-induced pulmonary oedema in lungs perfused with 
platelet-free solution. As was discussed in earlier chapters, the 
presence of neutrophils in increased numbers in the pulmonary 
capillaries, even if as here they are tightly apposed to endothelial 
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cells, does not neccesarily imply a causative relationship with the 
observed lung injury. PAF may have promoted secondary effects such as 
the production of leukotrienes (293) or thromboxane A2 (287), 
which could have initiated or accentuated pulmonary microvascular lung 
injury. Alternatively, PAF may have damaged the endothelium directly 
and the presence of the neutrophil only reflect an inflammatory 
response to injury. This is supported by work in the rat and rabbit 
systemic microcirculation showing that despite leucocytic infiltrates 
after PAF, neutrophil depletion did not alter the vascular 
permeability changes induced (287). 
The haemodynamic results of this study are very similar to those 
reported by Kenzora and colleagues who assessed the effects in dogs of 
0.4ug/kg PAF infusion (294). They found similarly, a marked drop in 
systemic arterial blood pressure and cardiac output gradually 
returning towards the normal range by 60 min. Unlike this study, the 
effect on pulmonary vascular resistance appeared more transient, 
lasting only a few minutes, although this may reflect the smaller dose 
used. Higher dose infusions (20-22ug/kg) produce profound circulatory 
collapse and occasional death in dogs (295). The particular interest 
of the haemodynamic findings relates particularly to whether PAF, 
since it appears to produce similar effects, is a mediator of 
endotoxic shock. A recent study addressed this notion, by assessing in 
rats the effect of a specific PAF antagonist on endotoxin-induced 
cardiovascular changes (296). The PAF antagonist reversed 
endotoxin-induced hypotension and improved survival, implying a 
central role for the mediator in endotoxaemia. 
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The haemodynamic data are of additional interest, since it is 
conceivable that the cardiovascular changes are playing a part in the 
genesis of the lung injury. Shock of any cause may predispose to ARDS 
(297) and the possibility exists that the lung injury in this study 
was initiated or accentuated by the sustained systemic arterial 
hypotension or indeed by the elevated pulmonary microvascular 
pressure. In an in vitro system, nitroglyc~rin infusion maintained 
baseline pulmonary artery pressure and prevented the development of 
PAF-induced pulmonary oedema (290). This suggested that the oedema was 
hydrostatic in nature. A similar mechanism undoubtedly played no part 
in the abnormalities observed in this study as left atrial pressure 
never rose above 9mm Hg and endothelial cell injury and vascular 
permeability increase were clearly demonstrated. It is still feasible 
however, that arterial hypotension played a role in the pathogenesis 
of lung damage, although this latter feature has been noted with PAF 
when there were no associated haemodynamic alterations (66). The 
extremely transient nature of the reduction in airway calibre, as 
inferred from the peak inflation pressure, is in keeping with data 
from human studies of aero so 1 i sed PAF (298 ,299). As in this ·study, the 
maximum response was seen within minutes of inhalation of the 
mediator. 
This study has provided conclusive evidence that PAF can 
experimentally produce lung injury. This appears independent of 
platelets but the neutrophil or its toxic products may be playing a 
role in the response. The data implicate this unique phospholipid as 
an important mediator of acute lung injury. Further studies are 
required however, to define its complex mechanism of action. 
TABLE 6: Platelet counts before and after platelet activating factor infusion 
CENTRAL VENOUS LEFT ATRIAL 
Pre PAF 103.9 ± 19.6 98.4 ± 15.1 
Post 5 min 54.7 ± 3.5 * 46.2 ± 5.3 
15 64.4 ± 4.0 * 70.5 ± 8.8 
30 76.9 ± 10.3 73.9 ± 15.0 
60 96.1 ± 14.9 96.2 ± 9.4 
END 210 94.6 ± 10.5 95.0 ± 6.0 
* p < 0.01 versus baseline value 




TABLE 7: Neutrophil counts before and after platelet activating factor infusion 
CENTRAL VENOUS 
Pre PAF 2.1 ± 0.5 
Post 5mi n 1.1 ± 0.3 * 
15 1.5 ± 0.3 * ** 
30 1.7 ± 0.4 
60 2.6 ± 0.7 
END 210 5.3 ± 1.3 * 
* p < 0.01 versus baseline sample 
** p < 0.01 versus baseline transpulmonary gradient 
All counts are mean± SEM (X 1o3;mm3) 
LEFT ATRIAL 
2.1 ± 0.4 
0.9 ± 0.3 
1.1 ± 0.4 
1.4 ± 0.4 
2.6 ± 0.7 


























TIME (halfhour periods) 
This demonstrates the individual canine transvascular protein flux at 
baseline (1st· data point) and for consecutive half hour time periods 
after infusion of platelet activati.ng factor. Meantransvascular protein 
flux became significantly incr-eased only after 90 min (see text). One 
animal had an immediate increased value after infusion, while another 




This electron micrograph (as with the others in th is series ) i s from 
lung biopsies taken at the completion of the study (210 m1n afte r 
platelet activating factor infusion ) . This example (x 20,000 ) shows 






( ' ~ , 
I , 
.,. .l 
2 2 8 
... . .. ~ ~ 
• r , .~ I . ' 
Electron micrograph (x 12,600 ) showing , on the left, a red eel 1 (1) 
surrounded by plasma in the capi l lary lun1en. On the right the 




Electron microg raph (x 12,600 ) showing a neutrophil (1) with its 
multilobed nucleus (2), apposed to the endothelia l lining (3) . 
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Figure ..?.f. 
Electron m1crograph (x 32,000) showing the neutrophil (1) and the red 
cell (2) within the capillary lumen. The neutrophil is apposed to the 
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Figure 23 
Mean arterial blood pressure (MABP) response. to platelet activating 
factor infusion, expressed as the percentage of the baseline value. 
Significant falls were noted until 15 min after infusion, thereafter 
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Fig~re 24 
Pulmonary vascular resistance (PVR) response to platelet activating 
factor infusion, expressed as a percentage of the baseline value • 
. Si gni ffcant increases were transient, 1 ast i ng unt i 1 10 min after 


























Pre 15 30 60 210 
TIME (mins) 
Graphic representation of neutrophil counts in central venous (CV) and 
left atrial (LA) blood after platelet activating factor infusion. 
Significant falls were noted until the 15 min sample (p< 0.01), and it 
was only in this sample that a significant transpulmonary gradient 
existed. By the end of the procedure a marked neutrophilia was noted in 
both CV and LA blood. 
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SECTION 3 
MODULATION OF LUNG PERMEABILITY_CHARACTERISITICS BY SELECTED MECHANICAL OR 
PHARMACOLOGICAL INTERVENTIONS 
CHAPTER 11 
THE EFFECT OF POSITIVE END-EXPIRATORY PRESSURE ON PULMONARY DTPA 
CLEARANCE IN NORMAL SMOKERS AND NONSMOKERS 
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11. THE EFFECT OF POSITIVE END-EXPIRATORY PRESSURE ON PULMONARY DTPA 
CLEARANCE IN NORMAL SMOKERS AND NONSMOKERS 
11.1 - Introduction 
The adult respiratory distress syndrome (ARDS) usually requires 
high inspired oxygen concentration during ventilatory support. In 
order that a lower inspired oxygen concentration can be used, positive 
end-expiratory pressure (PEEP) is often applied. Although its early 
application probably does not alter the pathophysiology of ARDS (300), 
its effect on the permeability characteristics of the 
alveolar-capillary unit in man is uncertain. If PEEP were to increase 
solute flux across the barrier, this could conceivably worsen alveolar 
flooding and therefore gas exchange. 
As has been discussed, the clearance of inhaled 99mTcDTPA 
from lung to blood has been used as an index of the permeability of 
the alveolar epithelium. As far as the effect of positive pressure 
breathing on this measurement is concerned, anaesthetised dogs show an 
increase in 99mTcDTPA clearance during ventilation with 10 em 
H2o -of PEEP ( 134). More recent studies in norma 1 humans report 
either an increase in clearance (301) or no significant change (143) 
·during positive pressure breathing. None of the previous studies 
however, measured the effect of PEEP on lung solute clearance in 
healthy smokers. The study described in Chapter 4 showed that chronic 
tobacco smoke inhalation increases 99mTcDTPA clearance to the same 
extent as severe lung injury. Definition of the mechanism of 
increased solute clearance in healthy smokers is thus important and 
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should enhance the value of the technique in assessing lung disease. 
This study therefore compared the effects of 10 em H2o of PEEP on 
99mTcOTPA clearance in healthy smokers and nonsmokers. 
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11.2 - Methods 
Subjects 
Twelve subjects were studied, consisting of six nonsmokers (5 
male, 1 female with a mean age of 32 years, range 24 to 40) and six 
healthy smokers (5 male, 1 female with a mean age of 31 years, range 
27 to 35). Of the six smokers, four were moderate cigarette smokers 
(10-20/day), one smoked a pipe (50 g of tobacco/week), and one smoked 
5-8 large cigars/day. None of the subjects had a recent history of 
upper respiratory tract infection or medication use. The study was 
approved by the hospital ethical committee, and all subjects gave 
informed consent. 
Positive End-expiratory Pressure Apparatus 
PEEP was provided by wide-bore tubing immersed in 10 em of 
H2o. A one-way valve allowed unrestricted inspiration. While on 
PEEP, each subject breathed through a mouthpiece with the nose 
occluded. 
Measurement of Pulmonary DTPA Clearance 
The methodology of study was identical to that outlined in other 
chapters. Briefly, with the nose occluded, each subject inhaled the 
aerosol thr_ough a mouthpiece during tidal breathing for three 
minutes. This produced a scintillation count rate of 40,000 per min. · 
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After inhalation, radioactivity was counted for 20 min with two 
scintillation counters placed over the right anterior chest and the 
right thigh. On each study day, a small dose (100 uCi) of 
99mTcDTPA was given intravenously to allow correction for blood 
and tissue background within the chest, as previously described. From 
a computer-fitted regression line, the half-time clearance (T112) 
of 99mTcDTPA from lung to blood was calculated. All regression 
lines had an r value of 0.95 or greater. 
Measurements of Lung Volume 
Forced expiratory volume in one second (FEV1), vital capacity 
(VC), and total lung capacity (TLC) were measured by body 
plethysmography. To determine the degree of hyperinflation induced by 
PEEP, volume measurements were recorded during relaxed and PEEP 
breathing in ten of the subjects (5 smokers and 5 nonsmokers). 
Ventilation was monitored with inductance plethysmography (Respitrace 
Ambulatory Monitoring Systems Inc., New York, USA) calibrated with a 
single posture technique as previously described (302). The net 
change in lung volume produced by 10 em H2o of PEEP was measured. 
For each subject, the mid-inspiratory level of breathing (functional 
residual capacity plus half the tidal volume) was determined at 
baseline and during PEEP. 
Protocol 
Each subject was studied in a semi-recumbent position on two 
separate days. On the first day, each subject inhaled the 
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99ITTcoTPA, and baseline clearance was measured for 10 min. The 
subject then breathed against PEEP, while clearance was measured for 
another 10 min period. An intravenous bolus of 99mTcOTPA was then 
given to allow a correction factor to be derived while breathing 
against PEEP. On the second day, 99mTcOTPA clearance was measured 
for 20 min without PEEP.and then corrected with a similar bolus of 
99mTcOTPA. The last 10 min of this period served as a second 
baseline. 
Statistical Analysis 
Results were analysed using paired Student t-tests within each 
group and unpaired Student t-tests between groups. A value of P < 0.05 
was accepted as being statistically significant. Values are presented 
as means ± standard error of the mean. 
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11.3 - Results 
Fig.26 shows the corrected values for 99mTc-OTPA clearance 
for both groups. The mean baseline T112 value for nonsmokers was 
48.6 ± 4.7 min (mean± S.E.) and declined significantly on PEEP to 
31.6 ± 4.7 (p < 0.05). All six subjects showed a fall in T112 on 
PEEP, demonstrating increased clearance of 99mTcDTPA from lung to 
blood. In contrast, the mean T112 for the smokers was 27.7 ± 5.0 
min at baseline and was unchanged by PEEP (30.4 ± 6.5 min). None of 
the smokers' individual values changed significantly. 
To assess the possible influence of PEEP-induced changes in blood 
volume within the chest, the mean PEEP T112 values, using day 1 
correction factors, derived while on PEEP, were also compared with the 
baseline measurements obtained on the second day, when no PEEP was 
applied (Fig.27). For the nonsmokers, the mean T112 on PEEP (31.6 
± 4.7 min) was significantly lower (p < 0.05) than either baseline 
value (48.6 ± 4.7 min on the same day, using that day's correction 
factor and 53.8 ± 6.3 min using the day 2 correction). In contrast, 
the mean T112 for smokers on PEEP was no different from eithe-r 
baseline value. (26.5 ± 5.1 min on the same day and 27.7 ± 5.0 min on 
the second day). 
The mean FEV1, VC, and TLC for the nonsmokers (3.61 ± 0.28, 
4.64 ± 0.31, and 6.26 ± 0.30 liters respectively) were slightly higher 
but not statistically different from the same measurements in the 
smokers (3.29 ± 0.29, 4.00 ± 0.38, and 5.54 ± 0.71 liters 
respectively). No subject showed evidence of airway obstruction. While 
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breathing against PEEP, all subjects demonstrated an increase in tidal 
volume. The mean changes in lung volume produced by 10 em H20 
PEEP were 925 ± 170 ml in the nonsmokers and 785 ± 203 ml in the 
smokers, which were not significantly different. 
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11.4 - Discussion 
This study supports the conclusion of Marks and colleagues (301) 
that positive pressure breathing increases 99mTcDTPA clearance in 
nonsmoking humans, and demonstrates in addition that PEEP has no 
effect on 99~cDTPA clearance in smokers. 
In the nonsmokers, there are several possible mechanisms by which 
PEEP may accelerate the flux of solutes from alveoli to blood. 
Firstly, PEEP may increase 99~cDTPA clearance by slowly 
redistributing blood from the chest to the rest of the body during the 
course of the study. This would increase the apparent rate of decline 
of the radioactive count rate measured by the chest probe and 
accelerate the increase in count rate measured over the thigh, 
producing an artefactual increase in 99mTcDTPA clearance from lung 
to blood. However, as demonstrated in Fig.27, the mean clearance 
T112 for the nonsmokers during PEEP was lower than both the 
pre-PEEP baseline (Day 1) and the baseline value corrected for 
background blood in the chest while off PEEP (Day 2). 
PEEP may also be increasing 99mTcDTPA clearance through its 
effects on alveolar surface area. Although there are no studies on the 
effects of hyperinflation on human alveolar surface area, Gil et al. 
(303) showed in excised rabbit lungs that there was very little change 
in alveolar surface area with expansion to 80% of total lung capacity. 
The small increase which did occur was due mainly to unfolding and 
unpleating of the alveolar septa. Furthermore, during inhalation the 
99m TcDTPA presumably disperses throughout the alveolar surface 
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lining (301), so it is difficult to imagine how a small increase in 
surface area can significantly alter the transmembrane 99mTcDTPA 
distribution or contentration gradient. 
Another possible explanation in the nonsmokers is a true increase 
in permeability of the 11 alveolar-capillary barrier ... There is both 
morphological (304,305) and physiological (306,307) evidence that the 
alveolar membrane has a low permeability to small solutes. 
Hyperinflation of atelectatic or isolated fluid-filled animal lung 
segments increases the flux of small molecular weight compounds (308). 
In the present study, alveolar wall stretching may have expanded 
slightiy the intercellular junctions, allowing increased access of the 
99mTcOTPA to the lung interstitium. 
The lack of effect of PEEP on 99mTcOTPA clearance in smokers 
is difficult to explain. The protocol was identical to that followed 
by nonsmokers. There were no significant differences in lung expansion 
produced by PEEP, and the distribution of inhaled one micron particles 
has been shown to be similar in healthy smokers and nonsmokers (309). 
Because of the uncertainty regarding normal pathways for solute flux 
through the alveolar-capillary barrier (310), one can only speculate 
on the reason for this discrepancy between smokers and nonsmokers. The 
most likely explanation is that smokers may have relatively wide 
intercellular junctions that do not vary with lung volume. Simani and 
co-workers (311) showed in guinea pigs that cigarette exposure caused 
penetration of horseradish peroxidase into intercellular clefts of the 
alveolar and bronchiolar epithelium. Small hydrophilic molecules such 
as DTPA are thought to pass from alveoli into blood through such 
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junctions. Although a .. pore radius 11 of about 1 nm has been. ca 1 cu 1 a ted 
(306), a heterogenous population of small and large pores probably 
exists, as suggested by Theodore and colleagues (312) and Kim and 
Crandall (308). If the mechanism of PEEP's effects in normal lungs 
involves 11 0pening up" of the small intercellular clefts, smokers may 
be immune because their junctions are already opened up by 
inflammation and therefore unable to respond to further changes 
induced by volume or pressure. The rate of solute clearance from lung 
to blood in smokers may be limited by the integrity of the 
alveolar-capillary barrier at some point distal to the alveolar 
epithelium. A final possible explanation for these data is that in 
smokers, the rate constants measured may partly reflect dissociation 
of the 99mTcOTPA complex; this would yield free pertechnetate 
(Tc04 -) which will be cleared from the lung at an increased 
rate. Support for this notion comes from recent preliminary 
observations (313). 
In conclusion, these studies have confirmed that the pulmonary 
clearance of 99mTc-OTPA is increased by the application of 
positive end-expiratory pressure in healthy nonsmokers. This effect 
was not however, seen in otherwise healthy smokers. Further studies in 
patients with inflammatory lung disease and using differently labelled 
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Figure 26 
This shows the corrected half-times of 99mTcDTPA clearahce in 
smokers and nonsmokers, before and after breathing with positive 
end-expiratory pressure (PEEP). The nonsmoking group show a significant 













































A comparison of baseline (off 
99mTcDTPA on Days 1 and 2. On 
PEEP) half-time clearances 
day 1 the correction factor was 
of 
derived while breathing with PEEP, unlike day 2, when it was calculated 
without positive end-expiratory· pressure. This shows that in both 
groups clearances were similar on both their respective baseline days, 
negating a role for PEEP-induced changes in pulmonary blood volume in 
causing the fall in nonsmokers half-time. 
CHAPTER 12 
THE EFFECT OF POSITIVE END-EXPIRATORY PRESSURE ON CANINE LUNG 




1£. THE EFFECT OF POSITIVE END-EXPIRATORY PRESSURE ON CANINE LUNG 
PERMEABILITY CHARACTERISITICS AFTER ACUTE LUNG INJURY INDUCED BY 
CARDIOPULMONARY BYPASS 
12.1 - Introduction 
The use of positive end-expiratory pressure (PEEP) during the 
ventilation of patients with pulmonary oedema was first described in 
1938 (314), and is now commonly used in treating patients with the 
adult respiratory distress syndrome (ARDS). Although the application 
of PEEP usually improves oxygenation, whether the use of PEEP can 
alter the course of the disease process remains controversial. In the 
late 197o•s, two randomized controlled studies suggested that the 
early use of PEEP could reduce the incidence of ARDS in patients 
thought to be at risk (315,316). In a more recent study however 
(alluded to in Chapter 11), the prophylactic use of PEEP was not 
associated with differences in the incidence or mortality of ARDS 
(300). 
As discussed in previous chapters, the initial pathophysiological 
consequence of diffuse lung injury is increased permeability of the 
capillary endothelium, alveolar epithelium, or both. Therefore, 
measurement of alveolar-capillary barrier integrity can provide a more 
direct assessment of the effects of therapy such as PEEP. In Chapter 
11, the finding that positive airway pressure increased 99mTcDTPA 
clearance was confirmed in nonsmoking humans. The effect of elevated 
airway pressure on microvascular protein flux has been studied in 
several animals. Ten em H20 of continuous positive airway pressure 
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had no effect on vascular protein and fluid flux in normal sheep lungs 
(317). However, peak airway pressures greater than 45 em H20 have 
been reported to produce increased microvascular fluid and protein 
flux in isolated dog lungs (318) and in rats (319,320). Data on the 
effects of raised airway pressure on microvascular protein flux in 
injured lungs are more limited. In two studies of oleic acid injury in 
dogs, PEEP had no effect on extravascular albumin accumulation (321) 
or the resolution of lung injury (322). In the rats reported by Webb 
and Tierney, however, the addition of 10 em H2o of PEEP to the 
high peak inspiratory pressures was associated with decreased edema 
and mortality (320). 
PEEP thus appears to increase small solute flux from alveolus to 
blood in uninjured lung tissue, while its effect on damaged lung 
alveolar permeability is uncertain. If the application of PEEP also 
caused an increase in capillary endothelial permeability for large 
molecules, then the accumulation of solutes in the interstitium could 
adversely affect lung function and hasten the development of ARDS. In 
this study, the effects of PEEP on solute flux were determined before 
and after cardiopulmonary bypass (CPB) in dogs. As in all studies, the 
clearance of 99mTcDTPA from lung to blood was used as an index of 
epithelial permeability, and the integrity of the pulmonary 
microvascular barrier was assessed by measuring the rate of 
accumulation in extravascular lung tissue of intravenous 
113min-transferrin. 
Lung injury was induced with CPS for reasons outlined in Chapter 
7. Briefly, it was felt to be a model where the putative mechanism of 
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lung injury had more widespread relevance to the pathophysiology of 
AROS than the more generally used chemical means of directly injuring 
the alveolar-capillary unit. In addition, the initial study reported 
in Chapter 7 did provide conclusive evidence that CPB induced an 
increase in microvascular permeability, and that this was associated 
with morphological features of lung injury. Clinically, CPB is 
associated with an early reversible post-operative increase in the 
clearance of 99mTcDTPA (161). This study examined: 
a) whether this was reproducible in canine CPB 
b) if so, what the effect of PEEP was on this change 
c) what the effect of PEEP was on the previously demonstrated 
CPS-induced microvascular permeability increase 
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12.2 - Methods 
Animal Preparation 
Fifteen mongrel and greyhound dogs were used. The anaesthetic 
protocol was virtually identical to that described in Chapter 7. 
Seven days prior to the day of surgery, each animal was anaesthetised 
with intravenous thiopentone (10 mg/kg), intubated, and ventilated 
using a Starling_ pump (rate of 14 per min, tidal volume 10 ml/kg) with 
an inspired gas mixture of 1% nitrous· oxide in oxygen. Following 
determinations of solute flux, the animal was allowed to recover and 
returned to the kennel. 
On the day of surgery, the animal was anaesthetized in the same 
way, except for the addition of a dose of meperidine (2 mg/kg) for 
analgesia. Indwelling lines were placed in the femoral artery and 
femoral vein for blood sampling and continuous pressure monitoring. A 
right thoracotomy was then performed, and a monitoring line was placed 
in the left atrium. Study animals (n = 9) were then given bovine lung 
heparin (300 IU/kg), and cannulae were inserted directly into the 
aorta and vena cava via the right atrium. Cardiopulmonary bypass was 
performed using the identical schedule to that outlined in Chapter 7. 
Fluids were administered to maintain central venous pressure between 5 
and 10 mm Hg. Arterial oxygen and carbon dioxide tensions were 
measured with an automated analyzer. Following haemostasis, the ribs 
were apposed and the animals ventilated for a further four hour 
peri ad. 
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Following thoracotomy in the six control dogs, a left atrial 
catheter was placed and positive pressure ventilation continued as a 
sham bypass procedure. In a similar fashion to the bypass animals, the 
chest wound was closed after 90 min and ventilation continued for four 
additional hours. This was also identical to the control protocol 
used in the initial study. 
Positive End-Expiratory Pressure and Lung Volume Measurements 
PEEP was provided by placing the exhaust tubing of the ventilator 
into a water cylinder to a depth of 10 em. To assess the change in 
·volume produced by PEEP, compliance curves were generated in five 
bypass and three control dogs. Expired tidal volumes were measured 
using an electronic Wright spirometer attached to the endotracheal 
tube. Each dog was placed on 5 em H2o of PEEP for several minutes 
until a stable tidal volume was recorded. PEEP was then withdrawn at 
end-inspiration, and the subsequent expired volume was recorded. This 
procedure was repeated at 10 and 15 em H2o of PEEP. The difference 
between the tidal volume and post-PEEP expired volume was plotted 
against the level of PEEP to obtain a compliance curve for each dog 
both before and after the operative procedure. 
Measurement of Pulmonary DTPA Clearance 
The clearance of inhaled 99mTcDTPA (radioactive half-life 360 
min) was measured as described previously. The aerosol was delivered 
by Ambu bagging through tubing equipped with one-way valves. After 2-3 
min of nebulization (to achieve a lung count rate of 30,000/min), 
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radioactivity was counted for 20 min with scintillation counters 
placed over the right lateral chest and the right thigh. A small dose 
(50 uCi) of 99mTc-OTPA was given intravenously to allow correction 
for blood and tissue background within the chest. From a 
computer-fitted regression line of the corrected lung counts plotted 
logarithmically, the half-time clearance (T112 ) of 
99mTcDTPA 
from lung to blood was calculated. 
Measurement of Microvascular Protein Flux 
An identical methodology to that used in the initial CPB study 
was employed. Data was also acquired and analysed in the same way. 
Protocol 
Each animal was studied on two days. On the control day, the dog 
was anaesthetized and ventilated as described. The clearance of 
inhaled 99mTcOTPA was measured at baseline (10 min), during 10 em 
H2o of PEEP (10 min), and following injection of the 50 uCi of 
99mTcDTPA (10 min). A sample of blood was then taken for labelling 
· · h ggm - h 1 11 11 w1t Tco4 , and t e abe ed red ce s were reinjected, 
along with llJmindium. After a 15 min equilibration period, 
113mrn~transferrin microvascular flux was measured at baseline 
(20-30 min) and during PEEP (20-30 min). The animal was then allowed 
to recover. 
On the following week, the animal was anaesthetized, ventilated, 
and instrumented as described previously. The pulmonary circulation 
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was bypassed, and the blood was oxygenated for 90 min. Two hours after 
restoration of the dog's circulation, measurements of inhaled 
99~cDTPA clearance were made at baseline (10 min), during PEEP 
(10 min), and following the intravenous injection of 99mTcDTPA (10 
min). Transferrin flux was then measured at baseline (20-30 min) and 
9uring PEEP (20-30 min). The six control dogs were studied using a 
similar protocol but with no diversion of pulmonary blood flow. 
Statistical Analysis 
The results were analyzed using analysis of variance. Data are 
expressed as means± standard error. A p value of< 0.05 was accepted 
as being significant. 
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12.3 - Results 
Physiologic Status 
The haemodynamic response to the operative procedure, in both 
gruops of animals, is summarised in Table 8. Central venous 
pressures were maintained between 5 and 10 mm Hg with fluid 
administration. In both groups of animals, left atrial pressures 
(referred to midsternal level) remained less than 5 mm Hg throughout 
the procedure. After closure of the chest, mean arterial pressures in 
both groups declined gradually during the subsequent four hours. 
Blood gas measurements during surgery, in both bypass and control 
animals, are shown in Table 9. In the bypass gro~p, P02 levels 
were significantly lower after completion of the procedure, 
necessitating an increase in the inspired concentration of oxygen. 
The mean P02 in the thoracotomy group did not change as a result 
of the procedure. 
DTPA Clearance 
Measurements of 99mTcDTPA clearance before and after CPS are 
shown in Fig.28. Prior to bypass, the mean T112 for the group was 
18.8 ± 1.9 min. When placed on PEEP, all dogs demonstrated an 
increase in 99mTcDTPA clearance; the mean T112 declined to 
9.4 ± 2.0 min (a net decrease of 50%). The following week, two hours 
after CPB was completed, the mean T112 was 8.1 ± 1.6 min at 
baseline. When placed on PEEP this time, only two dogs showed a 
decline in T112 , one showed an increase, while the remaining six 
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were essentially unchanged. For the group as a whole, the mean 
T112 during PEEP (8.6 ± 2.9 min) was unchanged from the baseline 
value. 
Values for the six control dogs are shown in Fig.29. Prior to 
thoracotomy, all dogs responded to PEEP with an increase in 
99mTcDTPA clearance. The mean T112 fell from 14.9 ± 2.1 min 
during the baseline to 7.1 ± 1.3 min during PEEP (a net decrease of 
52%). After thoracotomy, the baseline clearance was 6.4 ± 1.0 min. 
In contrast to the bypass group, five of the six control dogs showed 
an increase in 99mTcDTPA clearance during PEEP, and the mean 
T112 of 4.1 ± 0.9 min was slightly faster than the baseline 
clearance (p < 0.05)~ 
Pulmonary transvascular transferrin flux 
The overall effect of-PEEP on 113mrn-transferrin flux in the 
animals was greater after the operative procedure compared to 
baseline studies (p < 0.05). 
Fig.30 shows individual measurements for 113min-transferrin 
flux in the nine bypass dogs. On the control day, the mean protein 
flux units (slope/min X lo-3; intercept of line) was -0.36 ± 0.27 
at baseline (i.e. not significantly different from zero) and 0.31 ± 
0.34 during PEEP. Two hours after CPB,_ it was significantly increased 
to 3.25 ± 0.95 at baseline. Only five of the nine dogs- however, 
showed a significantly positive slope index of transferrin flux, 
using as the normal range the mean value ± 2 standard deviations in 
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the 15 control measurements. During PEEP, the mean value was 1.71 ± 
0.80, which was not significantly different from the baseline value 
(p = 0.10). Nonetheless, of the five dogs with a significantly 
positive value at baseline, four showed a decrease during PEEP. The 
one dog that failed to show a lower transferrin flux during PEEP, 
depicted in Fig.30 as a dotted line, died after only 6 min of PEEP. 
Measurements of 113min-transferrin flux in the six control 
dogs are shown in Fig.31. Before thoracotomy, the mean values were 
0.03 ± 0.30 at baseline and 0.57 ± 0.21 during PEEP. After 
thoracotomy, the mean values were unchanged at 0.30 ± 0.39 at 
baseline and 0.82 ± 0.32 during PEEP. 
Lung Volume Measurements 
For both the bypass and control animals, changes in lung volume 
produced by PEEP were higher after thoracotomy. In the experimental 
animals, 10 em H20 of PEEP increased lung volume by 556 ± 44 ml 
prior to surgery and 710 ± 77 ml after bypass. In the control 
animals, 10 em H2o of PEEP increased lung volume by 473 ± 135 ml 
at baseline and 697 ± 109 ml after thoracotomy. 
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12.4 - Discussion 
In this model of early acute lung injury, the application of 10 
em H2o of PEEP had contrasting effects on solute and protein flux 
through the alveolar epithelial and microvascular membranes. In the 
baseline state prior to thoracotomy, the effect of PEEP on canine 
99mTcDTPA clearance is consistent with a recent report in the 
literature; the changes in both the experimental group (50% increase) 
and control group (52% increase) are similar to the previous findings 
of a 49% increase in dogs (134). The mechanism by which 
hyperinflation increases 99mTcDTPA clearance in normal lungs 
remains open to speculation, and may in part be due to the factors 
alluded to in Chapter 11: changes in the alveolar surface fluid 
lining (323), surface area (301,134), or intercellular pores 
(301 ,134). 
In contrast to the normal lungs, the mean 99mTcDTPA clearance 
after cardiopulmonary bypass did not change when hyperinflated. This 
was probably due to changes in the pathways by which 99mTcDTPA 
usually passes from alveolus to blood, such that they no longer 
responded in the same way to hyperinflation, and thus were subject to 
a different rate-limiting step. Explaining the cause of this acquired 
lack of responsiveness is hampered by definitive knowledge about the 
normal pathways for solute flux through membranes in the lung (310). 
Nonetheless, the cardiopulmonary bypass procedure itself is directly 
implicated for two reason~: Firstly, the lack of responsiveness to 
PEEP after bypass theoretically could have been due a smaller change 
in lung inflation. However, the measured change in lung volume 
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produced by PEEP after thoracotomy (with or without CPB) was actually 
greater than before thoracotomy. This is likely to be due to an 
increase in chest wall compliance which offset any changes in lung 
tissue compliance caused by the operative procedure. 
Additional evidence is provided by data from the control 
animals. Compared to their baseline measurements, all dogs after 
thoracotomy alone had an increased clearance of 99mTcDTPA. In five 
of the six, the clearance accelerated slightly during PEEP, whereas 
the bypass animals showed no further change. The main conclusion to be 
drawn about 99mTcDTPA clearance is that dogs do not show the same 
increase during PEEP after chest surgery that they show prior to 
surgery. Although most of this lack of responsiveness appears to be 
due to the thoracotomy alone, part of the change is due to the bypass 
procedure itself, which in some way renders them less responsive to 
PEEP. 
Concerning the measurement of microvascular integrity, a similar 
percentage of dogs demonstrated a significantly positive value for 
transvascular protein flux as in the initial study. Four of the five 
dogs with a significant rate of extravascular 113mrn-transferrin 
accumulation demonstrated a slower rate during PEEP. The dog· that 
failed to show this change died 6 minutes later from circulatory 
collapse. This merits comparison with previous reports of 
microvascular protein flux during positive pressure breathing. 
Woolverton and co-workers (317) showed that in chronically 
instrumented unanaesthetized sheep, 10 em H2o of positive airway 
pressure did not significantly change lymph protein concentration, 
261 
although the flow trended downwards. In two studies involving lung 
injury, 10 em H20 of PEEP was applied to dogs that had previously 
received oleic acid. Sugerman et al. (321) failed to show a change in 
99mTc-albumin flux during 10 min of PEEP in pairs of dogs who 
received several doses of oleic acid. Luce and colleagues (322) 
applied PEEP for 21 hours to dogs that had received oleic acid 3 hrs 
previously and noted no difference in outcome. One must however, bear 
in mind that oleic acid produces a type of lung injury that probably 
bears little correlation with any type of human lung injury. As 
discussed in Chapter 7, cardiopulmonary ·bypass, although rarely 
causing AROS, does usually produce complement activation, neutrophil 
retention, and gas exchange abnormalities, and thus can serve as a 
model of early, subtle lung injury. There are, of course, multiple 
events associated with CPS (e.g. anaesthesia, thoracotomy, 
hypothermia, protamine administration, and exclusion of the pulmonary 
circulation) that may be responsible for the changes observed. The 
possible influence of these associated perturbations on transvascular 
protein flux were discussed in Chapter 7. Normal transvascular protein 
flux in the control animals would suggest that the changes observed 
were not simply due to prolonged anaesthesia and thoracotomy. 
The clinical significance of these data relates to patients with 
early lung injury.that may progress to AROS; based on these findings 
I 
it appears that the application of PEEP is unlikely to affect solute 
flux from the alveolus to blood and interstitium. In this respect, 
they behave like the healthy human smokers. whose results were 
discussed in Chapter 11. Likewise, PEEP is not likely to increase the 
flux of protein through the vascular endothelium, and in some cases 
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may actually slow the rate of protein accumulation in the 
interstitium. 
TABLE 8: Haemodynamic response to operative procedure in bypass and control animals 
Bypass animals 
Before During 90 min 0.5 Hr Post ·2 .0 Hr Post 4.0 Hr Post 
Thoracotomy Bypass Bypass Bypass Bypass 
·cvP (mm. Hg) 7.1 ± 0.5 4.2 ± 1.4 6.3 ± 0.4 5.4 ± 0.6 4.1 ± 1.2 
LAP (mm Hg) 3.0 ± 0.3 0.7 ± 0.3 4.2 ± 0.3 3.0 ± 0.3 3.3 ± 0.3 
MAP (mm Hg) 110 ± 3.8 68.0 ± 1.1 105 ± 4.2 98.0 ± 2.4 81.3 ± 1.0 
Thoracotomy animals 
Before During 90 min 0.5 Hr post 2.0 Hr post 4.0 Hr Post 
Thoracotomy Open Thoracotomy Chest Closure Chest Closure Chest Closure 
CVP (mm Hg) 7.1 ± 0.5 6.9 ± 0.6 5.3 ± 0.7 5.4 ± 0.8 5.0 ± 0.8 
LAP (mm Hg) 3.0 ± 0.4 3.1 ± 0.3 3.2 ± 0.3 2.7 ± 0.2 2.1 ± 0.3 
MAP (mm Hg) 112 ± 4.6 115 ± 5.5 109 ± 4.0 103 ± 3.2 96.6 ± 2.5 
Values are means ± S.E. of central venous pressure (CVP), left atrial pressure (LAP), and mean arterial 
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36 ± 1.2 
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0.95 
7.47 ± 0.02 
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Open Thoracotomy 
0.5 
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213 ± 16.1 
36 ± 1.6 
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0.5 
7.38 ± 0.01 
78 ± 4.2 
35 ± 0.7 
0.5 Hr Post 
Chest Closure 
0.5 
7.35 ± 0.01 
223 ± 8.6 
37 ± 1.4 
4.0 Hr Post 
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7.32 ± 0.01 
85 ± 7.7 
38 ± 0.9 
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7.33 ± 0.02 
198 ± 13.5 
36 ± 1.6 
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Figure 28 
This shows in those animals undergoing cardiopulmonary bypass (CPB), the 
response in half-time clearances of 99mTcDTPA to positive 
end-expiratory pressure before, and after the procedure (see- text for 
protocol). As a group, a significant fall (*)in half-time clearance was 
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Figure 29 
The change in half-time clearances of 99mTcOTPA with positive 
. end-expiratory pressure (PEEP) in the control animals (who underwent 
thoracotomy alone) before and after the procedure. In contrast to the 
animals who underwent cardiopulmonary bypass, this group retained 
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This shows 113m In-transferrin transvascul ar flux in the 
cardiopulmonary bypass group, before and after the procedure. This was 
expressed as protein flux units (slope/intercept, not slope alone as in 
figure). No significant change is noted with PEEP before bypass, and 
although this is also true after bypass, 4 animals did show a downward 
trend. The dotted line refers to the data derived from a dog who died 6 
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Figure 31 
The pulmonary transvascular protein flux response, in the control 
(thoracotomy alone) animals to PEEP, before and after the procedure. 
PEEP produced no change in this variable, either before or after 
thoracotomy 
CHAPTER 13 
THE EFFECT OF INFUSED BETA-ADRENERGIC AGONIST ON ACID-INDUCED 
LUNG INJURY IN THE RAT 
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11· THE EFFECT OF INFUSED BETA-ADRENERGIC AGONIST ON ACID-INDUCED LUNG INJURY 
IN THE RAT -----
13.1 - Introduction 
No clear consensus has emerged concerning the role of 
a-adrenergic agonists in modulati.ng lung injury. Initial experimental 
work in guinea pigs suggested that terbutaline (a selective 
82-adrenergic agonist) pretreatment protected against 
histamine-induced pulmonary oedema (324). Subsequent studies using 
isolated perfused lung systems tended to confirm a protective role for 
a-adrenergic agonists in both acid (325,326) and endotoxin (327) 
mediated lung injury. In contradistinction however, pretreatment of 
monkeys with terbutaline prior to anaphylactic shock accentuated 
injury with over half the animals developing fulminant pulmonary 
oedema (328). Likewise clinically, the use of 82-adrenergic 
agonists to treat premature labour is occasionally associated with the 
development of pulmonary oedema (329). In four out of five reported 
cases where pulmonary capillary wedge pressure has been measured 
(330-333), it was below 15mm Hg implying permeability rather than 
cardiogenic pulmonary oedema. The cause of this syndrome is unknown, 
but it appears to be an idiosyncratic rather than a dose related 
phenomenon. 
To investigate adrenergic mechanisms in lung injury further, I 
have examined the effect in the rat of a e2-adrenergic agonist, 
salbutamol, on lung injury induced by intratracheal acid 
instillation. Aspirated acid injures the lung immediately because of 
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a direct effect, although the resultant inflammatory response probably 
amplifies tissue damage (334). Alveolar-capillary permeability 
increases with resultant increase in transendothelial water filtration 
and solute flux. I sought to measure these latter parameters after 
experimental acid-induced injury by respectively determining 
1) gravimetric lung water by the ratio of lung wet:dry 
weight ratio and 
2) the clearance from the lung of 99mrc-DTPA as an index 
of alveolar epithelial permeability. 
This latter technique is highly reproducible in rats (335) with 
clearance of the tracer solute increasing markedly after experimental 
acid-induced injury (D.Royston, submitted) 
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13.2 - Methods 
Experimental technique 
Studies were performed on female specific ·pathogen free 
Sprague-Dawley rats (weight 200-250 gm). Anaesthesia was induced with 
a 1:1 by volume mixture of nitrous oxide and oxygen together with 
halothane 3%. The tail vein was cannulated and atropine 1.5-2mg/kg 
given by slow intravenous injection. After tracheal intubation with a 
16 gauge cannula (Abbot) the animals were mechanically ventilated 
using a small animal ventilator (Harvard apparatus, Kent, U.K.) with 
a tidal volume of lOml/kg and rate of 80/min. The inspired gas 
mixture consisted of air with supplemental oxygen to achieve a 
concentration of approximately 40%; this was verified with an oxygen 
analyser (Servomex 570). Anaesthesia was maintained with an 
intraperitoneal injection of Diazepam 10mg/kg and intramuscular 
•Hypnorm• 0.8ml/kg (Fentanyl 0.2 mg/ml, Fluanisone 10 mg/ml). The 
latter was repeated at hourly intervals throughout the study. After 
ten minutes mechanical ventilation hydrochloric acid (pH2, lml/kg), 
or saline in equivalent volumes in the control animals, was injected 
down a fine polyethylene catheter which protruded 3mm from the tip of 
the endotracheal cannula and this was flushed with a lml bolus of 
air. The animals were held vertical throughout this procedure. 
Immediately thereafter, infusions of salbutamol in saline (lug 
kg- 1 min-1), flow rate 5m1 kg-l hour- 1) or equivalent 
volumes of normal saline in controls were begun. After three further 
hours of controlled ventilation the following studies were 
performed. 
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1) Pulmonary clearance of 99mTcDTPA 
A similar technique to that described by Minty et al (12) was 
employed. Briefly, with the animals held vertically 0.1 ml of a 5 
mBq/ml (approximately 0.12 mCi) solution of 99mTcDTPA was 
instilled through a polyethylene catheter of similar length to that 
used to introduce the hydrochloric acid. A lead shield was then 
placed around the animal with windows removed to expose the thorax 
and one of the rear legs. Scintillation detectors were placed above 
the windows and the clearance of 99mTcDTPA from the lung 
(corrected for blood and tissue background in the field of the 
detector) determined. A computer fitted regression line enabled the 
half-time (T112) lung to blood clearance to be calculated. 
2) Gravimetric lung water (lung wet:dry weight ratio) 
The animals were exsanguinated by percutaneous cardiac puncture. The 
heart and lungs were removed en bloc; The lungs were dissected free 
of attached tissue, weighed and immersed in liquid nitrogen for two 
hours. They were then dried to constant weight by vacuum desiccation 
for 24 ho'urs and then reweighed. 
3) Lung histology and verification of 99mTcDTPA deposition 
Two separate groups of rats (n=6) were studied to determine the 
pattern of DTPA deposition and to assess lung injury histologically 
(n=4, acid instillation; n=2, saline instillation). In studies 
examining DTPA deposition the DTPA solution was mixed with colloidal 
carbon particles. For conventional lung histology 10% neutral 
formaldehyde was instilled intratracheally with the lungs in situ to 
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a constant pressure of 15cm H2o. The lungs of animals into which 
carbon particles had been instilled with the DTPA solution were 
inflated with 4 ml of air and then removed and fixed with 10% neutral 
fonnaldehyde. 
Study design 
Four experimental groups were studied: 
1) Acid i nst i 11 at ion and sa 1 butamol infusion (n=l4) 
2) Acid instillation and saline infusion (n=14) 
3) Saline instillation and salbutamol infusion (n=5) 
4) Saline instillation and saline infusion (n=18) 
Statistics 
The four groups were compared by one way analysis of variance and 
unpaired t tests. Because of unequal variances data for DTPA 
clearance was logarithmically transformed. All results are expressed 
as mean ± standard error of the mean. P values of less than 0.05 were 
deemed significant. 
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13.3 - Results 
Five animals (all Group 1) died during the three hour period of 
mechanical ventilation after acid instillation. Results in the 
remaining Group 1 animals (n=9), together with the other study groups 
are represented graphically in Table 10. Lung wet:dry weight ratios 
in the acid and saline infusion group were significantly greater (6.4 
± 0.3) than the group 4 controls (5~4 ± 0.2) (p<0.01). The Group 1 
rats (acid+salbutamol infusion) however, showed a dramatic increase 
in lung weight ratios (10.0 ± 0.6) . as compared to Group 2 
(acid+saline infusion)(p<0.001). Lung weight ratios were measured in 
three of the five rats who died and ranged from 8.5 to 11.1. These 
latter results were excluded from statistical analysis. In addition, 
lung dry weights in the salbutamol treated groups did not differ 
significantly from the other groups. 
Pulmonary clearance of instilled 99mTcDTPA was increased 
significantly in Group 2 rats (T112 in minutes, 19.4 ± 2.6) as 
compared to Group 4 controls (98.1 ± 7.2)(p<0.0001). As with the data 
for gravimetric lung water the group who had salbutamol infused after 
acid instillation had faster clearance of DTPA (11.5 ± 1.9) than the 
saline infused rats (Group2) (19.4 ± 2.6, p<0.05). 
Group 3 rats (salbutamol infusion after saline instillation) had 
values for lung water (6.0 ± 0.3) and for DTPA clearance (126.2 ± 
18.4) similar to Group 4 rats who were treated identically, but had 
saline rather than salbutamol infused. 
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Histology 
Acid treated rats alone showed severe alveolar-capillary injury which 
was bilateral and represented in every lung lobe. Prominent features 
were marked alveolar and interstital oedema with neutrophil 
i nfil trat ion. 
DTPA deposition pattern 
In control animals there were virtually no carbon particles deposited 
in airways although this was noted to a minor degree in acid-treated 
animals. In the latter group however, the vast majority of carbon 
particles were seen in alveolated areas. 
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13.4 - Discussion 
This study has demonstrated that after acid-induced injury there 
is significantly increased gravimetric lung water and pulmonary 
clearance of 99mTcDTPA in anaesthetised, intubated and ventilated 
I 
rats who had salbutamol rather than saline intravenous infusion. The 
histological findings together with the DTPA deposition data suggest 
strongly that the increased tracer solute clearance seen in the 
acid-treated animals was due largely to alveolar epithelial rather 
than airway injury. 
There is little evidence that e2-adrenergic agonists have a 
direct permeability enhancing effect. Experimental studies in skin 
and other extra-pulmonary tissue (336-338) show a protective role for 
these agents in mediator -induced permeability increase. The 
rationale for this could partly be explained by the Starling equation 
for transendothelial water filtration, which was outlined in the 
first Chapter of this thesis. It states that nett fluid filtration 
is the product of the driving pressure, the surface area and the 
hydraulic conductivity. Where e-adrenergic agonists have previously 
reduced water filtration in experimental lung injury in vivo, it has 
been as a function of reduction in pulmonary microvascular pressure 
(339). Our finding of markedly increased gravimetric lung water in 
salbutamol treated animals implies a predominant e1 agonist 
inotropic effect with consequent increases in pulmonary artery 
pressure. 
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Salbutamol could possibly have impaired a physiological 
protective response. Both salbutamol (340) and other 
a2-adrenergic agonists (341) inhibit hypoxic pulmonary 
vasoconstriction (HPV). This would increase perfused surface area and 
would tend to accentuate any s1-agonist mediated increase in 
microvascular press~re, resulting in the vastly increased gravimetric 
lung water noted in the salbutamol treated animals. It is unlikely 
however that salbutamol influenced the gravimetric lung water data by 
increasing residual blood volume, since dry lung weights were similar 
in all study groups. This would suggest that dry blood weight did not 
contribute significantly to total dry weight in the salbutamol 
treated animals. Although an inspired oxygen concentration of 40% 
should in itself inhibit HPV, areas of poor ventilation with alveolar 
flooding will still remain hypoxic; thus in these areas the response 
- will remain intact despite supplemental oxygen. Clinically, Brigham 
et al have shown that· in the adult respiratory distress syndrome 
(ARDS), a persistent high permeability:surface area product for urea, 
implying continuing perfusion ·of already injured alveolar capillary 
units, correlated with the severity of the gas exchange deficit and 
was associated with a poor prognosis (108). It is interesting 
therefore to speculate whether inhibition of HPV by salbutamol, with. 
subsequent impairment of pulmonary vascular autoregulation, 
exacerbated the pre-existing alveolar-capillary injury and increased 
pulmonary oedema and epithelial solute flux. 
How can these data be reconciled with the studies (325-327), 
showing an apparent protective effect of s2-adrenergic agonists 
in experimental acute lung injury?These studies all used an isol~ted 
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perfused lung preparation where the HPV response, although present 
(342), is undoubtedly more difficult to sustain (343). In this 
situation, after induced lung injury, there is presumably already 
progressive mismatching of ventilation and perfusion due to the lack 
of the HPV response and .any further 62-receptor mediated 
inhibition of HPV may be relatively unimportant. It may therefore. be 
that the possible beneficial effects of a 62-agonist (pulmonary 
vasodilatation and putative permeability protection) may actually 
confer a degree of protection in this in vitro preparation. In the 
whole animal however, HPV may represent a crucially important 
protective response and its inhibition correspondingly more 
detrimental. 
In summary, salbutamol infusion mediated an exacerbation of 
acid-induced pulmonary injury with significant further increases in 
gravimetric lung water and 99mTcDTPA clearance. Loss of 
protective HPV, but probably more importantly, 61 agonist 
mediated increases in cardiac output and pulmonary artery pressures 
may be important factors accounting for these findings. 
TABLE 10: Gravimetric ~water and 99mTc-OTPA clearance data in the 1 study groups 
Group n DTPA clearance 
1 (acid+ salbutamol) 9 * 10.0 ± 0.6 ** 11.5 ± 1.9 
2 (acid+ saline) 14 *** 6.4 ± 0.3 **** 19.4 ± 2.6 
3 (saline+ salbutamol) 5 6.0 ± 0.3 126.2 ± 18.4 
4 (saline+ saline) 18 5.4 ± 0.2 98.1 ± 7.2 
Results are mean ± SEM. DTPA clearance is expressed as the corrected half 
time in minutes. W/D is the wet to dry -1 ung weight ratio, an index of 
gravimetric lung water. 
* p < 0.001; ** p < 0.05 vs Group 2. 
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14. GENERAL DISCUSSION and CONCLUSIONS 
The body of work upon which this thesis is based was prompted 
initially by the lack of a specific method of assessing 
alveolar-capillary barrier integrity in clinical acute lung injury. 
Two nuclear medicine techniques have been modified and developed to 
provide indices of the permeability characteristics of both 
microvascular endothelium and alveolar epithelium. Either or both of 
these techniques were utilised clinically and experimentally in order 
to fulfill the broad aims of the thesis as outlined in Chapter 1. 
The initial study pointed to the non-specificity of 
99mTcDTPA pulmonary clearance in smokers and based on this, use 
of the method should be restricted clinically to nonsmokers. 
Attention should be focussed particularly on earlier diagnosis of 
lung injury and subsequent serial studies to monitor recovery or 
otherwise of lung epithelial integrity. This approach would identify 
patients at risk earlier and thereby maximise the efficacy of any 
pharmacological or other therapeutic intervention. The 
113m . In-transferr1n pulmonary transvascular flux method does 
appear - on the basis of these clinical studies and other 
experimental work, previously described - to be specific to 
microvascular injury. It is likely therefore, that a single study may 
be useful in the management of patients with pulmonary oedema of 
doubtful hydrostatic or permeability aetiology. As discussed, there 
is probably a spectrum of permeability alterations in pulmonary 
oedema and unless the clinical and haemodynamic status of the patient 
points unequivocally to a hydrostatic aetiology, an assessment of 
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microvascular permeability may be worthwhile. This approach would 
avoid dichotornising, based on an arbitrarily chosen value of the 
pulmonary capillary wedge pressure, assessed at one time point. This 
may provide misleading information as: 
i) an elevated wedge pressure does not exclude a coexisting 
permeability alteration and 
ii) a normal wedge pressure does not, per se, in the context of acute 
respiratory insufficiency with radiological infiltrates, imply a 
permeability derangement as the definition of ARDS would imply. A 
normal value may only reflect a reduction in a previously elevated 
value, usually in response to therapy. 
Notwithstanding this, as with 99mTcDTPA pulmonary clearance, 
future studies should be concerned particularly with patients at risk 
of developing lung injury, rather than those where the disease 
process is already well established. 
Experimentally, canine cardiopulmonary bypass was used as a 
subtle model of lung injury to assess the role of the neutrophil. 
This model was used as it had more general pathophysiological and 
clinical relevance than the more widely recognised chemical methods 
of directly injuring the alveolar-capillary endothelium and/or 
epithelium. Invariable morphological lung injury was induced and in 2 
separate studies the majority of animals demonstrated increased 
microvascular permeability. As a result of these studies, as well as 
further clinical studies in bone marrow transplant patients and 
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experimental work with endotoxin and platelet activating factor, the 
following conclusions about the role of the neutrophil in acute lung 
injury were reached: 
1) The neutrophil is not a sine qua non for lung injury development 
as has been suggested. Classical AROS was verified by permeability 
and subsequent histological studies in grossly neutropaenic patients 
after bone marrow transplantation. 
2) Lung neutrophil sequestration can occur in dogs after endotoxin 
without lung damage ensuing. This suggests that the relationship 
between intrapulmonary neutrophils and the development of lung injury 
is complex with additional, hitherto undefined, humoral and cellular 
factors playing a role. 
3) Studies after cardiopulmonary bypass show that in this model the 
neutrophil does appear to be playing a central role in the functional 
and morphological alterations observed. Similar conclusions apply to 
the studies with platelet activating factor, although in both cases 
definitive conclusions about the role of the neutrophil should await 
appropriate depletion experiments. 
It seems therefore, that in certain specific models of lung injury 
the neutrophil is playing a key role, but in others injury can occur 
independently of the cell. The same is true of the clinical 
-situation, where the neutrophil may be important with particular 
precipitating events. Additionally, the mere presence of 
intrapulmonary neutrophils, sequestrated within capillaries, does not 
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necessarily imply that alveolar-capillary injury will ensue. Thus the 
use of these permeability techniques has emphasised the heterogeneity 
of pathogenetic mechanisms and pointed to a more complex role for the 
neutrophil in acute lung injury. 
Of the putative humoral mediators of lung injury, it is likely 
that only PAF has a significant role. The reservation should be 
expressed that hist~mine and bradykinin were studied after 
aerosolisation in humans, because of the limitation of administering 
a dose which· provided limited but non-severe reduction in airway· 
calibre. These studies were however, in line with previous 
experimental studies using higher doses which were described in 
Chapter 9. Thus the conclusion of a limited role, if any, of these 
mediators, is probably correct. Use of a dynamic technique, 
transvascular 113mrn-transferrin flux, to study pulmonary 
microvascular integrity emphasi$ed the potential importance of PAF as 
an inflammatory mediator in the lung. The data demonstrated a 
temporal dissociation between the early haemodynamic changes and the 
later sustained permeability increase. This underlined its possible 
significance in endotoxaemia, where the time sequence of events is 
similar. 
The studies reported in this thesis provide evidence of the 
non-specificity of 99mTcDTPA pulmonary clearance. The changes 
seen in normal smokers have already been alluded to and the studies 
described in Chapters 11 and 12 have extended the technique•s 
non-specificity. Although in normal nonsmokers solute clearance is 
clearly volume-dependent, this was not found in smokers or, more 
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importantly from the view point of clinical applicability, after 
experimental acute lung injury. The finding however, that thoracotomy 
alone increases DTPA clearance is difficult to explain; if this were 
true clinically it would severely circumscribe its potential 
usefulness. Taking all these factors into account it appears that in 
acute lung injury 99mTcOTPA clearance has a limited role. There 
should be awareness of the various perturbations that may influence 
it and caution applied in the interpretation of data. 
The study examining the role of beta adrenergic agonists in an 
acid-aspiration model (Chapter 13) used DTPA clearance and 
extravascular lung water as indices of lung damage. Although this was 
not a comprehensive examination of adrenergic modulation of water and 
solute balance, the study did focus attention on the potentially 
deleterious properties these agents ·may possess. This interesting and 
unexpected finding underlines the need for further careful studies of 
how pulmonary haemodynamic alterations may influence established 
acute lung injury. 
In summary this research programme has provided important 
evidence for more routine use of these techniques - particularly 
pulmonary transvascular protein flux - in the management of 
critically ill patients with, or at risk of developing, adult 
respiratory distress syndrome. This latter permeability index appears 
at present the most specific and sensitive method of assessing 
clinically, pulmonary microvascular integrity. Based on studies 
presented here, and other work quoted in this thesis, the 
abnormalities in this index appear to antedate both significant 
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extravascular lung water accumulation and severe morphological lung 
injury. Experimentally, important insights have been gained into 
aspects of lung injury pathogenesis and modulation. This has led 
particularly, to an appreciation of the diversity of pathogenetic 
mechanisms which operate ·in this syndrome and the variable role 
played by the neutrophil in them. These suggest that a final common 
pathway of of lung injury does not exist. These clinical and 
experimental findings imply that examination of the permeability 
characteristics of the alveolar-capillary unit has a pivotal role to 
play in furthering understanding of pathophysiological mechanisms in 
- and aiding clinical management of patients with- the adult 
respiratory distress syndrome. 
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380 PRINT G$;G$;G$: GOTO 300 
1000 PRINT I3$:CU = PEEK (37): POKE 37,CU - 1: PRINT S$: HTRB ( LEN CS$) + 
1 ): INPUT 0$:0 = I..Jl=:L ( 0$ ): F:ETUPt~ 
1010 FOR N = 1 TO LEN (S$):CH = RSC ( HID$ (S$,N,l)): XORRH CH: NEXT: RETURN 
1100 X= <<T- 1) * C1::0- 16: IF X> 235 THEN X= 235 . ·~ 
1105 >=:DF:R~·i 114 AT :=<,Y3 + 13: S$ = "= 11 + ~:;TF:$ 0:: f:;;l ): GOSUE: ·1010: >::Or:R~·~ 114 f:IT 
. -·:=-; .. r,-'4 +. 13:':;$ = u::::u +- STf.::r. (FQ):·· GCI~;I_!P 101.0: r:ETUF:P 
1110 X= CT * Cl)- 16: IF X> 23~ THEN X= 235 
~ 115 :=<r,r:;:P.~·-~ 114 r~T ::-:: .. ~.;~~ -+· -l'7··~·:! =· ··=i' J :~;"'!::;::! .:~~~~ >: c::c·:~;: __ 1F .·~ ..... ~ . .~ .... 
• .. ' • .• t·:: --
_., ··- . - .: . : .. : - ·'-'' 
··,.I ··- .:..· ... :ll.,_,_... - -
j200 Sl = 0:82 = 0:S3 = 0:01 = 0:02 = 0:D3 = 0:04 = 0:D5 = 0 
12l0 FOR N = Nl TO N2:S1 = Sl + Li=:(N):S2 = S2 + L8(N):S3 = S3 + N: NEXT : 
N = N2 - Nl + l:Hl = Sl / N:H2 = S2 / N:H3 = S3 / N 
1220 FOF: t·~ = t·H TD t-t2: D! = D1 + ( ( LH( t·1· - tij ) .···. 2 >: D2 = D2: -!- ( ( :...E:-: '.' :' - r·i2 
) A 2):03 = 03 + ((N- M3) A 2):04 = 04 + ((L~(N)- Ml) * (N - H3)):0 
5 = 05 + ((L8(N) - M2) * (N - M3)): NEXT 
1230 Rl = INT ((04 * 100 / SQR <Dl * 03)) + .5) / 100:R2 = INT ((05 * 1 
00 / SOR (02 * 03)) + .5) / 100:81 = 04 / 03:82 = D5 / 03~ RETURN 
1300 X2 = ( 0 0L (0) * 259 / 255) + 20:X = X2: GOSUB 1380:X3 = ( POL fl) * 
258 / 255) + 20:\ = X3: GOSUP l380 
1310 0 = PEEK ( - 16384): POKE - 16368 .. 0: IF Q > 127 THEN GOTO 1350 
1320 XO = ( POL (0) * 259 / 255) + 20: IF X0 > X2 + 2 OR X0 t X2 - 2 THEN 
X = X2: GOSUB 1380:X = XO: GOSUB 1380:X2 = XO 
1330 Xl = ( PO~ Cl) * 25S / 255) ~ 20: IF Xl > X3 + 2 OR Xl < X3- 2 THEN 
X = X?: GOSUB 1380:/ = Xl: GOSUB 1380:X3 = Xl 
134(1 GOTO 13j fi 
1350 X = X2: GOSUB 1380:X = X3: GOSUB 1380:N1 = X0:N2 = Xl: IF XO > Xl THEN 
t·~ l = ::-:; 1 : t-~~~ = ::-::(1 
1360 Nl = INT ((CNl- 20) / Cl) + 1.5):N2 = INT (((N2- 20) / C1) + 1.5) 
: IF N2 - Nl > 0 THEN RETURN 
1370 130TO 130(1 
1380 :::CRLE= 28: F:OT= 48: >::ORR~~ 95 RT :=<..13!3: J=::OT= ~3: SCRLE= 1: RETUR~~ 
1400 HGR : HPLOT 17,0 TO 20,0 TO 20,140 TO 279,140: IF Q < 31 THEN. FOR I 
= 0 TO Q: HPLOT 20 + (! * C1),141 TO 20 + CI * C1),143: NEXT: FOR I 
= 0 TO Q- 1 STEP 2:S$ = STR$ (J):X = 18 + CI * C1):Y = 154: IF I> 
9 THEN X= 15 + CI * C1) 
1410 IF 0 > 30 THEt~ FOR I = 0 TO Q :::TEP 2: HPLOT 20 + (I '* Cl ),141 TO 2(1 
. +<I* C1),143: NEXT: FOR I= 0 TO Q- 1 STEP 4:8$ = STR$ (J):X = 
18 + CI * Cl):Y = 154: IF I > 9 THEN X= 15 + CI * C1) 
1420 ORRH 31 RT X,Y= GOSUB 1010: NEXT :T = 1 
1430 FOR I= 0 TO 4:Y = 140- ( LOG (10 A I)* 140 / LOG (10 A 5)): HPLOT 
1 7, v TO 19 ,.,.. : DF:R~-~ 31 RT e .. 'r' + s: S$ = " 10" : GC6UE: 1 ~310: DF:m~ 3 1 RT 13 
,Y- 4:8$ = STR$ (1): GOSUB 1010: NEXT: RETURN 
1500 REM :THIS REQUIRES Ti .. T2 RND THE UTILITY RRRRY /U/ TO BE LORDED 
1510 Cl = 259 / CT2- Tl) 
1520 Y0 = UCT1):Y1 =YO 
. 1530 FOR T = Tl TO T2: IF UCT) < YO THEN YO= UCT) 
1540 IF UCT> > Yl THEN Y1 = U(T) 
1550. t·iE:=<T 
1580 C2 = 140 / CY1 - Y0) 
1570 HGR : HPLOT 17 .. 0 TO 20,0 TO 20,140 TO 278,140: FOR I = 0 TO T2 - Tl: 
HPLOT 20 + CI * C1),141 TO 20 + CI * C1),143: NEXT: FOR I= Tl TOT 
2 - 1 :::TEF' 2: ::;$ = ~:;TF!$ (I):;< = 18 + ( (I - Tl ":1 * i-:1 ":t·· 1T' = 1 c:;4. Ii= I '> 
• - • Q • ,_ • • • • ... ...... :~- • ... • 10' •• - ...... -, .. ~;..... .r.-· .. 
9 THH~ :=·=: = l 5 + ( ( J - T 1 ) * C 1 ) · ··· · . . . . . 
1580 ·ORRH 31 AT X,Y: GOSUB 1010: NEXT 
1590 Y = .140 + (Y0.* C2>~ FOR I= Tl TO T2- 1~ HPLOT 20 +((I- Tl> * tl) 
~Y- (U(I) * C2> TO 20 +((I- Tl + 1) * Cl),Y- (1_1(1 + 1> * C2): NEXT 
1 f;(1(1 F:ETUFh 
1700 TE:=<T : Hot1E : I..JTRB ( ::: ) : HTRE: ( 1 E;): FLHSH : PF: I NT II CRUT I Ot~ II: I t·H.JEF:SE 
: ·PR I tn : PF: r NT : PRINT " ~r·ou RF:E ABOUT To EF:ASE UNSAI..JED DRTP. " : tmF:r-1P.L 
: PRINT GS;G$;G$ . 
1710 PRINT : PRINT : PRINT "ENTER '1/ TO CONTINUE'': PRINT : PRINT "PRESS 
RNY OTHER KEY FOR CONTENTS'': UTRB (17): HTAB (34): GET Q$: IF Q$ = "1 
II THEN F:ETURN 
1720 POP : GOTO 100 
1800 IF os = c1 THEN o~: = 1 : ss = "Nm~ PLOTT I t·~G OFF SCRLE" : DF:RH 31 RT 12E; ~ 
135: GO~:;UE: 1 (11 0 
1810 RETURN , 
2000 N = 0:BC = 0:BL = 0: IF C + K > 0 THEN GOSUB 1700 
2002 FOR Q = 0 TO 2 + l:P.(Q) = O:BCQ) = 0: NEXT :C = 0 
2005 .TEXT : HOME : UTRB (8): PRINT "HELLO. BRCKGROUNO COUNTS FIRST:": POKE 
2010 N = N + 1: HOME :S$ = Sl$~ GOSUB 1000: IF Q < > 0 THEN BC = ((BC * ( 
t·~ - l )) + 0) ...- t·~:H(0) = BC 
2020 SS = 82$: GOSUB 1000: IF 0 < > 0 THEN BL = ((8L * CN- 1)> + Q) / N: 
8(0) = BL: GOTO 20]0 
2030 TEXT : HOME : UTRB (8): PRINT ''BEFORE YOU ENTER POST-NEBULISER RERDI 
NG::;": PRHH "PLEASE Et-HEF: THE t11=1>=:H1Ut·1 Tit1E THP.T THE": PF:HF : PRitH " 
E:=<PER H1Et-H I~:; L I KEL 'r' TO GO Ot-~ FOR, IN": S$ = "t·1 It-~UTES - ": GC6UB 10r:.:m 
2032 IF 0 ( > INT (Ql OR 0 < 2 OR 0 > Z THEN PRINT G$,GS,G$: FOR Q = 0 
TO 1000: NEXT : GOTO 2030 
2035 Cl = 259 / Q~ GOSUB 1400 
2040 POKE 34 .. 20: H0~1E : PRit-H II TI t·1E - II; T _;II t·1I t·~. II: POKE 34,21: ss = ~::1 $: GOSUB 
1000: JF Q = 0 THEN GOTO 2120 
2050 HOME :R<T> = Q:LR(T> = LOG (Q - BC>:SS = S2$: GOSUB 1000: IF Q = 0 THEN 
2060 BCT) = Q:LB<T> = LOG (Q - BL) 
2065 IF T > = (259 / C1) + .5 THEN GOSUB 1800: GOTO 2090 
2070 Y1 = 140- ( LOG (R(T)- BC) * 140 / LOG C100000)·):Y2 = 140- ( LOG 
<B<T>- BL> * 140 J LOG <100000)) 
2072 IF Yl < 1 THEN Yl = 1 
2074 IF Y2 < 1 THEN Y2 = 1 
2076 IF T = 1 THEN Y3 = Yl:Y4 = Y2 
2080 HPLOT 20 + ((T- 1) * C1),Y3 TO 20 + CT * C1),Yl: HPLOT 20 + ((T- 1 
) * C1>,Y4 TO 20 + (T * Cl ),Y2 
2090 IF T > 10 THEN GOSUB 1100 
2100 IF T > 9 THEN N2 = T:N1 = T - 5: GOSUB 1200: GOSUB 1110 
2110 Y3 = Y1:Y4 = Y2:T = T + i: GOTO 2040 
2120 TE~n : HOt·1E : '..JTPE: <::: >: PHI NT "TH1E = ";T: PHI NT : IF T > s THEN PF:INT 
"REG. CO. FO~: CHEST DRTR = ";Rl: PRitH : P~:IHT "F:EG. CO. FOH LEG DRTR 
= "';F:2 
2130 I..JTAB ( 14 ): PF:ItH "1 ) GIUE I .l.J. DOSE": PRINT : PRHtT "2) ADD t10RE OAT 
Ru: PRINT: PRINT "3) COtHENTS": I)TRB (18): HTRB (14): GET 0$ 
2150 IF 0$ = "1 11 THEt~ HOHE: I..JTRB (8): PF:INT "Gil.JE DOSE t·40ktu: I..JTRB (13>: 
INPUT "PRES;:::; ..-RETUF:~4 TO CotHINUE" .;0$: POKE - 1E;3(14,0: GOTO 2180 
2160 IF 0$ = "2" THEt~ POKE - 16304 .. 0: GOTO 2040 
2170 IF O:t. = "3" THEN TD = T- l:AO::Z + 1) = TD: GOTO 100 
2180 PRINT G$;G$;G$: GOTO 2120 
2190 TD = T - 1.: H( Z + 1) = TD: IF T > 9 THH~ GOS;UB 1100 
2200 POKE 34 ... 2(1: HOt1E: PRitH "TIHE- II_;T;" t·1IN.": POKE 34 .. 21:5$ = Sl$: GOSUB 
1000: IF Q = 0 THEN GOTO 2280 
2210 HOHE :H(T) = Q:LRCT) = LOG (Q - BC>:S$ = 82$: GOSUB 1000: IF 0 = 0 THEN 
GOTO 22'BI?! 
2220 B<T> = Q:LB(T) = LOG (Q - 8L) 
2225 IF T > = ( 259 / C1) + • 5 THEN GOSUB 18t1l:h GOTO 2250 
2230 Y1 = 140- ( LOG CR(T)- BC) * 140 / LOG (100000)):Y2 = 140- < LOG 
CBCT>- BL> * 140 / LOG (100000)) 
2232 IF. Y1 < 1 THEN Y1 = 1 
2234 IF Y2 < 1 THEN Y2 = 1 
2240 HPLOT 20 + <<T- 1) * C1)~Y3 TO 20 + <T * C1>~Y1: HPLOT 20 + ((T- 1 
) * Ci. ) ... Y4 TO 20 + (T * Cl ),',.'2 
2250 IF T ) TO + 7 THEN GOSUB 1100 
2260 IF T > TD + 6 THEN N2 = T:Nl = T - 4: GOSUB 1200: GOSUB 1110 
2270 Y3 = Y1:Y4 = Y2:T = T + 1: GOTO 2200 
2280 TE:x:T : HOt1E : !)TAB ( f: ): PRINT 11 Tit·1E. = 11 ;T: Pr:ItH : IF T > TD + E; THHi 
PRINT "REG. CO. FOR CHEST DATA = ";Rl: PRINT : PRitH "F:EG. CO. FOR L 
EG DI=ITP. = '·'; F:2 
2280 PF: Hn : PF: nn : PR It..fT "DO 'r'OU ~·iRNT TO -II : PR HH : PF: Hn II 1 - ROD HOR 
E DRTR": PRINT : PRINT "2 - SOMETHING ELSE": PRINT : PRINT : POKE 37, 
PEEK ( 37 > - 1 : PR It..fT II EtHER NUHBER II : HHiB ( 15 ) : GET 1)$ 
2300 IF Q$ = "1" THEN POKE - 16304 .. 0: GOTO 2200 
2310 IF 0$ = "2" THEH GOTO 100 
2320 PRJ NT G$, G$, G$: GOTO 22::::0 
3000 TEi<T : Hot·1E : P~:HH "t·m. CHEST LEG": POKE ·34 .. 2: HOt·1E 
3010 IF N > TL - 15 THEN N = TL - 15: IF N < 0 THEN N = 0 
3020 FOR Q = N TO N + 15: IF TO < > 0 RND Q = TO + 1 THEN INUERSE : PRINT 
TPE:O:: 20 ) "l . !..J. DD::;E" ~ t·K•F.:r··!!=::.... 
3030 PRINT TR8( 3 - LEN ( STR$ (Q)))Q; TH8( 10 - LEN ( STR$ (R(Q))));R 
( 0 ) ; TI=!B( 1 :;::: - LH~ ( STR:t. ( 8( D ) ) ) ) ; E:( '~'): t··!E><T 
1 hX1 POKE 34, 20: HOt·1E : PR nn II 1 ' coRF:EcT" : PFU tH II 2 ) cHRt·iGE I .1...1. T H1E II : PRINT 
"3 > P.DD/DELETE" ~ POKE 33~ H::: POKE 32,22: HC•t·1E 
31(12 IF t·~ > 0 THEt·i PRitH "4) ERF:LIEF: DRTR" 
31 o4 IF t·4 < TL - 15 THEN PF: I t·n "5 > LRTEF: DI=!TR" 
3106 t.)TI=!B ( PEEK ( 37) + 1 ): PF:ItH "6 > CONTEtHS": POKE 32 .. ~3: POKE 33 .. 40 
3108 UTRB (23): HTP.8 (38)~ GET 0$:0 = UP.L (Q!) 
3110 IF 0$ = "1 II THH~ GOTO 320(1 -
312(1 IF 0:!- = "2" THH~ I30TO 3400 
3130 IF O:t = "3 11 THEt·~ t30TO 3500 
3140 IF (.1$ = "4 II P.t·~[! t·~ > (1 THEH t·~ = t·4 - 15: IF t·~ < (i THH~ t·~ - 0 
:<:14~ IF 0$ = "4" THH~ 130TO 300[1 
• •• ~;t:. 
3150 IF Q$ = "5" At·~D H < TL - 15 THD~ N = N + 15: GOTO 3000 
3160 IF 0$ = "6" THEN 130TO 100 
3170 PFUHT G$;8$;8$: GOTO 3100 
3200 HOHE : INPUT "WHICH REROING ? ";Q$:Q = URL (Q$): IF Q < > INT (Q) 
OR 0 < N OR 0 > t·~ + 15 OF: 0 > TL THEN PRINT G$;G$;G$: GOTO 31(10 
3205 U = 3 - N + Q: IF Q > TO RNO TO > N THEN U = 4 - N + 0 
3210 HTRB (5): UTRB CV): CRLL. - 888 
3215 IF Q = 0 THEN 130TO 3260 
3220 INPUT Q$: IF QS < > "" THEN RCQ) = URL (QS):C = 1: IF URL CQ$) < 
RC0) THEN 0$ = STR$ (H(0) + 1> 
3225 IF Q$ < > II II THEt·~ U:K 0 ) = L0(3 ( I.)RL ( 1)$ ) - H( ~) ) ) 
3230 I.)TRB ( 1.) ): HTAB ( 12 )~ INPUT 1)$: IF 0$ < > "." THEN 8( 0) = I..JI=il ( 0$ ":r: C 
= 1: IF URL O::Q$) < B<0> THEN Q$ = STR$ O::BCO> + 1) 
3235 IF Q$ < > "" THEN LBCQ) = LOG ( URL (Q$) - 8(0)) 
·3240 GOTO 3000 
32E:O I t~PUT 0$: IF Q$ < > II II THEN 130SUB 3300 
3270 I)TAB ( 1.) ) : HTAB ( 12 ) : I t~PUT Q$: IF 0$ < > If II THEN GO SUB 3350 
3280 GOTO ::moo 
3300 BC = VRL C0$):RC0) = BC: FOR I= r TO Z:N = H(!): IF N < BC + 1 THEN 
t·~ = BC + 1 
3310 LRO::!) = LOG (N-BC): NEXT: RETURN 
3350 BL = URL (Q$):8(0) = BL: FOR I= 1 TO Z:N = 8(!): IF N < BL + 1 THEN 
N = BL + 1 
3380 LB(l) = LOG CN- 8L): NEXT : RETURN 
::-:400 HOt-iE : PRHH "r.u. oo:::E ~Rs GI'-..'EN IHt1EDIRTEL'r: PF:un : HWUT "P~TEF;: 
~~HI CH F:ERD I t·~G 7 II ; (.1$: 0 = I..JRL ( Q$ ) : IF Q < > I tH ( Q ) OR Q < (1 OF: Q 
> TL THEN . PRINT G$;G$;G$: GQTO 3100 
3410 TO= URL (QS):RCZ + 1) = TO:C = 1: GOTO 3000 
3500 HOHE : PF:HH : PF:HH "1) RDD 2) DELETE": PRHH : GET Q$ 
3510 IF OS = "2" THEN GOTO 3600 
3520 IF Q$ <" > 11 1" Qf=;: R<Z> < > 0 THEt·~ GOTO 3100 
3530 HOHE : PRINT : PRHH "HHICH NU~1BER DO YOU ~~RNT THIS": 'PRINT :. INPUT 
"TO BE ? II ;I)$: 0 = I..JQL ( [.1$) 
3540 IF Q < > INT CO> OR Q < N OR Q > TL + 1 OR 0 > N + 16 OR Q < 1 THEN·. 
PRINT G$,G$,G$: GOTO 3100 
3550 TL = TL + 1: FOR I = TL TO 0 + 1 STEP - l:RCI) = RCI- 1):8(!) = 8(! 
- 1):LRO::I> = LRCI- 1):L8CI) = LBCI- 1 ): NEXT IF Q < = TD THEN T 
0 =TO+ l:R(Z + 1) =TO. 
35E:O HmiE : PF:HH : HWUT 11 NEH RERDING - CHEST 11 ; I$: I = l..JQL (I$): IF I 
$ = II II THH~ GOT(! 31 f10 
3570 IF I< > INT (!)OR I = 0 THEN PRINT G$;G$;G$: GOTO 3560 
3580 AC 0 ) = I : LR( f) ) = LOG ( A( 0 ) - BC ) : PR I t·~T : HTH8 ( 14 ) ~ J NPUT II- LEG II 
;I$:! = !NT< URL CI$)):8(Q) = I:L8CQ) = LOG (8(Q)- 8L): 130TO 3000 
3E:00 HOME : PfU NT : I Nl..JEF:SE : INPUT II HH I CH ENTR'r' DD 1T10U HHNT DELETED ? II 
;QS: NORHRL :Q = UHL (Q$): IF Q < > INT (Q) OR Q < 1 OR Q < N OR Q 
> TL OR Q > N + 15 THEN PRINT I3$;G$;G$: GOTO 3100 
3610 FOR I= Q TO Z- l:H(I) = HCI + 1):8(I) = BCI + l):LR(I) = LR<I + 1) 
:LBC!) = L8CI + 1): NEXT :RCTL) = 0:BCTL> = 0:LRCTL) = 0:L8CTL) = 0:T 
L = TL- 1: IF Q < =TO THEN TO= TO- l:HCZ + 1) =TO 
3E:2(1 GOTC! 30CCi 
. 40~3[1 PCW:E 34,20: Hot·iE : PF:H:H 11 HHEF:CEPT::: FOF: CORRECTION FRCTOR": POKE 34 
.-. ·! 
.Jf.,;:....l 
4010 HOt·1E : F'F:HH 11 E:F:PCKET ORTR FRoti FIRST CHEST TF:RCE": PRitH 11 PND PRESS 
·' F:ETUF:t·~ .. · II 
4020 Tl = 1:T2 =TO: FOR I= 0 TO Z:UCI) = LHCI): NEXT : GOSUB 1500: GOSUB 
4030 GOSUB 1200:11 = Hl + 0::04 * CTD- M3) / 03): HOME: PRINT ''CORR. CO. 
= II ;Rl; II INTEF:CEPT II.; Jt:H ( E;:<:P (I 1 ) ): I~WUT II(_, 1 -·· TO RE-DO OF: JUST 
.. · RETUF:t·~ _, ) II ; Gl$: IF (.1$ < > II II THEt·~ f30TO 4(11 (1 
4040 HOHE : PR un II BRRCKET DPTR FF:Ot·1 F r F::::T LEG TRQCE": PF: nn II Rt·m PREt:::=.: ··· 
F:ETUF:t·~ ... II 
4050 FOR f = 0 TO Z:UCI) = LBCI): NEXT: GOSUB 1500: GOSU8 1300 
40E:O GO:::;UE: 1200 ~ I 2 = t·i2 + ( [!~5 * ( T[l - t·13 ) . ...- D3 ) : HOt·iE : PF: I t.JT "COf=;:F:. CO. 
= II ;F:2; II HHEF:CEPT II; HH ( E::-::P ( 12) ): H~F'I_IT "( ·' 1··· TO RE-00 OF: .JUST 
·'F:ETU~:t·~··· > ";o:r.~ r::- o:r < > "" THH~ GOTO 404(! 
4070 HOt·1E : PF:HH "E:RHCf<ET DHTH F~:Ot·1 SECOt-m CHEST TRI="!CE": PRINT 11 HND PRE::; 
~: ···F:ETLiF:r·~ ··· •• 
4080 Tl =TO+ l:T2 = TL: FOR I= 0 TO Z:U(I) = LR(I): NEXT: GOSUB 1500: GOSUB 
1300:N1 = Nl + TO:N2 = N2 + TO 
4[1:30 GOSUB 12(H3: I3 = t11 + ( D4 * (TO - ~13) / 03 ): HOHE : PF:HH ''CORR. CO. 
= II ;F:l; II INTERCEPT II; INT ( E:=<P ( I3) ): INPUT 11 ( '1,.. TO RE-DO OR JU:3T 
,•'F:ETUF:N ... ) II ;0$: IF 0$ < > II II THEN i.30TO 4070 
4100 HOHE : PRINT "BRRCKET DRTR FF:Ot1 ::;ECOND LEG TF:RCE 11 : PFUtH "Rt~D PF:E:3S 
.·· F:ETURN ... II • 
4110 FOR I = 0 TO Z:UCI) = LB<I>: NEXT: GOSUB 1500: GOSUB 1300:N1 = N1 + 
TD: t·C = t·42~ + TD 
4120 . GOSUB 12(1(1: I4 = t·12 + ( D5 * ( TD - t-13). / D3 ): H0~1E : PF:INT 11 CORR. CO. 
= ";R2;" INTEF:CEPT ";HiT ( E><P (14)): INPUT "(-'t··· TO RE-DO OR JUST 
.. · F:ETUF:~4' ) II .;0$: IF 0$ < > II II THEN GOTO 4100 
··4130 FX = ( EXP (!3)- EXP (Jl)) / < EXP (14)- EXP (J2)):FX = INT ((10 
~) * Fi< ) + • 5 ) ..... 1 [10: PCI~::E 34 .. 20: HCIHE : PR I t·~T II (:IJRRECT I ON F~CTIJR = II ; 
4140 F'RitH : HWUT "PRESS ·'F:ETURN' TO COt-~TINUE 
GOTO 100 
. 5000 FX ~ B<Z + 1): IF FX < > 0 THEN GOTO 5005 
u ;Q$: B< Z + 1 ) = F:X:: C = 1 : 
5001 TD::T : HOt·1E : I..JTRB ( 8 ) : PF: I NT II NO CORRECT I Ot-4 FP.CTOF: 'l'ET II : POKE 34 I 11. 
5002 Hm1E : UTI=IB ( 11 ): PRINT "PLEI=ISE ENTEF: I..JRLUE AND PRESS -'RETURN": PRHH 
: PRINT "< .JUST PRESS ·• RETUR~~ ·' FOR CONTENTS >" : PF: I tn : PRINT : r NPUT " 
COF:F:ECTiot-~ FACTOR : ";0$: IF 1)$ = 1111 THEt·4 GOTO 100 
5004 C = l:FX = URL (QS):BCZ + 1) = FX 
5005 TE~<T : Hot-1E : !.)TAB ( 8 ) : PR I tH II CORRECT I ON FI=ICTOR : II ; 8( z + 1 ) : PRINT 
: PRINT : PR ItH II 1 ) CHANGE ~JAL.UE II : PRINT : PR ItH II 2 ) CONTENTS II : PR I HT 
: PF:Hn "3) CO~HINUE": POKE 37,13: PRINT : HTRB ( 15 ): GET Q$: IF 0$ = 
"2" THE!~ GOTO 100 
5[H36 IF 0$ = "3" THEN 130TO 50~39 
5007 IF Q$ = "1 11 THEN GOTO 5002. 
5008 PRINT G$;G$;G$: GOTO 5005 
5009 Tl = 1:T2 =TO- 1: FOR I = 1 TO TO:UCI) = CH(I)- BC)- ((8(1)- BL> 
* F;:.:; ): IF LV I ) < 1 THH·i U( I ) = 1 
5010 U(J) = LOG (U(J)): NEXT 
5015 GOSUB 15•'313: HOHE: I..ITRB (22): PRINT "BRACKET USEFUL DATA 11 : GOSUB 130 
0:TR = Nl:TB ~ N2 
. 5020 T1 = TR:T2 = TB: GOSUB 1500: HOHE : UTRB (22): PRINT ''BRRCKET DRTR ~0 
R HRL~Tit1E CP.LCULRTIONS": GO:::tiB 1300:N1 = Nl + TR- l:t·C = t·Q + TH-
1 
5030 Sl = 0:83 = 0:D1 = 0:D3 = 0:04 = 0: FOR N = Nl TO N2:S1 = Sl + UCN):S 
3 = S3 + N: NEXT :N = N2 - Nl + l:Hl = Sl / N:H3 = S3 / N 
5040. FOR N = Nl TO N2:01 = [11 + ((I_I(N)- H1) A 2):03 = 03 + ((N- H3) A 2 
):04 = 04 + ((lJ(N)- Hl) * CN- H3)): NEXT 
5050 N = N2 - Nl:R1 = !NT CCD4 * 100 / SOR CD1 * 03)) + .5) / 100:HF = 
( LOG (2) * 03 / 04) 
5051 R = t-11- (04.:,;. ~13 . ...- D3>:Il = P + ([14 * Tl=l . ...- 03):Il = 'r1 - CI1 * C:2): IF 
Il < 0 THEN Il = 0 
5052 IF Il > 140 THEN 11 = 140 
~053 HPLOT 20~11 
5055 FOR N = TR + 1 TO TB:Il = P + (04 * N / [13):!1 = Y- Cil * C2): IF I 
1 < 0 THEN J1 = 0 
5056 IF Il > 140 THEN Il = 140 
5057 HPLOT TO 20 + ((N- TR) * Cl>.Jl: NEXT 
5060 ·HOME : UTHB (22): PRINT "HALFTIME = 1'; INT CCHF * 10) + .5) / 10; SPCC 
6 ),; "CORF:. co. = II ;F::l: PF:INT : PC!f:::E 37,22: P~:It·H "1) F:EPERT 2~ ') f;TRJP 
3 > COtHEtH::;": HHH:: ( 35 >: GET 0$ 
50f:!0 IF 0$ = "1" THH~ HOt'IE : HGF: : GOTO 5[12[1 
50:3(1 IF 1)$ = "2" THEN r30TO 5110 
5(195 I~ 1)$ = "3 II THEN G("ITO 10(1 
5100 PRINT 13$;G:f;Gf: GOTO 5060 
5110 R = Ml - (04 * M3 / 03): FOR N = TR TO TB:Il = R + (04 +.N / 03):UCN) 
= F=<F' ( U< t·~ > ·:o - E::<P .:' I 1 ) ~ J F U( t·~ ·:o < 1 THEH U< t··! ·:o = l 
5120 NEXT : FOR N = Tq TO TB:U(N) = .LOG CU(N)): NEXT : GOTO 5020 · 
6000 TEXT : HOME : PRINT 
8(1(15 PF: I t-H [1$; II CRTRLOG II 
I=: PI H1 PRJ HT ~ HJPUT "ENTEF: ~..%...__...--
6020 IF (.!$ = II II THEN GOTO 1 (10 
8100 TEXT: HOME: UTAB (12): HTRB (20- ((10 + LEN (Q$)) / 2)): INUERSE 
: PRINT .. SQI.)JNG 11 0$ 11 II: t·K!F:t·iHL 
6110 RD = PEEK (107) + PEEK (108) *· 256 
6120 PRHn D$; 11 BSI=l'-.JE ";O:t; II .. 1=1~~ ;P.D; II .. L"< c c c z + 2 > * 5 > + 7 > * 4) 
6130 C = 0:K = 0: GOTO 100 
7000 IF C + K > 0 THEN GOSUB 1700 . 
7010 TEXT : HOME : PRINT 
7020 PRINT 0$; 11 CRTI=!LOG" 
7030 PRINT : INPUT II Et-HER FILE NRHE II ; Q$ 
7040 IF Q$ = "" THEN GOTO 100 
7102 TEXT : HOME: HTRB (20- ((10 + LEN CQ$)) / 2)): UTRB C12): INUERSE 
: PRINT . It LOHD I W3 II(.!$ II II : t·KtF:t·iHL 
7105 RO = PEEK (107) + PEEK (108) * 258 
7110 PRINT [1$; "BLORD 11 ;0$; II ,P. 11 ;1=![1 
7120 IF PEEK (43816) + PEEK (43817) * 256 = ((CCZ + 2) * 5) + 7) * 4) THEN 
GOTO 7140 
7130 PRINT GS .. G$ .. 8$: TEXT : HOME : UTRB (8): PRINT ''THIS ORTR FIL~ IS OF 
THE ~..JROHG FOR~1P.T": PRIHT : PRINT "FOR THI~: DI~:CETTE .. RND HR~: DRt1RGED 11 
: PRINT : PF:HH "THE PF:OGRRHHE": PRitH : PRitH : PRINT 11 PLERSE STRRT 
RGHIN. II: Ef-.j[l 
7140 C = 0:K = 0: GOTO 100 
8000· GOSUB 1700 
8010 HOME : PRINT 
8020 PRIHT [1$;"CPTHLOG" 
S030 · PR I tn : r t·~PUT II Et-HER ~iRHE oF FILE " ; os 
8040 IF O:t = '"' THEt-4 GOTO 10f• 
8050 HOHE: UTRB (12): HTRB (20- ((11 + LEN CQ$)) / 2)): FLRSH PRINT 
II DELET r NG II ; o:t; " II : tKtF:t·1RL : PF: I fn 
8060 PRINT 0$; 11 0ELETE 11 i0$ 
E:070 GOTO 801 (1 
9000 ERR = PEEK ( 222 ): TEXT : HOHE : t...fTRB ( 8 ): PRINT G:t.,G$ .. 8$ 
8010 IF ERR = 8 THEN PRINT "NO SUCH FILE RS "Q$: ·GOSUE: 910(1: GOTO 10f.1 
9020 IF ERR = 8 THEN PRINT "I CHW"T RERO THE OISCETTE. ": PRit~T : PRINT 11 
PLEASE CHECK IT"S IN PROPERL'r: GO~:t,JB 9H30: GOTO 100 
8030 IF ERR = 11 THEN PRINT 11 THRT IDIOl"S ~1ROE RNOTHER SYNTRX": PRINT : PRINT 
"ERROR. YOU"D BETTER ~SK ..JOHt~ TO": PRHH : F'RIHT "LOm~~ ~T IT.": GOSUE: 
910~3: GOTO 100 
9(140 PRIHT "THERE SEEMS TO BE Rt~ ERROR SOt-1E~HERE. ": PRINT : PRHH "PLERSE 
CHECK THE DRTH FOF: HE": GOSUE: 91f1[1: E = 0 
8050 POKE 768 .. 104: POKE 789 .. 168: POKE 770 .. 104: POKE 771 .. 166: POKE 772 .. 223 
: POKE 773 .. 154: POKE 774 .• 72: POKE 775 .. 152: POKE 77E: .. 72: POKE 777 .. 96 
9060 CRLL 7E:8: GOTO 100 
9100 FOR I = 0 TO 2000: NEXT : RETURN 
APPENDIX 2: 
Computer programme for acquisition and analysis of data for 
transferrin flux study. 
350 
In this study data is being acquired from two scintillation detectors 
simultaneously, from 2 different isotopes (99mTc and 113min). 




20 '* COUNT305 (C) 19/02/85 * 
30 '* D HEMSLEY Ro Po Mo & * 
40 '* INSTRUMENTATION DEPT * 
50 '* JOB NUMBER 84/6 * 
60 '************************** 
70 CLEAR 200,&H5FFF : CLS 
:;:::o PH I NT "LOADING l'lACH I NE CODE" 
9'0 bCI~ll_:.!..Eo;::.!Oo:,;;il Ll--i-1. f. IN II 
PRINT" PLEA~~ E. wAr r II 
I '1 c.. (... 0 I.J D1. L..OU •V T '::LOCf\../1 
100 EXEC &H7000 ' CSTART 
j . l 1 0 PM ODE 4, 1 
120 DEF FNP<N>=256*PEEKCN)+PEEK<N+1) 
1::::0 CLS 
140 Pr~INT@O, 11 ---------MENU----------" 
150 F'HINT"(S)TART DATA COLi ... EC:TJUt\1" 
1(·,(; PHINT"<H>ALT DATA COi....LECTION" 
J 170 PfUNT"DISF'LAY \AiLL. CHAi~NEL:.:." 
lt:O PRINT "DISPLAY CHANNELS" 
J. 90 p;~ I NT " ( .1 ) ; ( 2) ' ( ::; ) 1 OR ( 4) I 
) 20(J PRINT "Dl:~:PLAY (I) NDIU1'1" 
:LlO PRINT "DH;PUW < T) ECHNET IUM" 
220 FF\ 1 j\iio "u l :::;F'LA 'r" ( R ) AT 1 u i /T II 
240 PF\ I NT ":::A:::::;t:TTE < W ) R I IE < L) OAD,. 
250 PRINT "E.< X) IT TCI BA:~:IC" 
-) . 260 PRINT 
270 NPOINT=CFNPC&H6000>-&H6006)/10 
2f:::O PRINT"NUME:ER OF DATA POINTS="; NF'I]lNT 0 








THEN GOSUB 2270 




J.F I Nl;::::. "~= 11 THEN GO:::;UE: 285(1 
::::;41) IF INt.=" x" THEN oostH.:: zo:;:o 
850 IF lN$="H" THEN POKE ~-..:H7FEC:, (I 
360 IF lN$="L" THCN G():::aJB 12.90 
37(1 IF I N!t;::" w II THEN GO!:::UB 1450 
:3:30 IF I N:b= II p II THEN Ci0:3UB 1 /;.(JO 
:390 IF l N$<::> II:::; II THEN GOTO 4:30 
4oo INPUT"CDUNTINCi PCF~roz.; IN s;Ec ";PER~ 
410 PER=VAL<PER$) 
420 IF PEk=:O THEN 130Tfo.: 41:.0 
.. 
.. 
4::::c1 r F F'EF025~:• THEN Pr.: r NT II NOT t-10RE THAi\! 25::-:, ::::Ec::; PLEA::::t.~" ooT c 4(H) 
) 
) 
440 r F FER< 1 THr:~N Pi.( r NT" NOi u:.::;:;:; n !r.;rJ t ::::;:;::=: r--LE:?';:;;r:: ,. : c;cnt; ..;ooo 
450 F'Ui<E ~:~H(.(l(l<L PEh: 000 0 (:<F'EF.; I :JD 
430 IF 1 N$=" ~'" THEN GOTf"l 
490 C:HAI\l=VAL ( IN$ ) 
,-- I •. 
;,:).;, '·' 
500 IF CHAN >4 OR CHAN <l THEN GOTO 140 
:;:; l 0 AENO=:i7 NF' ( ~~H/.000: 00 (:,(l(H)=€.DATf""io~T 
520 NPOINT=CACND-&H6006)/10 
530 IF NPOINT=O THEN NPOiNT=l 
540 X8TEP=256/NPOJNT 
~;:_;o M?-\X:.:.oFot\lio' ( ~dk.OO::~) 
560 l~ MAX=O lHEN MAX=l 
570 YSCALE=l~;/MAX 
·.-..... ·.· 
















620 PCLS: SCRECN l.O 
6~0 FOR Y=191-STP TO 0 STEP -STP 
640 PSET(O,Yl : PSET(l,Y) 
,:,~:.u NI.-":.XT Y 
660 FOR X=10 TO 256 STEP 10 
(:,7(1 





720 ,. = l:II:3PLAY •::l·-u:·,NNEU3 l TO ;..;-= 
730 ~========================== 
740 STP=19l*l0000/MAX 
750 IF MAX<=IOOOO THEN STP=191*1000/MAX 
7~0 IF MAX<=iOOO THEN STP=191*100/MAX 
770 IF MAX<=lOO THEN STP=191*10/100 . YSCALE=191/100 
7::::0 GO:=;UB f.:. .t 0 
790 IF IN$= 11 A11 , THEN GOTO 820 
GOO C:i0:3UB 9:20 
:3t 0 CiOTO ::::50 
820 FOR C~~N=i TO 4 
:3:~:0 G0:3UB 9 1 0 
:~:40 i'·IE X T CHAN 
:350 IN$= I NKEY $ 
Clf::,(l 1 F IN$= II II THEN ::::51) 
::no GOTO :300 
890 '========================= 
900 '= DISPLAY SUBROUTINE = 
910 ~========================= 
920 ADDR=&H6006 
930 X=O : Y=l91-YSCALE*FNPCADDR+CHAN*2) 
940 LINECX,Y)-(X, Y>,PSET 
950 FOR ADDR=&H6010 TO AEND-1 STEP 10 
'.i(-:-0 X=X+X:3TEF' 
970 Y=191-YSCALE*FNP<ADDR+CHAN*2) 
~80 IF Y <O THEN Y=O 
990 LINE-(X,Y),PSET 
1000 NEXT ADDR 
1 0 1 0 fi:ETURN 
1020 
1030 /========================= 
1040 /= STOP COLLECTION S/R = 
1050 ~========================= 
lot:.o cu:; 
1070 PRINT "DO YOU WI:~;H TO STOP". 
lO:'::Cl PRINT "DATA COLLETION Y/N/"; CHH$( 127) 
1090 I 1\1$= I NI<E"f'$ 
1100 IF IN$="" THEN 1090 
1110 IF IN$="Y""THEN POKE&H7FEC,O 






r- t1~o -===========~============== 
t1 ;o FR r N r "· 
.:_ U:::Cl ;~-'{:( I NT II 
11 ·::'o 1='R .r N r " 
'~ ' . JAFd\J 1 N;:.; * n 
·ll- *~·>'d~·i<· >HHH:.- :1:· ' 1 
L:-::uo F'fU!'JT "THE; WJLL :::;nJ;~:· ·;·;:E c:...CiU<" 
12.!. n I:'R I NT "~iND UATf-.1 ;::Cii .. LECT l UN" 
J. :2::-~o ~~·R I NT "no YCk.l Rc:;t_ y r·iLAN IT y /N" 
I. z::o IN:$=.£ Nt:::FY$ 




1 ::.::1 o PR r NT "LOAD FROi'1 cA~:;~;::;ETTE" 
1320 PRINT "------------------" 
1::::::::0 PRINT 
1 ::i4o GC(;UB l1 L.O 
1 ~::50 IF I N1i<)" Y" THEN RCTUHN 
13(:·0 PRINT 
1 :2:70 INPUT "ENTER FILE NAr1E "; NAI'1C$ 
1 :3:::o PRINT "~3EARCH I NG r:oR !; ; N~lt-i!:::·.j; 




14~~:(f ·' ======================== 
1440 '= WRITE TO CASSETTE 
1450 '========================= 
t 4,:.o cu:; 
1470 PRINT "WRITE TO CA:3~::;ETTE" 
1480 PRINT "----------------~" 
14·:.:~0 PRINT 
1 ~iOO Uu::~UB ll•SO 
1510 ~;:- IN$<>"Y" Tl-it::i\j Rt::TUFi:N 
1520 PRINT 
15~:.a; INPUT ''ENTEfi FILE NAf1l:. "; NAt"l£$ 
·~ 






1590 /= PRINTOUT -
1600 '======================== 
.16 l 0 G0:3UE: 1050 
1620 IF INS=CHR$(8) THEN RETURN 
lt:.30 CL:::; 
1640 PRINT "(T)ADULAF-: OR <G>RAPH. PRINTOUT" 
ll:-50 PRINT "-------------------------------" 
1 .::.t;G PRINT 
1670 LINE INPUT "NAME ";NAME$ 













tT::o PRINT#-2, "Mf.)XIMUM COUNT="; I"IAX;" COUNTING F'ERIOD=="i t 
1740 PRINT#-2 
1750 LN0=5 
.17/:..0 F'FUNT:tf-2, "TIME :3EC : CHAN! : CHAN2 : CHAN3 : CHAN4 : 11 ; 
J.770 F·RINT#-2, II IN[I!I.JM : TECN. : RATICt u 
1780 PRINT#-2, ''------------------------------------------"; 
1790 PRINT#-2, "---------------------------" 
1800 FOR ADDR=&H600/:.. TO CFNPC&H6000)-10) STCP 10 
1810 F'RINT#-2, II: II; 
1820 FOR CHAN=O TO 4 
1~3o PRINT#-2. u::::ING" ##### : II; FNP < ADDR+CHAN*2 >; 





"1890 IF Cl=O OR C2=0 OR C3=0 OR C4=0 THEN 1930 
1900 PRINT#-2, u:;;;T.NG" #. #### : "; C2/C4, 
1"910 PRINT#-2,USING 11 #. ####: ";C1./C3; 
1920 PRINT#-2, u::::ING" #. #### : "; <C2./C4>.1CC1/C:3L 
1 ?::::() PRINTt}-2 
1940. LNO=LNO+l 
1950 IF .LN0=57 THEN LNO=O 
1'?60.NEXT ADDR 
1970 PRINT#-2,CHR$C&HOC) 




2010 '~===~=================== . 
2020 '= EXIT TO BASIC = 
2030 '======================== 
2040 GOSUB 1050 
2050 IF. IN$=CHR$(8) THEN RETURN 
.2060 CLS 
2070 PRINT "EXIT TO BASIC" 
20:30 PRINT II ___ .. _____ .... ______ u 
· 2090 ·PRINT 
2100 PRINT "TO REt:TART WITH NEW DATA" 
21l0 PRINT "TYPE RUN.i.OO" 
.2.1.20 PRINT 
21::.:::0 PRINT "TO RE!~:TART WITH OLD DATA~' 
2i4(l PRINT "TYPE RUNllO" 
2150 PRINT 
2160 PRINT "DO YOU WISH TO ~;TOP" 
2170 PRINT "THE CLOCK YfN " 
21 t=;O J. N$= l Ni<EY$ 
2190 IF IN$="'' THEN 2181.l 
2200 CLS 
2210 IF IN$·C.>"Y" THE:N END 
2220 EXEC M·l7009 
2:?.:::0 END 
2~50 ~======================== 
22e·O -'= DI:3PLAY TNDIU!"l 
2270 ~======================== 
~22~:::() ::;l .. F'= 1 ;::1 




2~~~!~::<) J r c::4.=(J -i i-!E~t~ c:4= 1. 
2340 X=O v~l91-l91/1*C7/C~ 
2::~::5t) Jj::' ')'<~_(! -rriE.r~ \{=<) 
. . .; .. 
: ~ . 
. ~-. -: ,. 
2360 LINE<X.Y)-(X,Y>.PS~T 
2370 AEND=FNPC&H6000) 
23.:::0 NPO I NT::: ( AEND-~d i,~.OO.:'. ) ./ l (l 
2390 IF NPOINT=O THEN NPOINT=l 
2.)0 XSTEP=256/NPQINT 




2450 IF C4=0 THEN C4=1 
2460 Y=19l-19l*C2/C~ 
2470 IF Y<O THEN Y=O 
24:::0 LlNE ..... (X, '/), P:.:;F.T 
2490 N::XT ADDF\ 
·7:500 t N~= I Nl<EYj. 
251(1 J F IN$=" II THEN 2500 
2520 RETURN 
2540 ·======================== 
2.5~~n ·' = [IT :O::PLAY TFC:HNET .1 I.IM = 
2560 '======================== 
2570 STP:19 
25CO GOSUD 1...10\ 
25-:;.o ADi)R:&i-i~~.o()~~ 
. 2600 Cl=FNPCADDR+2) 
26l0 C3=FNPCADDR+6) 
2~20 Ir C8=0 THEN C3=1 
2630 X=O : Y=191-191/l*Ct/C3 




2680 IF NPOINl=O THEN NPOINT=l 
2690 XSTEP=256/NPOINT 




2740 IF C3=0 TH~N C3=1 
27~~;o Y= 191- l ':) t *L-1 /C::.:: 
276U J~ Y<O THEN Y=O 
?77(; L rNF- < x. ·t), r--:_.r· T 
:::.7 ::·:o rli~::x -; A; .un 
·27·~c~ Jt,j.., .. -:If\H.:t-.:-'r':.i· 
~;:;a)(l IF I Ni>= 11 11 THE.N 27 ')(l 
. 2::.:: 1 u RE rum~ 
-~ ·:····:l."w\ 
...:,.. '··' .~·- '•/ 
;:~!:~:t) .·· =-======================= 
2850 ~========================= 




t 2870 G03UB 610 
2890 Cl=~NP<~GDR+2) 
2'::JtJO £ F C J. =-(1 fHEN :.:: 1:.:: ! 
2910 C2=FNP<ADDR+4>. · 
2920 IF C2=0 THEN C2=: 
(. 2?30 C3=FNPCADDR+6) 
2940 IF C3=0 THEN C3=! 
2950 C4=FNPCADDR+8) 
2960 IF C4=b THEN C4=1 
2970 X=O : Y:191-191/3*<C2/~4)/CC1/C3) 




:3000 AEND=FNP < g~.HI::oOOt)) 
3010 NPOINT=<AEND-&H6006)/10 
3020 IF NPOINT~O THEN NPOINT~l 
3030 XSTEP=256/NPOINT 
3040 FOR ADDR=&H6010 TO AEND-1 
:3050 X=X+XSTEP 
3060 C1=FNP<ADDR+2> 
3070 IF Cl=O THEN C1=1 
3080 C2=FNP<ADDR•4) 
:3090 IF C2=0 THEN C2= 1 
3100 C3=FNP<ADDR+6) 
311.0 IF C3=0 THEN C3=1 
3120 C4=FNP<ADDR+S) 
3130 IF C4=0 THEN C4=1 
STL:P 10 
3140- Y=l91-191/3*<C2/C4)/<C1/C3l 
~150 IF Y<O THEN Y=O 
Sl60 LINE-CX,Y>,?GET 
:J1.70 Ni::Xi- ADDR 
3180. IN$-= I NKEY$ 
3190 IF IN!!>='"' THEN 3180 
:::200 RETURN 
3210 CSAVE"COUNT305 
3220 CSAVEM"COUNT2CM", &H7000, &H717F; &H7001) 
' 
